A study to evaluate the quality of medication-related information in the discharge summary of elderly patients discahrged from an acute hospital  by Purser, Kevin Anthony
This electronic thesis or dissertation has been 











The copyright of this thesis rests with the author and no quotation from it or information derived from it 
may be published without proper acknowledgement. 
 
Take down policy 
If you believe that this document breaches copyright please contact librarypure@kcl.ac.uk providing 
details, and we will remove access to the work immediately and investigate your claim. 
END USER LICENCE AGREEMENT                                                                         
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 
International licence. https://creativecommons.org/licenses/by-nc-nd/4.0/ 
You are free to: 
 Share: to copy, distribute and transmit the work  
 
Under the following conditions: 
 Attribution: You must attribute the work in the manner specified by the author (but not in any 
way that suggests that they endorse you or your use of the work).  
 Non Commercial: You may not use this work for commercial purposes. 
 No Derivative Works - You may not alter, transform, or build upon this work. 
 
Any of these conditions can be waived if you receive permission from the author. Your fair dealings and 








A study to evaluate the quality of medication-related information in the discharge




Download date: 05. Apr. 2019
  
 
A study to evaluate the quality of medication-related 
information in the discharge summary of elderly patients 




Kevin Anthony Purser 
 
Student Number 85941310 
 
A thesis submitted in partial fulfilment of the requirement for the  
Doctor of Healthcare of King’s College London 
Institute of Pharmaceutical Sciences 
King’s College London 
 
 
2 July 2018 
 
 
The copyright of this thesis rests with the author and no quotation from it or 





It has been found that patients are often readmitted to hospital due to medication-related 
incidents.  The quality of medication-related information in the discharge summary may 
be a contributory factor leading to readmission.  This study evaluated the quality of 
medication-related information in a discharge summary of elderly patients discharged 
from an acute hospital in relation to locally determined standards.  The study was carried 
out in three phases: Phase I involved determining a local consensus for the essential or 
gold standards and desirable standards for medication-related information on a discharge 
summary using a modified e-Delphi technique.  Phase II was carried out to measure the 
level of adherence to the standards determined by a retrospective, observational study 
of elderly patients of 65 years of age or older discharged from an acute hospital.  Phase III 
involved a local expert panel assessing whether any subsequent readmissions within 30 
days were due to the quality of discharge information.  The results of the modified e-
Delphi study using an expert panel had a response rate of 55.2% after round one and 
34.4% after round two and provided the local standards.  155 patients’ discharge 
summaries were then evaluated.  An overall adherence score of 64.6% was found in 
relation to the gold standards.  A level of adherence of 51.1% with medication changed 
with a reason stated on the discharge summary; 75.4% for medication stopped with a 
reason stated on the discharge summary and 84.8% for medication started with a reason 
stated on the discharge summary was found.  There was some evidence that GPs do not 
always act upon the information in the discharge summary.  In Phase III it was found that 
six patients were readmitted to hospital within 30 days due to medication with only two 
(1.3%) influenced by the quality of medication-related information.  The study discusses 
the implications for clinical practice in preparation of a gold standard discharge summary 
including the need to design electronic discharge templates to include the gold standards 
and recommendations for training of junior doctors.  An assessment tool to prioritise high 
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Chapter 1: Transitions of care at discharge and medication errors - a 
review of the literature and current practice 
 
1. Introduction to discharge issues 
One of the significant challenges facing the provision of healthcare services today is to 
ensure that patients are treated both effectively and safely on transfer or transition of 
care from one location to another.  Patient health outcomes may be influenced by how 
safely they transition across different healthcare services, for example on the admission 
into a hospital and the subsequent discharge from a hospital.  There is evidence that there 
is often a breakdown in arrangements for medication information and supply in the 
transition of care for patients into hospital, whilst in hospital between various care teams 
and wards and then upon discharge (NICE, 2007).  This challenge is even more so in the 
context of increasing demands on scarce resources in England with increasing activity, 
reductions in length of inpatient stay and bed numbers and a population that is getting 
older and needing acute healthcare more.  In 2015-2016 in England there were 16.3 
million finished admission episodes, an increase of 2.3% from 2014-2015 and an increase 
of 28.2% from 2005-2006.  This demonstrates a dramatic increase in activity in hospitals.  
In comparison, the average (mean) length of stay for an episode has decreased to five 
days in 2015-2016 from just less than seven days in 2005-2006.  The age group of patients 
being treated is also of importance.  In 2005-2006 the 15-44 age group accounted for the 
greatest number of episodes (4.4 million).  However, episodes for the 65-84 age group 
saw the greatest increase rising to over six million in 2015-2016.  This is also reflected in 
the average age of patients being admitted to hospital, increasing from 49 in 2005-2006, 
to 53 years of age in 2015-2016 (NHS Digital, 2016).  Conversely, the number of hospital 
beds has been declining over recent years.  The number of available beds has reduced by 
more than a half over the last 24 years.  This has placed an additional burden on hospital 
care with bed occupancy rates for acute beds increasing from 87.7% in 2010-2011 to 
89.5% in 2014-2015 (Kings Fund, 2015). 
 
One of the consequences of this conflict between an increase in demand and reduction 
in available beds for an ageing population is less time being available to have a co-
ordinated and well-planned discharge process from hospital.  This can have patient safety 
consequences if the discharge is not managed in an optimal manner especially in relation 
to medication.  Two studies investigating the rate of reconciliation discrepancies related 
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to medicines on admission found that there is a risk of 30% to 70% of an unintentional 
variation between the medicine being taken before admission and the prescription on 
admission (Cornish et al, 2005; Gleason et al, 2004).  Tam et al, (2005) undertook a 
systematic review of studies that considered the frequency, type and clinical importance 
of medication history errors on hospital admission.  Twenty-two studies were identified 
involving 3,755 patients published for English-language articles over the period from 1966 
to April 2005.  This systematic review found that the error rate for prescription errors on 
admission was high (up to 67% in some cases).  Between 10% and 61% cases had at least 
one omission error and between 60% and 67% had at least one omission or addition of a 
drug not used before admission.  Of all the 22 studies, only five made a distinction 
between unintentional and intentional discrepancies of the patient’s medication 
prescribed upon admission.  A further concern was that between 11% and 59% of the 
medication history errors were clinically important and therefore a patient safety issue.  
This was assessed in the studies by using a consensus method of a panel of experts which 
included doctors and pharmacists or both.  The therapeutic classes most often involved 
in the medication history errors were cardiovascular agents, sedatives and analgesics. 
 
Whilst these studies were on admission, it clearly demonstrates the risk at the point of 
transition of care for the patient.  Coupled with this is the increasing awareness that timely 
discharge for patients is crucial, particularly the elderly.  Elderly or Older patients for the 
purposes of this review are those over the age of 65 as they are the main users of 
healthcare and prescribed medicines (Tangiisuran et al, 2014).  They often have multi-
morbidities and polypharmacy which may increase further the risk of an adverse drug 
event (ADE) or error on discharge (NICE, 2017).  In the period between October 2012 and 
September 2013 there were around 10,000 reports to the National Reporting and 
Learning System (NRLS) of patient safety incidents related to discharge (NHS England, 
2014).  Of the 10,000 incidents, approximately 33% were related to communication at 
handover.  This area of risk at the point of discharge has identified that patients may be 
discharged without adequate and timely communication of essential information.  Safe 
discharge from hospital, therefore, requires some key principles to be applied.  These 
principles include having effective discharge planning and for organisations to have 
medicines reconciliation processes in place.  Ideally, there should be a ‘whole system’ 
approach to discharge with organisations working together.  This ‘whole system’ 
approach includes having clear documentation of discharge/transfer plans.  When a 
patient is in hospital it is likely that regular medication will be changed, particularly for 
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patients who were in hospital after an emergency admission.  This means that the patient 
and/or carer needs to understand how to take the medication regimen and the general 
practitioner (GP) needs up-to-date information to be able to continue the medication plan 
after the patient has been discharged (Department of Health, 2003).  However, it has been 
identified that there are deficiencies in the communication of medication-related issues 
on discharge (Care Quality Commission (CQC)), 2009). 
 
The hospital discharge summary is the accepted document used to communicate 
information about patient care and ongoing medication-related information.  A high-
quality discharge summary is important to ensure that medication information is accurate 
and to a recognised standard to minimise errors and optimise on-going treatment.  Van 
Walraven and Rokosh (1999) found that the content of a discharge summary was more 
important than the process used to create it.  The definition of a high-quality or gold 
standard discharge summary in relation to medication has been defined to include 
accurate and relevant details such as the medicine name, dose, frequency, route, duration 
and reasons for changes in medication (SIGN, 2012; NICE, 2015b). 
 
However, the level of quality achieved in the final discharge summary may be influenced 
by a number of factors such as: the discharge template design (Hammad et al, 2014) or 
the training and competence of the person completing the discharge summary (Yemm et 
al, 2014). 
 
The traditional method of generating a hospital discharge summary is by hand.  These 
handwritten discharge summaries are often written by junior medical staff who may have 
little or no prior training or experience in producing the discharge summary (Yemm et al, 
2014; Legault et al, 2012).  Consequently, it has been found that discharge summaries 
they produced contain more errors compared to those produced by more experienced 
medical staff (MacAulay et al, 1996).  The concept of a ‘gold standard’ discharge summary 
has resulted in standards being published to define the minimum dataset that a discharge 
summary should contain in relation to medication (SIGN, 2012; Aziz et al, 2016).  In 2011, 
the European Union (EU) introduced a directive on the use of electronic discharge 
summaries to encourage improvements in communication and to reduce prescribing 
errors (EU, 2011).  Despite these official statements of standard setting and processes 
being advocated, there is still a lack of evidence that this is being put into everyday clinical 
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practice. Mills et al, (2016) have recently demonstrated the lack of effective 
implementation of electronic discharge summaries. 
 
This introduction will therefore provide some background to the issues regarding the risks 
and organisational problems associated with the transition and communication between 
hospitals and primary care in relation to medication-related information and harm.  It will 
also examine the discharge process and standards related to the content of a ‘gold 
standard’ discharge summary. 
 
 
1.1 Transfer or transition of care from hospital 
Whilst the numbers of episodes of care are increasing in hospital, there is a corresponding 
decrease in the duration or average length of stay.  This is in the context of fewer available 
hospital beds and the rising number of high-risk and elderly patients who require more 
frequent and complex care (Halasyamani et al, 2006).  An important responsibility for 
doctors is to ensure that patients are discharged from hospital care in a safe, timely and 
efficient manner to improve outcomes and safety.  Preen et al, (2005) identified that 
having a multidisciplinary discharge care plan improved the quality of life and experience 
with discharge for patients with long-term conditions.  It is well recognised that during a 
patient stay in hospital their medication may be changed, and a previous Audit 
Commission report and other publications have highlighted the need to pay attention to 
effective processes to safely manage medicines, particularly in the elderly at the point of 
discharge (Audit Commission, 2001; Duffin, 1998; McMillan et al, 2006; RPS, 2012).  To 
ensure safe and effective transfer of care, any changes in medication must be clearly 
communicated in a timely manner to the GP when a patient is discharged.  The CQC, 
(2009) undertook a survey of GP practices of discharge summaries received from hospitals 
and found that only 53% were received in time to be useful.  A further study carried out 
in GP practices found that 39% of the practices reported instances where late discharge 
summaries had directly compromised patient safety (NHS Alliance, 2007).  
 
 
1.2 Hospital discharge 
A patient will usually have been admitted to hospital for either an emergency or an 
elective procedure or treatment.  Once the patient is medically fit they will be ready for 
discharge.  The final discharge destination will depend upon the functional capacity of the 
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individual.  It will either be a transfer back home, to a community hospital or to a nursing 
or residential care setting and needs to be well planned and timely.  For optimal discharge 
it has been recommended that it is treated as a process and not an isolated event 
(Department of Health, 2003).  The discharge process should include the production and 
implementation of a discharge plan to support the transfer of care of a patient.  A few key 
principles for effective discharge and transfer of care have been recommended 
(Department of Health, 2003). 
 
These key principles include: 
• Effective discharge is facilitated by a ‘whole-system’ approach; 
• Discharge is a process and not a single event; and 
• The process of discharge planning should be co-ordinated by a named person who 
is responsible for co-ordinating all stages of the patient’s journey. 
 
It is anticipated if these and other key principles of effective discharge are carried out, 
there will be benefits for patients, carers, staff and organisations such as effective care 
and optimal use of resources.  The stages of effective discharge planning were described 
by Marks, (1994) and are shown in Table 1. 
 
Table 1:  Stages of a discharge plan (adapted from Marks, (1994)) 
Stage of patient journey Comment 
Preadmission Assessment carried out eg preadmission clinic 
Admission procedure Assessment of patient’s needs after hospitalisation 
Inpatient assessment and 
preparation for discharge 
Preparation of a discharge plan based on 
individual’s patient needs 
Discharge from hospital and 
implementation of a discharge 
plan 
Provision of transport and medicines including a 
discharge summary 
Post-discharge follow-up For example, audit of the implementation of the 
discharge plan such as a satisfaction survey for the 
patient or GP. 
 
 
A recent Cochrane review of hospital discharge planning has described the differences 
between an individualised discharge plan and routine discharge planning (Gonçalves‐
Bradley et al, 2016).  Randomised clinical trials that compared an individualised discharge 
plan with a routine discharge care plan that was not tailored to individual participants 
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were analysed.  Thirty trials involving 11,964 participants were included in the qualitative 
review.  There was evidence from 12 of these trials of a small reduction in hospital length 
of stay for patients allocated to discharge planning in trials recruiting elderly people 
following a medical admission (Mean Difference (MD) −0.73, 95% confidence interval (CI) 
−1.33 to −0.12 with a moderate certainty of evidence).  Also, there was found to be a 
reduced risk of readmission to hospital at three months’ follow-up for elderly people with 
a medical condition.  None of the trials reported in the review commented on the quality 
of communication in the discharge planning process, which is surprising. 
 
 
1.3 Timeliness of discharge 
The timing of discharge for patients can also be critical and may contribute to how 
effective the whole process is.  In 2016 the National Audit Office (NAO) reported its 
findings on discharging elderly patients from hospital.  It found that nearly two-thirds of 
hospital bed days are occupied by people over 65 years of age with an 18% rise in 
emergency admissions for elderly people in the previous four years.  It was also reported 
that 1.75 million hospital bed days were lost due to delayed transfers of care - so-called 
DTOC in 2015 (NAO, 2016).  A concerning aspect of unnecessary delay in discharging 
elderly patients from hospital is that it can lead to worse health outcomes and increase 
their long-term health needs.  Elderly people can quickly lose mobility and the ability to 
do simple everyday tasks.  It is estimated that 10 days of bed rest for healthy elderly 
people can equate to 10 years of muscle ageing.  This is termed ‘de-conditioning’ of a 
patient (Vernon, 2016; Gillis and MacDonald, 2005).  Hospitals need to have in place 
effective and timely discharge processes to ensure that delays in discharge are minimised.  
Issues that can reduce delays in discharge include the minimisation of waiting times for 
diagnostic tests, waiting for senior medical review to authorise discharge, waiting for 
transport and discharge medication and poor or inadequate discharge planning with lack 
of communication and co-ordination of discharge deadlines.  Clearly, there will also be 
external factors that delay discharge including lack of facilities for residential or nursing 
care, waiting for funding from social services and so on.  An important factor to reduce 
delays in discharge and ensure that the discharge is effective and efficient is having 




1.4 Completion of the discharge summary 
In the United Kingdom (UK) the preparation of a discharge summary is primarily the 
responsibility of junior doctors.  In 2009 a UK study reported that 90% of all discharge 
summary items were written by doctors in their first and second Foundation Years (FY) of 
training (Dornan et al, 2009).  This is in the context that the hospital consultant has overall 
responsibility for the care of the patient and the content of the discharge summary.  In 
practice this will rarely be checked by the consultant at the point of discharge.  However, 
a pharmacist usually carries out a final check or verification of the discharge prescription 
(Abdel-Qader et al, 2010). 
 
 
1.5  Types of hospital discharge 
It is recognised that there are two main types of discharge from hospital.  Most patients, 
about 80%, will be discharged after having a relatively straightforward discharge plan in 
place.  This will typically be for patients who are going home and have simple on-going 
care.  This is known as simple discharge.  The remaining 20% of patients who may be over 
the age of 65 years old will have more complex needs.  The discharge plan may need 
support from other health and social care workers and more specialist knowledge is 





Figure 1:  The discharge and transfer planning processes for simple and complex 
discharges 
 
Figure 1 shows the distinction in the pathway for a patient for the discharge and transfer 
planning process for both emergency and elective admissions dependent upon whether 
the discharge is complex or simple (adapted from Department of Health, 2010). 
 
There may be an implication on the type of discharge on the quality of discharge 
information in relation to the medication as patients with a complex discharge are more 
likely to be on more medicines, to have more changes to the medicines and been in 
hospital for a longer time.  Failure to follow the established best practice may result in 
unsafe patient discharge or delays in the transfer of care and this was identified in a recent 




The human costs of poorly planned discharge have been grouped into four key themes: 
• Patients discharged before they are clinically ready, resulting in emergency 
readmission and/or potentially avoidable death; 
• Patients discharged when they are clinically ready but without assessments and 
adequate support in place which result in emergency readmission and additional 
health problems; 
• Relatives and carers not being consulted in care planning; and 
• Patients who are medically fit but having to stay in hospital which can result in 
worsening health. 
 
One of the clear findings of the House of Commons report (2016) is that best practice 
guidance in patient discharge is not consistently implemented across healthcare 
providers.  In 2015 NICE published a clinical guideline ‘Transition between inpatient 
hospital settings and community or care home settings for adults with social care needs’ 
(NICE, 2015a).  This guideline provides best practice guidance to optimise the transfer of 
care or transition on discharge.  The overarching principles again include providing person 
centred care, having effective communication and sharing information.  This includes 
providing information on medication which is communicated on the discharge summary.  
It is, therefore, important that the format and content of a discharge summary is carefully 
considered to allow inclusion of all the necessary medication-related information to the 
next care provider and patient. 
 
 
1.6  Medicines Optimisation and Elderly People 
An important component of discharge for elderly patients is to optimise the use of 
medicines.  Medicines Optimisation aims to improve medicines use and has been defined 
as requiring “evidence-informed decision-making about medicines, involving effective 
patient engagement and professional collaboration to provide an individualised, person 
centred approach to medicines use within the available resources.” (Shah et al, 2014).  The 
decision and process of prescribing may be complex.  It will include the decision as to 
whether a medication is indicated, which agent to choose depending upon factors such 
as the patient’s condition, safety profile and cost.  The dose will then need to be chosen 
and dosing schedule appropriate for the patient’s condition.  Once prescribed the 
medication will need to be dispensed and the patient informed how to use the medication 
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to ensure maximum benefit.  The effectiveness and toxicity of the medication will need 
to be monitored and follow-up of any issues if necessary.  Prescribing for an elderly patient 
therefore provides further challenges.  Medicines are often not assessed in clinical trials 
in elderly patients and so the pharmacokinetic and pharmacodynamic profile of the 
medicine may not be known when first licensed for use.  Also, elderly patients are likely 
to have impaired ability to handle certain drugs for example impaired renal function 
reducing drug clearance or age-related decline in liver function which may affect 
variability on liver metabolism.  Elderly patients will often have multiple medicines 
prescribed - so-called polypharmacy. 
 
Polypharmacy is not necessarily wrong but if medicines are prescribed that are no longer 
appropriate then this can lead to problems.  The consequences of polypharmacy can 
mean that it puts an individual at increased risk of harm, contribute to hospital 
readmissions and poor therapeutic outcomes (Pirmohamed et al, 2004; Kongkaew et al, 
2013).  The elderly may be at increased risk of readmission due to an Adverse Drug 
Reaction (ADR), with 5% of 380 matched control elderly patients over the age of 65 
readmitted as an emergency admission within 28 days due to an ADR compared with 1.6% 
in a control group in Hong Kong (Chu and Pei, 1999).  Also, there is a risk of poor adherence 
in the elderly and it has also been found that in some cases that 50% of patients do not 
take their medicines as prescribed (Nunes et al, 2009; Marinker and Shaw, 2003).  So, the 
risk of medicines not being taken as prescribed is increased following discharge from 
hospital when new medicines have been prescribed. If the discharge summary is 
inaccurate this may compound the problem. 
 
Policies have been developed at national level to improve services to elderly people.  In 
2001 the UK National Service Framework for Older People was published providing some 
standards for care (Department of Health, 2000a) including a supporting document to the 
National Service Framework about the safe and effective use of medicines (Department 
of Health, 2001b).  This document focused on how medicine use could be improved for 
elderly patients which included having timely and effective discharge procedures.  A 
recommendation was made to provide full information to GPs and patients on medication 
at discharge including reasons why any changes that had been made.  Despite this, there 
was no clear statement to ensure that the transfer of care of an elderly patient is carried 




Knight et al, (2013) carried out a small qualitative study of 19 individuals over 75 years old 
taking four or more medicines following discharge from hospital in the UK.  Seventeen of 
the 19 elderly people in the study had some of their medications changed during their 
hospital stay.  The study clearly identified the need to involve the patient or carer more 
in the discharge process.  They found that patients would value clear and concise lists of 
prescribed medicines much like that which is contained within the discharge summary. 
 
 
1.6.1  Transition of care for elderly people 
Transfer of care takes place when responsibility for a patient’s care is passed from one 
professional, agency and/or location to another as their health and care needs change 
(Oboh, 2016).  Transition mainly occurs on the discharge from a hospital to community 
setting but can also occur during patient transfer between wards, to an intermediate care 
unit, back home and from the community into a hospital or care home.  Frail elderly 
patients are considered in this thesis as: they occupy 62% of hospital bed days in 2014-15 
(NAO, 2016), are often discharged into the community on more than one occasion, and 
take more medicines (Scholes et al, 2013).  The proportion of people aged 65 and over 
who were dispensed 10 or more medicines increased from 4.9% in 1995 to 17.2% in 2010 
(Wimmer et al, 2016).  This is important as complex medication regimens and 
polypharmacy in elderly patients may be predictors of mortality (Wimmer et al, 2016). 
 
 
1.7 Consequences of poor discharge 
A successful discharge for a patient will be measured by positive health outcomes, 
absence of readmission and the effectiveness of the communication of information to the 
next place of transition of care.  This information includes communication with the 
patient’s GP to facilitate ongoing management of the patient.  This is often the time, 
especially after an emergency admission, that changes have been made to the patient’s 
medication regimen and therefore medication-related incidents can occur.  It has been 
estimated from a national patient safety alert that there were in the region of 10,000 
reports made to the National Reporting and Learning System (NRLS) of patient safety 
incidents related to patient discharge from hospital each year (NHS England, 2014).  This 
was in part recognition of the complexity and multi-factorial nature when patients are 
transferred from either secondary care to primary, community or social care.  An issue 
identified was the risk at the point of transition of care of inadequate communication and 
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information.  In fact, poor communication accounted for 33% of the patient safety 
incidents reported.  It was identified that patients require high quality and timely transfer 
of essential information to reduce readmission and to have discharge medicines 
reconciliation (DMR) in place.  In the period 2003 to 2004 it was found that 19.6% of 
patients were readmitted to hospital within 30 days of discharge and 34% within 90 days 
of discharge in the United States of America (USA).  It was estimated that 10% of the 
readmissions were planned and the costs to the healthcare system significant (Jencks et 
al, 2009). 
 
In the UK, the CQC undertook a national study about managing patients’ medicines after 
discharge from hospital (CQC, 2009).  Two hundred and fifty GP practices were studied 
and only 27% reported the discharge summaries are “hardly ever” or “never” inaccurate 
or incomplete.  One of the main inaccuracies reported related to medicines that had been 
prescribed when the patient was discharged.  A total of 81% of practices reported that 
details of prescribed medicines were incomplete or inaccurate on discharge summaries 
“all of the time” or “most of the time”.  The implications are that a patient could be 
readmitted due to a failure to identify ADEs, medication non-adherence and medication 
discrepancies.  
 
In 2015 Healthwatch in England published a report ‘Safely Home: what happens when 
people leave hospital and care settings’ (Healthwatch, 2015).  The report related to the 
experience of over 3,200 people about their discharge and found that there were often 
delays and a lack of co-ordination between different services. 
 
One of the basic failings was of hospital staff not passing on details about medication to 
GPs. 
 
Hesselink et al, (2013) meanwhile examined the experiences and perceptions of patients, 
relatives and care providers at discharge based on one university and a related community 
care facility in the Netherlands about good handover.  The key finding was that continuity 
of care at discharge was not guaranteed.  Three main reasons for this were highlighted: 
the quality of information exchange; the coordination of care; and communication 
between hospital and community care providers.  Importantly hospital healthcare 
professionals were often unacquainted with the care provision in the community and the 
requirements for community staff in caring for patients after discharge.  Poor information 
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about medication was highlighted in the study.  This study provides a valuable insight into 
the need to consider not only the hospital information requirements but also those in the 
community which may be different.  A mutual understanding is required to appreciate the 
differing priorities at the point of transition of care and should be considered when 
designing a good quality discharge template and process. 
 
 
1.7.1 Adverse Drug Events (ADE) after discharge from hospital 
One of the consequences following hospital discharge is that the patient may suffer an 
ADE.  At the point of discharge there may be significant changes in medication that has 
been stopped, started or changed.  This is a time of high risk of discrepancies and poor 
communication in the provision of medication-related information (MRI).  It has been 
estimated that between 19% and 23% of patients suffer an ADE after discharge (Forster 
et al, 2003; Forster et al, 2004).  Forster and colleagues (2004) carried out a prospective 
study across a multi-site tertiary teaching hospital in Canada.  327 patients with an 
average age of 71 were assessed for the incidence, severity, preventability and 
ameliorability of adverse events when discharged with 23% of patients experiencing an 
adverse event.  The severity ranged from symptoms only in 65% of adverse events, to 
permanent disability in 3% and death in a further 3%.  The most common adverse events 
were medication-related (72%), with 6% experiencing preventable adverse events and 5% 
an ameliorable adverse event.  It was felt that the best method to reduce the likelihood 
of an ADE was to improve monitoring for medication side-effects after discharge, 
particularly in frail patients.  One method to overcome this was to improve 
communication with community care providers although there was no description on how 
this would be undertaken in practice.  Also, a small pilot retrospective observational study 
of 43 patients, followed up after hospital discharge, was carried out in an academic family 
medicine outpatient clinic by a pharmacist in the USA.  It found that 2.9 ADEs or 
preventable ADEs were identified in the cohort per patient.  The most common types of 
ADEs were non-adherence or underuse of medication (18%) and lack of therapeutic 
monitoring (13%) of medication.  It was felt that the lack of a complete and accurate 




1.7.2 Medication discrepancies on discharge from hospital 
A low-quality discharge summary may influence the occurrence of medication 
discrepancies post-discharge.  Wong et al, (2008) carried out a study in a tertiary care 
teaching hospital in Canada of 150 discharged patients.  They found that 106 (70.7%) 
patients had at least one unintentional medication discrepancy and a third of these had 
the potential to adversely affect patient safety.  The factors which influence discharge 
summary information include those that may be system related such as the design or 
template of the discharge summary content, whether the document used to transfer 
information is handwritten or electronic, the time available to document and 
communicate information, and whether the admission was planned or an emergency. 
 
At discharge there are reasons why the pre-admission medication may be different to 
those prescribed on discharge.  It is important to consider these reasons to try and reduce 
the likelihood of any discrepancies or omissions being continued after discharge.  The 
patient journey in relation to the review and prescribing of medication can provide a 




Figure 2:  The journey for a patient following admission showing where medication 
discrepancies may occur and their potential outcome 
 
Figure 2 shows the journey of a patient following admission, showing the points where 
there may be an intentional or unintentional difference between pre-admission 
medication and discharge medication leading to poor outcome to the patient eg 
medication-related harm.  
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On admission there may not be a comprehensive and accurate medication history 
undertaken - the so-called Admission Medicines Reconciliation (AMR).  There may be time 
constraints, patient language or health reasons, healthcare staff lacking medication-
history competency skills and so on.  There may be poor or limited access to sources of 
medication history information such as GP records, patients own medicines and 
community pharmacy records.  Often multiple healthcare professionals may, at various 
levels, undertake a medication-history and obtain conflicting information leading to 
discrepancies with no one single accountable person taking the lead.  During the inpatient 
episode of care there may be several changes to the patient’s medication regimen based 
on their health status and requirements.  The hospital may have its own prescribing 
formulary with a limited choice of medicines available.  This may force a change in the 
patient’s medication regimen.  Finally, at the point of discharge the medication prescribed 
or described on the discharge summary should be done in a careful and considered 
manner.  Medicines may have been withheld or substituted for valid clinical reasons 
during the inpatient episode but may need to be restarted on discharge eg a diuretic that 
was stopped due to dehydration on admission, which has now resolved, but may need to 
be restarted again to control the symptoms of congestive cardiac failure (Kripalani et al, 
2007a).  These issues can lead to a medication discrepancy on discharge.  In 1996 these 
discrepancies were classified in prescribing as either ‘intentional’ or ‘unintentional’.  
Unintentional discrepancies may be due to a breakdown in communication across the 
care setting whereas an intentional discrepancy is one that has been considered and not 
due to a process or communication failure (Duggan et al, 1996).  It is important to note 
that both types need to be carefully considered as even an intentional discrepancy poorly 
communicated can still lead to an ADE. 
 
Coleman et al, (2005) undertook an evaluation of post-hospital medication discrepancies 
based in a community hospital setting in USA.  A total of 375 study patients were reviewed 
who were over 65 years of age.  They found that 53 (14.1%) study patients experienced 
one or more medication discrepancies.  Of these 53 study patients 62% experienced a 
single discrepancy and 25% experienced two discrepancies with a mean number of 1.6 
discrepancies.  Interestingly, patients who experienced a discrepancy had more 
medications (mean number of medications, nine) compared with those who did not 
(mean number of medications, seven).  Also, patients who had congestive heart failure 
were significantly more likely to be associated with having a medication discrepancy.  A 
total of 14.3% of the patients who experienced medication discrepancy were readmitted 
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at 30 days compared with 6.1% who did not experience a medication discrepancy.  It is 
not stated if these readmissions were due to medication or just a causal relationship. 
 
In a separate study from a teaching hospital in New Zealand, an audit of written discharge 
summaries for 100 medical and 100 surgical patients discharged from hospital was carried 
out (McMillan et al, 2006).  The mean length of stay for both patient types was about 
seven days.  The medical patients were more likely to have changes to their medications 
during the admission (1.70 medicines 95% CI 0.38-0.80) compared with surgical patients 
(0.59 medicines 95% CI 7.40-8.64).  There were 0.81 (95% CI 0.65-1.02) errors per surgical 
patient summary and 1.42 (95% CI 1.20-1.67) errors per medical summary.  The most 
common error was the failure to list one or more of the medicines that the patient was 
taking.  A consensus panel was convened of doctors and a pharmacist to grade the 
severity of the error.  Most of the errors, 87.4%, were minor or potentially troublesome 
whereas 1.8% had a potential to cause readmission.  
 
A retrospective review of medication-information on discharge summaries found that 
most discrepancies originated at discharge and not earlier in the inpatient stay 
(Michaelson et al, 2017). 
 
The implications of failure to list a medicine and give a reason on the discharge summary 
include the patient and the GP believing that a medicine has been stopped when it has 
not.  Also, if a medicine is intentionally stopped on admission but this is not clear on the 
discharge summary and the GP restarts the medication because they believe it has been 
unintentionally omitted from the discharge summary.  In 2012 a Belgian study 
investigated discrepancies in medication-information on discharge for patients 65 years 
old or older.  Of 189 discharged patients 47.6% (90) had one or more discrepancies in 
medication information at discharge.  In this study 41.9% of the discrepancies had the 
potential to cause moderate harm.  They recommended that patients prescribed more 
than five medicines at discharge should be prioritised to prevent discrepancies (Cornu et 
al, 2012).  Whereas Miller et al, (2000) developed a hospital readmissions predictive 
model that identified that elderly people taking four or more medicines have an increased 
risk of suffering a hospital readmission.  There are therefore specific risks if the 
communication about medication at discharge is not effective and timely for elderly 




Grimes et al, (2011) carried out a study in Ireland to investigate the factors contributing 
to medicines reconciliation on discharge and to identify the prevalence of non-
reconciliation.  This was a cross-sectional observational survey using consecutive 
discharges from purposively selected services in two acute hospitals in Ireland.  Of the 
study population 9,569 medication orders for 1,245 episodes of care were surveyed.  55% 
were male and 77% were under a medical team.  The median age was 62 years old.  The 
highest discharge day was on a Friday (24%) and the least on a Sunday (3%) with the 
median length of stay of seven days.  The median number of medicines was six with 70% 
of patients on discharge experiencing polypharmacy.  They found that medication details 
documented at discharge frequently had prescribing writing errors or failed to 
communicate information regarding changes made during inpatient care.  For example, 
of 1,245 discharge summaries, 268 (21.5%) did not communicate that a medication had 
been stopped, 233 (18.7%) omitted an active medication at discharge, and 140 (11.2%) 
omitted a preadmission medicine.  This was also the first study to provide evidence of the 
association between medication type and non-reconciliation.  There was a greater 
tendency for omission on discharge of endocrine, central nervous system, nutrition and 
blood and ‘other ‘medicines whilst those patients discharged using a handwritten 
discharge summary were more likely to experience non-reconciliation. 
 
 
1.8 Quality improvement initiatives to reduce hospital readmission 
The high rate of hospital readmissions related to ADEs and medication discrepancies has 
promoted the adoption of quality improvement initiatives to reduce the likelihood of 
readmission.  An important guide to reduce risk and readmission in relation to medicines 
was produced in 2005 called ‘Moving patients safely’ produced by the Royal 
Pharmaceutical Society (RPS) of Great Britain in collaboration with the Guild of Hospital 
Pharmacists, The Pharmaceutical Services Negotiating Committee and the Primary Care 
Pharmacy Association (RPS, 2005). 
 
This extensive resource noted that medicines that patients received at discharge fell into 
several broad groups, namely: 
1. Regular medicines started before the hospital admission. 
2. Replacement of regular medicines because of changes to routine prescription 
whilst in hospital and additional regular medicines, that is, those that have been 
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added during the hospital stay and will be required as an ongoing treatment on 
discharge. 
3. Short term medicines directly related to their hospital stay eg antibiotics, pain 
relief medication and not required for long term use. 
 
The guidance recommended that protocols should be in place to ensure that information 
received at discharge be handled in a way that ensures it is acted upon in an appropriate 
manner by the GP (or the community pharmacy).  However, in terms of the quality of 
information related to medicines, the only recommendation to communicate to the GP 
was related to justifying medication changes on discharge including omission, addition 
and rationalisation. 
 
Mandatory documentation for medication-information at discharge is an initiative that 
has been introduced in the USA by the Joint Commission on Accreditation of Healthcare 
Organisations (JCAHO).  A medication reconciliation process that requires a patient’s 
discharge medication to be compared with previous home medicines and differences 
reconciled should be carried out and a discharge summary completed within 30 days 
(Sentinel Event Alert, 2006).  Despite these initiatives there has been a paucity of evidence 
about the relationship or benefits between such mandatory requirements and 
readmission.  Data from patients discharged from hospitals in the USA in 2007 that 
examined hospital performance on two measures of discharge planning namely: the 
adequacy of documentation on the chart that discharge instructions were provided to 
patients with congestive heart failure and patient-reported experiences with discharge 
planning and readmission with congestive heart failure and pneumonia found no or little 
association with readmission (Jha et al, 2009). 
 
A systematic review in 2007 attempted to identify the types and prevalence of 
deficiencies in relation to communication and information transfer between the hospital 
and the primary care physician as well as the efficacy of interventions undertaken to 
improve this process (Kripalani et al, 2007b).  They found that there were deficits in 
communication and information transfer at hospital discharge which adversely affected 
patient care with between 2% and 40% of medicines omitted from the discharge 
summary.  Interventions such as the use of computer-generated summaries and 
standardised formats may improve timely transfer of information to the care provider on 
discharge.  A recommendation was made to include details of the reconciled discharge 
33 
 
medication regimen with reasons for both any changes made and the indications for 
newly prescribed medications.  A further study in the USA was undertaken to consider the 
effectiveness of different components of the discharge process including medicines on 
reducing hospital readmission.  This was a case-control study of 1,039 patients who had 
experienced readmission within 30 days of discharge and 981 non-hospitalised patients 
who were matched for admission diagnosis and severity of illness amongst others in 34 
hospitals (Hansen et al, 2011).  The study failed to identify any relationship between 
readmission and most of the components of the discharge process.  This included no 
association between readmission and documentation of medication reconciliation.  There 
was a small (2%) increase in readmission risk for each additional medication present upon 
discharge while accounting for severity of illness.  A potential reason for the lack of 
correlation with mandatory discharge processes and readmission within 30 days is that 
the quality of discharge may have been poor despite documented as being complete.  
However, despite the paucity of strong outcome data the adoption of medicines 
reconciliation processes has continued in the USA (Kripalani et al, 2007a). 
 
 
1.8.1 Standardised discharge summaries 
To improve the quality of discharge communication and information it is important to 
measure or audit practice against standards.  Standards for discharge have been described 
previously and many nationally recognised resources have been advocated for adoption.  
Recently an audit of discharges was carried out using the National Prescribing Centre 
(NPC) minimum dataset standards for discharge published in 2008 (Hammad et al, 2014).  
The audit was undertaken in the UK of 3,444 discharge summaries received by medical 
practices of patients who had been hospitalised for 24 hours or longer.  Patients had been 
discharged from two teaching hospitals and three district hospitals.  Unplanned 
admissions accounted for 63% of the audit sample and 74.6% of discharge summaries 
were electronic.  The median patient age was 66 with patients on a median number of 
medicines of five (range 2-8) and four days’ median length of stay.  The mean (95% CI) 
discharge summary adherence to the NPC minimum dataset was 71.7%.  Electronic 
discharge summaries demonstrated higher adherence than handwritten summaries.  
Discharge summary information of therapy that had been changed gave the lowest 
adherence of 48.9%.  The rationale for medicines initiated, discontinued or changed was 
persistently omitted.  Interestingly there was a considerable variation between hospitals 
in adherence with the minimum dataset.  This suggested that the use of a standardised 
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discharge summary may provide better quality discharge information as recommended in 
the national contract to avoid variation in the type of information given to primary care 
(NHS England, 2017).  A main limitation of this worthwhile study was that the NPC 
minimum dataset standards were not mandatory.  There was therefore no mandate for 
hospitals to adhere to the guidance. 
 
More recently Shah et al, (2016) have carried out a collaborative audit across England on 
the quality of discharge medication-related information provided when transferring 
patients from secondary care to primary care.  The audit standards were based upon 
those published by the Royal Pharmaceutical Society (RPS, 2012) and the Academy of 
Medical Royal Colleges medicine records on discharge (HSCIC, 2013).  1,454 discharge 
summaries were audited with 10,038 medicines prescribed across all discharge 
summaries which involved 159 hospitals.  The median age of patients was 72 years old 
and 47% were male.  The median length of inpatient stay was four days and 78.6% 
patients had an unplanned admission to hospital.  Allergy status documentation was 
identified as a high priority indicator of the quality of the discharge summary due to the 
recent NICE guidance published on drug allergy (NICE, 2014).  In terms of adherence to 
the RPS standards there was variability in the results obtained.  Only 11.7% of the 
prescriptions had the indication stated on the discharge summary whilst 60.3% and 72.5% 
had formulation and instruction of on-going use/supply stated respectively.  These results 
may have reflected lack of consistency with the discharge templates used.  Only 49% of 
medicines had a reason documented of why the medication had been commenced 
although some of this may, in part, have been because the medicine commenced did not 
need to be continued by the GP.  Similarly, only 57% of medicines had a reason 
documented of why the medicine was being stopped.  The study also identified that 1,565 
medicines were omitted which equates to a mean of 1.1 medicines omitted per discharge 
summary which may indicate poor or lack of medicines reconciliation on admission.  Of 
477 medicines that had a dose change, only 39% had a reason documented of why the 
dose had changed.  Interestingly only 49% of the discharge summaries had been screened 
by a pharmacist and 72% were delivered to the GP electronically.  
 
 
1.8.2 Method of transmission of discharge summaries 
The method and mode of transmission of the discharge summary may play a role in 
determining the quality and safety of the transition of care.  There has been a move 
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towards the adoption of either producing an electronic discharge summary as a 
standalone document or via a hospital electronic prescribing and medicines 
administration (HEPMA) system in part to reduce medication discrepancies and improve 
the quality and timeliness of discharge information. 
 
Mills et al, (2016) undertook a narrative literature review of hospital discharge 
information and prescribing errors primarily on HEPMA or other electronic 
implementation schemes from 2000 to 2014.  The review focused on the UK and other 
similar healthcare systems including Australia, Canada, Ireland and New Zealand.  Fifteen 
studies were reviewed and composed of eight studies from the UK, five from Australia, 
one from New Zealand and one from Ireland.  Many study designs and methods were 
used with the predominant type being a retrospective study in nine cases and six surveys.  
The review split the studies found into three groups to allow comparison and demonstrate 
the evolution of the discharge communication method over time.  Six studies investigated 
a handwritten, paper communication system.  Medicine information errors were found 
to be reported in up to 66% cases on discharge.  Four studies compared handwritten with 
electronic discharge summaries and had variable results.  Two studies found that if an 
electronic discharge was employed there was an improvement in compliance with 
information documentation of up to 82%, whereas the other studies found that there was 
an average error rate of 1.5 errors per patient with paper compared with 1.4 with 
electronic discharge summaries.  Finally, five studies evaluated electronic discharge 
summaries and found that electronic systems had an error rate of 8.4% of prescribed 
items.  The review highlighted the lack of literature that evaluates the HEPMA systems 
impact on communication of discharge information. In a further study by the same 
authors they found that the implementation of HEPMA improved hospital staff views of 
patient safety improvement initiatives (Mills et al, 2017a). 
 
 
1.8.3 Other factors 
The quality of the discharge summary may also be affected by other factors such as: 
whether a pharmacist was involved in the production and verification of the discharge 
summary, the extent of training and competency of the prescriber, the complexity of the 





1.8.4 Structured discharge care plans and Medicines Reconciliation  
Key initiatives to reduce the consequences of poor quality discharge related to medicines 
include the use of structured care plans and medicines reconciliation.  In Sweden, 
Bergkvist et al (2009) studied elderly patients (65 years or over) discharged from hospital 
where pharmacists had created a systematic medication care plan for each patient that 
was continually updated during the inpatient episode.  When the doctor completed the 
discharge summary, including the medication list, the pharmacist evaluated the 
document according to a checklist utilising the care plan and other records.  Any 
information that was omitted or incorrect was discussed with the doctor prior to 
discharge.  In so doing there were on average 45% fewer medication errors per patient 
on discharge and so improved the quality of transition of care.  In Germany the use of a 
structured medication report as part of the discharge summary improved adherence in 
stroke patients to hospital discharge medication (Hohmann et al, 2014).  Similarly, Midlöv 
et al, (2008) found that the use of a medication report reduced the number of medication 
errors when elderly patients were discharged from hospital in Sweden. 
 
Moreover, in many countries including the USA and England the process of medicines 
reconciliation has been advocated as a quality improvement measure to decrease 
medication errors on discharge and improve transition of care (Sentinel Event Alert, 2006; 
NICE - Clinical Guideline 5, 2015b).  The process of medicines reconciliation (MR) has been 
defined by the Institute for Healthcare Improvement (IHI) as the process of identifying an 
accurate list of a patient’s current medicines and comparing them with the list in use in 
the admission, transfer and/or discharge process, recognising any discrepancies and 
documenting any changes thereby resulting in a complete list of medicines accurately 
documented (IHI, 2017). 
 
MR can, therefore, be carried out at different points in a patient’s journey (NICE, 2015b): 
• In an acute setting - ideally within 24 hours or sooner of admission to hospital. 
• On transfer between wards - this may be necessary for patients on complex 
regimens and/or when new drug charts are re-written. 
• In primary care - medicines reconciliation should be carried out for all people who 
have been discharged from hospital.  This should occur as soon as possible after 
discharge and ideally before a new prescription or new supply of medicines is 




The process or service of carrying out MR is now considered to be a key performance 
indicator for chief pharmacists in hospitals in England as part of increasing the patient 
facing activity of pharmacy staff and to improve patient safety (Carter, 2016).  Hitherto 
the focus for pharmacy services in the UK has been on undertaking MR at admission to 
hospital, ideally within 24 hours of admission (Dodds, 2014).  However, increasingly there 
is a need to have more robust and systematic processes to ensure MR is undertaken not 
only during admission, inter-ward transfer but also after discharge from hospital - so-
called discharge medicines reconciliation (DMR).  When patients transition from hospital 
to primary care the medication regimen often changes either intentionally or 
unintentionally.  There is a risk of some patients being affected and so it is mandated in 
the USA (Sentinel Event Alert, 2006) and in Canada (Accreditation Canada, 2010).  
Interestingly in Canada part of the mandate includes process and evidence that two lists 
are compared of medicines listed prior to transfer with the list of new medication ordered 
at transfer.  Also, that any differences have been identified, discussed and resolved.  The 
actual evidence base for the effectiveness of MR alone is not strong.  A systematic review 
by Kwan et al, (2013) of 18 studies found that most unintentional medication 
discrepancies had no clinical significance and critically that MR alone probably does not 
reduce post discharge hospital readmission.  One of the reasons postulated for this was 
that many studies have not considered the long-term outcome of MR greater than 30 days 
post-discharge.  What is clear, however, is that pharmacists play a pivotal role in the MR 
studies to reduce risks (Kwan et al, 2013). 
 
Chhabra et al, (2012) also undertook a systematic review of studies evaluating MR 
interventions in patients transferred to and from long-term care settings.  Despite this 
being the focus of the review there was limited evidence of the value of MR as an 
intervention as the studies included in the review had flaws - although there was still 
evidence of the value of input of a pharmacist in the process. 
 
A primary care perspective of the value of MR after discharge was described by Avery et 
al, (2012).  This study investigated the prevalence and causes of prescribing errors in 
general practice the so-called ‘PRACtiCE study’ (Prevalence and Causes of prescribing 
errors on general practice).  In sub-analysis thirty-seven patients who had at least one 
hospital discharge during a 12-month retrospective review of their medical records from 
different areas in England were identified.  56.8% patients were female; the median 
number of medicines on discharge was seven.  In 36 (97%) patients there was a difference 
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between the medications the patient was taking before admission and those listed on the 
discharge summary.  The median number of days it took the GP practice to record on the 
practice computer the medications the patient was taking at the time of discharge was 
less than one day.  Of greater concern was that for 92% (80/87) of newly prescribed 
medicines in hospital the discharge communication did not specifically highlight 
medicines that had been newly prescribed and there were no cases where the discharge 
communication specifically highlighted changes in dose for medicines that patients were 
taking before admission.  Of 87 medicines newly prescribed by the hospital, 24 (28%) were 
either not continued or there was some discrepancy between the prescribing advice of 
the hospital and the subsequent prescription.  Of 26 medicines that patients were taking 
before hospital admission where the hospital suggested a change in dose, this designated 
dose change was not made by the GP practice in nine (35%) of cases.  Interestingly, a few 
GPs identified a need for any medication change to be made immediately obvious to them 
eg highlighted in bold type or in capital letters or clearly marked.  There was clearly a lack 
of effective integration of information on the hospital discharge summary and input into 
the GP practice prescribing record system. 
 
 
1.8.5 Format and content of a discharge summary 
The current NHS standard contract service conditions state that the provider ie hospital 
must comply with the transfer of and discharge from care protocols (NHS England, 2017).  
This means that the hospital must, within 24 hours following the transfer or discharge, 
issue a discharge summary to the patient’s GP using an applicable delivery method.  There 
is guidance where a patient has a clinical need for medication to be supplied on discharge 
that the patient has an adequate quantity of that medication to last for the period 
required by local practice and protocols (but at least seven days) or for a shorter period 
whichever is clinically appropriate.  The national NHS contract does not specify the 
content of a discharge summary.  However, it does recommend using or being consistent 
with clinical headings recommended by the Health and Social Care Information Centre 
(HSCIC) and more recently the Professional Records Standards Body (PRSB) and Academy 
of Medical Royal Colleges (HSCIC, 2013; PRSB, 2017). 
 
The format of the discharge summary has historically been a document that has been 
implemented locally.  The function of the discharge summary is to provide the GP with an 
accurate narrative of the patient’s episode of care.  The GP (or next care provider) will 
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invariably rely on the discharge summary documenting any changes in the patient’s 
regular medication regimen.  Additionally, information will be included on what has 
happened during the patient’s stay and what is recommended or expected once they have 
been discharged. 
 
The recently published PRSB standards (PRSB, 2017) are based on those previously 
recommended by the Health and Social Care Information Centre and Academy of Medical 
Royal Colleges published in 2013.  These standards for the clinical structure and content 
of patient records are a wide-reaching resource that covers standards for patient records 
such as hospital referral letters, inpatient clerking, handover communications, discharge 
summaries and outpatient letters.  The standards were published after a review of 
evidence and consultation with relevant stakeholders including doctors, patients, nurses 
and allied healthcare professionals.  The standards consist of a list of clinical record 
headings and a description of the information that should be recorded under each 
heading.  The discharge record or summary headings is comprehensive and detailed to 
include details such as: GP practice, referral details, patient demographics, social context, 
special requirements, admission details, discharge details, clinical details, procedures, 
clinical summary, safety alerts, medication and medical devices, allergies and adverse 
reaction details, investigations and procedures requested, patient and carer concerns, 
information and advice given, plans and requested actions, person completing record and 
distribution list.  
 
The elements and description for some of the medications, medical devices, allergies and 




Table 2:  Selected Elements for the standards for discharge 
Medications and medical devices 
Element Clinical description 
Medication name May be generic name or brand name (as appropriate). 
Medication form eg capsule, drops, tablet, lotion etc. 
Route Medication administration description (oral, IM, IV, etc): may 
include method of administration (eg by infusion, via 
nebuliser, via NG tube) and/or site of use (eg ‘to wound’, ‘to 
left eye’, etc). 
Dose This is a record of the total amount of the active ingredient(s) 
to be given at each administration.  It should include, eg units 
of measurement, number of tablets, volume/concentration of 
liquid, number of drops, etc. 
Medication 
frequency  
Frequency of taking or administration of the therapeutic 
agent or medication.  
Element Clinical description 
Additional 
instructions  
Allows for:  
• requirements for adherence support, eg compliance 
aids, prompts and packaging requirements  
• additional information about specific medicines, eg 
where specific brand required 
• patient requirements, eg unable to swallow tablets. 
Course status Details of the overall course of medication 
Indication for 
medication 
Reason for medication being prescribed, where known. 
Medication 
recommendations  
Suggestions about duration and/or review, ongoing 
monitoring requirements, advice recommendations on 
starting, discontinuing or changing medication. 
Medication 
discontinued 
The name of the medication to be discontinued. 
Reason for 
medication change  
Reason for change in medication, eg sub-therapeutic dose, 
patient intolerant.  
Medical devices  The record of dietary supplements, dressings and equipment 




Allergies and adverse reaction 
Element Clinical description 
Causative agent The agent such as food, drug or substances that has caused or 
may cause an allergy, intolerance or adverse reaction in this 
patient. 
Description of the 
reaction 
A description of the manifestation of the allergic or adverse 
reaction experienced by the patient.  This may include: 
• manifestation, eg skin rash 
• type of reaction (allergic, adverse, intolerance) 
• severity of the reaction  
• certainty  
• evidence (eg results of investigations). 
 
 
However, in addition to this, other organisations have published their own guidance or 
recommendations, particularly in relation to the details about medication on discharge.  
In 2012 the Royal Pharmaceutical Society published the final good practice guidance for 
healthcare professions related to the medication component of the discharge or transfer 
process called ‘Keeping patients safe when they transfer between care providers - getting 
the medicines right’ (RPS, 2012).  This guidance was also endorsed by the Academy of 
Medical Royal Colleges, Royal College of General Practitioners, Royal College of Nursing 
and Royal College of Physicians.  Core principles have been laid out to support the safe 
transfer of information about medicines whenever a patient transfers care provider.  The 
four core principles are that: 
 
1. Healthcare professionals transferring a patient should ensure that all the 
necessary information about the patient’s medication is accurately recorded and 
transferred with the patient and that responsibility for on-going prescribing is 
clear. 
2. When taking over the care of a patient there should be a check that information 
about the patient’s medication has been accurately received, recorded and acted 
upon. 
3. Patients should be encouraged to be active partners in managing their own 
medicines. 
4. Information should be communicated in a way that is timely, clear, and 




The recommended core content of records for medicines when patients transfer care 
providers is broadly consistent with the PRSB for medical records on discharge.  In 
Scotland, the Scottish Intercollegiate Guidelines Network (SIGN) published a minimum 
dataset standard for the immediate discharge summary in 1996.  This was subsequently 
revised and updated in 2003.  It was recognised that with the development of electronic 
documents and the increasing use of MR processes that a further revision was needed 
and was put in place in 2012 (SIGN, 2012). 
 
A similar resource for defining a national standard for patient discharge summary 
information was published from Ireland.  The Health Information and Quality Authority 
(HIQA) published a standard in 2013 (HIQA, 2013).  The scope of the standard provides a 
full picture for the patient’s GP of the inpatient stay including patient details, admission 
and discharge details, clinical course during the inpatient stay, changes to medication 
including a full list of medication, treatment plan and discharging details.  The standard 
was developed by the Health Standards Advisory Group and other stakeholders.  A study 
that considered adherence with this standard for discharge was that carried out by Aziz 
et al, (2016).  A retrospective audit of 198 randomly selected discharge summaries was 
conducted at a single hospital in Ireland.  The median age of inpatients was 63 years old 
with 50.3% male.  The mean number of medicines per patient at discharge was 8.9.  A 
total of 1,683 medications were prescribed at discharge from both medical and surgical 
patients.  Variable results were observed with adherence to the standard.  Only 17.7% 
had a documented change on the discharge summary with overall compliance with all 
medication criteria only 18.9%.  The generic drug name used (40.2%), dose indicated 
(41.8%) and frequency of administration (41.3%) were the next worst adherence scores.  
Interestingly, a mandatory directive was approved in Australia in 2013 for the adoption of 
a uniform approach in providing electronic patient information to a patient’s national 
electronic health record where the patient has one (SA Health, 2013).  This is still being 
implemented but it provides evidence of how to implement a national standard. 
 
Also, the National Institute for Health and Care Excellence (NICE) published National 
Guideline 5: Medicines Optimisation in 2015.  This guidance builds on the Royal 
Pharmaceutical Society guidance on transfer of care guidance (NICE, 2015b).  The 
guidance is a comprehensive resource and covers safe and effective use of medicines in 
health and social care.  It aims to ensure that medicines provide the greatest possible 
benefit to people by encouraging medicines reconciliation, medication review and the use 
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of patient decision aids.  One section of the guideline is devoted to medicine-related 
communication systems when patients move from one care setting to another.  This 
guidance replaced the recommendation in NICE Clinical Guideline 76: - Medicines 
Adherence (NICE, 2009).  NICE Clinical Guideline 5 is an important resource and states 
some principles for best practice as indicated below: 
 
• Complete and accurate information about the person’s medication is shared. 
• The new care provider receives the information and documents the information 
and acts on it. 
• The complete and accurate information should be proactively shared ideally 
within 24 hours of the person being transferred and in the most effective and 
secure way. 
 
In addition, the guideline specifies a minimum dataset about the patient and their 
medicines when there is a transfer from one care setting to another. 
 
There are therefore several sources of officially endorsed standards for the content of a 
discharge summary.  A comparison of the recommended information is illustrated in Table 
3.  This indicates the recommendations for standards from the Royal Pharmaceutical 
Society (RPS, 2012), the Professional Standards Record Board and Academy of Medical 
Royal Colleges (PRSB, 2017), SIGN, 2012; HIQA, 2013, NICE, 2015b and the electronic 
prescribing and medicines administration functional specification for NHS Trusts 2007 (e-
prescribing toolkit, 2007).  It can be observed that there is some degree of consistency in 
the standards for content of a discharge summary in relation to medication-related issues.  
However, none of the practice guidance has mandatory status or provide an evidence-
base for their validity to clinical practice.  It is therefore up to the local health services to 
define, design and implement a discharge record which then leads to lack of consistency 
across healthcare providers.  Increasingly, this process also involves the implementation 




Table 3:  Recommendations for the core content of records for medicines when patients 
transfer between care providers 














Patient details ✓ ✓ ✓ ✓ ✓ ✓ 














✓ ✓ ✓ ✓ ✓  
Dose ✓ ✓ ✓ ✓ ✓ ✓ 
Formulation ✓ ✓ ✓  ✓ ✓ 
Dose strength ✓ ✓ ✓  ✓ ✓ 
Dose 
frequency/time 
✓ ✓ ✓ ✓ ✓ ✓ 
Route ✓ ✓ ✓  ✓  
Duration of 
treatment (stop 
date or review) 
 ✓ ✓ ✓ ✓ ✓ 
Number of days 
of supply 




✓ ✓ ✓ ✓ ✓ ✓ 
Aids to 
compliance 
 ✓ ✓ ✓  ✓ 
Allergies and 
conditions 
✓ ✓ ✓ ✓ ✓ ✓ 
 
 
Additionally, there have also been other international guidelines that have been 
advocated to improve the transfer of medication-related information.  In Holland the 
healthcare inspectorate published a policy document that included six key criteria 
including actual medication and reasons for changes in the medication (Uitvlugt et al, 
2017).  In Australia the Australian Pharmaceutical Advisory Council (APAC) published 





1.9 The process of medication supply at discharge  
When a patient is discharged from hospital there is an expectation that a discharge 
summary is produced for the patient, the GP and a record for the hospital.  
 
In 2003 the Department of Health published best practice guidance on discharge from 
hospital considering the pathway, process and practice in the form of a workbook.  This 
guidance was based upon the Hospital Discharge workbook first published in 1994 
(Department of Health, 2003). 
 
It recognises that often a patient’s familiar medication pattern will be changed in hospital 
and it is important that the patient and/or their carer understand the rationale for the 
medication regimen.  In addition, the patient’s GP needs to have up-to-date information, 
so they can continue the medication plan when the patient is home.  Elderly people often 
have more complex requirements at the point of transfer of care and as part of 
communication and information-sharing a designated person should be in place to 
provide details of who to contact about medication problems that occur in the first 24 
hours after discharge (NICE, 2015a).   
 
A recommendation has been made for hospital pharmacists to write discharge letters on 
medicines giving full medication profiles and details of changes during the patient’s 
hospital stay (Department of Health, 2003). 
 
 
1.9.1 Description of current discharge processes for medication 
As previously described the type of discharge can be simple or complex.  In some cases, 
the patient discharge will be relatively straightforward.  This is often the case for patients 
who have an elective admission with a short length of stay and minimal medication 
changes.  However, for more complex discharges the process can be difficult and the full 
process is outside the scope of this thesis.  However, in relation to medication the process 
involves a combination of the generation of an accurate and timely discharge summary 
and the need to ensure the patient has sufficient supply of medication in an appropriate 
format either with them or at the next place of care that has been verified for accuracy. 
 
The discharge summary will have a section that includes directions for medication at 
discharge commonly referred to as ‘To Take Out’ (TTO) or ‘To Take Away’ (TTA) to be 
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completed.  If the patient has been in hospital, usually for greater than 48 hours, there is 
usually a requirement to provide a complete and accurate list of all medication the patient 
should take from hospital as well as details of medication that has been stopped on 
admission.  The process of generating a TTA is usually the responsibility of a junior doctor 
either by hand or preferably using an electronic system.  This TTA may well then be 
checked for accuracy or verified by a pharmacist.  It is recognised that there will be 
occasions when this verification by a pharmacist does not occur as pharmacy departments 
do not routinely provide a 24-hour service, seven days a week.  Part of the verification 
process will be to confirm if the patient has their own medication either in hospital with 
them or at home.  These are often referred to as ‘Patients Own Drugs’ or PODs.  The 
checking of supply means that there is avoidance of duplication of medication and reduce 
potential for confusion and medication error.  Also, there will be financial benefits of not 
oversupplying medication.  The pharmacist or ward-based pharmacy technician will also 
ensure that the patient is discharged on the optimal system for medicines adherence eg 
multi-compartment device.  If medication is required, then this will be dispensed by 
pharmacy staff either remotely on the ward or in the dispensary.  When the TTA is 
complete the discharging nurse will check the medication supplied against the final 
version of the electronic discharge summary.  This provides an opportunity to inform the 
patient (and carer) of any details in relation to medication prior to discharge.  The patient 
will be given a hard copy of the discharge summary. 
 
Transition of care to the community requires information being sent to the GP within 24 
hours of discharge.  This information includes details on the TTA of medication which is 
part of the discharge summary and allow the patient’s GP to be aware of the on-going 
care requirements (BMA, 2014).  This discharge process is often fraught with problems.  
It can be time consuming, especially if it is a complex discharge involving many medicines 
with complex regimens often dispensed in a multi-compartment device.  This can, in some 
cases, delay discharge due to poor discharge planning being carried out in advance of the 
actual discharge (Gross, 2001), and adversely affect the patient experience of discharge 
(Wright, 2017). 
 
Bullock et al, (2017) have evaluated the hospital discharge process from the perspective 
of medication-related issues.  The evaluation consisted of carrying out a semi-structured 
interview with 13 Senior Pharmacists in England.  This qualitative study identified that all 
the hospitals used electronic discharge summaries.  An electronic discharge summary 
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process allows hospitals to send information to the GP within the target of 24 hours.  
Several common themes were identified in the discharge process related to medication 
such as a lack of staff training on patient discharge and poor communication between 
hospital and community pharmacists.  This will be explored more, later in the discussion. 
 
 
1.9.2 Current discharge policies and processes at the study site 
The Ipswich Hospital NHS Trust (IHT) is a 550-bed acute hospital with integrated 
community units.  These community units provide intermediate and rehabilitation 
services located in Ipswich and East Suffolk in England. 
 
The acute hospital serves a local population of approximately 380,000 people for Ipswich 
and East Suffolk and provides a full range of services for both medical and surgical 
specialities, emergency department, critical care, paediatrics, care of the elderly, 
oncology and maternity services.   
 
 
1.9.3 The local standard contract for discharge 
The commissioning of services between IHT and Ipswich and East Suffolk Clinical 
Commissioning Group (CCG) includes a requirement to provide a high level of quality of 
discharge summaries (Anon, 2016). 
 
At IHT most of the discharge summaries are generated electronically using the Evolve® 
system, a commercially available medical document management system.  The electronic 
discharge summaries generated are then transmitted by email to the patient’s GP within 
24 hours of discharge. 
 
The Evolve® electronic discharge summary is composed of a clinical narrative detailing the 
patient’s inpatient stay with relevant clinical information such as: 
1. details of any operations and diagnostic procedures performed and their 
outcomes, and 
2. a summary of the key, confirmed, and tentative diagnosis made during the 




In addition, there are some details regarding the patient’s medication that are part of the 
patient’s electronic discharge summary namely (NHS Digital, 2016): 
(a) details of any medication prescribed at the patient’s discharge to include the 
number of days given, type and dosage. 
(b) details of medications stopped, changed, started with the reasons for change. 
(c) any details of adverse reactions or allergies to prescribed medicines that were 
observed during admission. 
 
These statements effectively define the local standard from a contractual point of view of 
what an ideal discharge summary should contain when sent to the patient’s GP on 
discharge as required by the CCG. 
 
 
1.9.4 The generation of the Evolve electronic discharge summary 
Generation of an electronic discharge summary is usually undertaken by junior medical 
staff under the supervision of a more senior member of the medical team.  At the study 
hospital it is known that the discharge summary is usually generated on the day of 
discharge in up to 95% of cases so there is often a need to complete the discharge 





Figure 3: The process for generating an Evolve® electronic discharge summary. 
 
Figure 3 illustrates the process for a junior doctor to produce a discharge summary 
indicating the different requirements for medicines depending if the admission is > or<48 
hours duration.  This requirement is specified within the NHS standard contract between 
the hospital and local CCG (Anon, 2016). 
 
In relation to medication there are free text boxes on Evolve® for doctors (or pharmacists) 
to note any changes to regular medication, any allergies or adverse drug effects or 
medication aids for discharge.  These are not mandatory fields.  The next step is to 
acknowledge if the patient’s stay is greater than or less than 48 hours.  If the stay is greater 
than 48 hours, then it is a requirement to list all the medication whether it is new or 
existing.   
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If the length of stay is less than 48 hours then the requirement is to list all new, stopped 
or changed medication only or indicate there is no change in medication.  Also, if the 
patient does not take any medication at all then this should be indicated on the discharge 
summary.  The next step of the Evolve® electronic summary production involves a drop-
down menu or fields for the doctor to type in or choose several different components.  
The first field requires the doctor to choose the medication.  A drop-down choice of pre-
defined medicines will appear to decide which preparation to select after typing in the 
first three letters of the medicine eg typing asp… will allow aspirin to be chosen.  There is 
then a choice for the prescriber to indicate whether the medication is unchanged, 
changed, stopped or new.  If the new statement is chosen, the prescriber is required to 
specify the indication of the new medicine.  The next field to complete in order are to 
specify the dose, route (a drop-down choice of options appear), frequency (a drop-down 
choice of options appear).  The prescriber is then required to specify whether the 
medication is required long term, as required or for a specific course.  If the medication is 
for a specific course, then the prescriber will need to specify the details of the course.  
This is then repeated for all the medications required upon discharge.  Finally, the 
prescriber is asked to specify if the patient has been informed of any side-effects of new 
medicines.  Once the doctor has completed the electronic discharge prescription it is the 
responsibility of a pharmacist to clinically screen and verify the prescription prior to 
discharge.  The pharmacist will check the patient’s inpatient medication chart and cross-
reference this to the electronic discharge summary.  The pharmacist will also undertake a 
clinical screen of the discharge summary checking aspects such as: appropriate doses, 
routes, frequency and drug interactions, dosing in renal failure, formulations required and 
so on.  A key component of this clinical screen is to identify any unintentional 
discrepancies to ensure there is accurate reconciliation on discharge between the 
inpatient medication chart and the final discharge summary that is clinically appropriate.  
The pharmacist will also indicate whether a supply of medication is required or not.  The 
patient may need a new supply of medication or the PODs can be re-issued on discharge 
or the patient has sufficient supplies at home.  Additionally, the format of the supply may 
need to be established such as whether a multi-compartment device is required for 
discharge.  The pharmacist can make additional annotations which can be chosen to 
appear on the final discharge summary or not. 
 
These annotations can be used to provide advice to the dispenser to know how to supply 
the medication or provide additional information to the patient’s GP about the discharge 
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medication eg details of a reducing regimen.  Once the pharmacist has completed the 
clinical verification for each medication this is acknowledged on the electronic discharge 
summary by a green tick and final authorisation or verification at the end of the process.  
Once this step has occurred the patient may then be discharged on the Evolve® system 
and physically discharged from the hospital once the discharge prescription has been 
prepared.  When the patient’s discharge summary has been authorised, a copy is given to 
the patient by hand and an electronic copy is sent automatically via email to the patient’s 
GP within 24 hours of discharge.  This is a crucial step in the transition of information from 
the hospital to the GP as it ensures the GP gets the correct information about the patient’s 
medication on discharge in a timely manner. 
 
However, it has been identified by local GPs using the study hospital that the process of 
ensuring there is an accurate and reliable source of information related to medication 
does not always occur.  GPs have made a few complaints related to details of medication 
being omitted or incorrect.  The hospital pharmacy service is from 8.30am to 7pm Monday 
to Friday and 9am to 5pm at weekends and bank holidays.  This means that any discharges 
that occur outside of these times will not be verified by a pharmacist. 
 
 
1.10 Thesis overview 
1.10.1 The clinical relevance of this study and the research question 
Despite national standards regarding best practice to produce a high-quality discharge 
summary in relation to medication, significant medication discrepancies, ADEs and 
readmissions persist.  There is therefore a clear need to improve the quality of 
information at the point of transition of care especially for elderly patients with increased 
co-morbidities and polypharmacy (Knight et al, 2013). 
 
The national best practice standards have lacked mandatory implementation and 
evidence for clinical application.  Generally, the discharge summary that is used is based 
on local development, iteration and policy rather than the adoption of national and clear 
evidence-based recommendations.  Increasingly it is recognised that elderly patients are 
particularly vulnerable to the consequences of poor quality discharge and the quality of 
the discharge summary in relation to medication may be an influence on this.  Research 
to provide evidence into the processes and quality of medication-related information on 
discharge is scant with few published studies being carried out in the UK particularly in 
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elderly patients.  In addition, there is a need to adopt a whole system approach to the 
discharge process and this includes the views and priorities of both hospital and primary 
care healthcare professionals on the standards of what constitutes a high-quality or ‘gold 
standard’ discharge summary. 
 
With these issues in mind it is increasingly important to establish a ‘gold standard’ for a 
high-quality discharge summary for elderly patients based on published evidence and 
expert opinion using a consensus method.  Furthermore, to measure adherence to this 
gold standard and obtain evidence of medicines reconciliation in the GP records. 
 
There are many factors that may influence the quality of medicines-related information 
in the discharge summary.  These factors can be split into three main groups namely: 
patient, medication, and system factors.  For example, patient factors include patients 
with a prolonged length of stay, age over 85 years old, having a Charlson Co-morbidity 
Index (CCI) measure of four or more.  Medication factors include number of medicines 
being taken greater than eight, classes of medicines.  Whilst system factors may include 
level of experience of the person producing the discharge summary, how the discharge 
summary is generated and design of the discharge summary template.  Some of these 
factors will be explored to establish if there is any correlation with the quality of 
medication-related discharge information. 
 
To establish the applicability and usefulness of the evaluation of the quality of a discharge 
summary to clinical practice a further aspect of the research question is to explore 
whether any patient’s readmission to hospital is caused wholly or partly by the level of 




1.10.2 Research aims and objectives 
 
Research aim:  To establish a locally agreed standard for the quality of medication-
related information on discharge from hospital of elderly patients from an acute 
hospital and the subsequent medicines reconciliation in primary care. 
 
Hypothesis:  The poor quality of medication-related information on discharge and 
subsequent medicines reconciliation in primary care of elderly patients is likely to lead 




1. To produce both ‘gold standards’ (essential standards) and desirable standards of 
a discharge summary for medicines-related information in elderly patients from an 
acute hospital.  
2. To determine the level of adherence to the ‘gold standards’ for medicines-related 
information on the discharge summary from the acute hospital. 
3. To determine the extent to which the GP has acted upon the information in the 
discharge summary in the patient’s primary care records. 
4. To determine the extent to which the quality of the medicines-related information 





1.  To determine the extent of pharmacy-led medicine reconciliation and verification 
of the discharge summary. 
2.  To determine the demographic, medication and service characteristics of the 
discharge summaries reviewed. 
3.  To determine if any patient, medication or service variables influence the level of 
adherence to the gold standards. 
4. To recommend how the quality of medication-related information on discharge 




1.10.3 Study design 
The study design was composed of three distinct phases to meet the purpose of the aims 
and objectives of the study. 
 
Phase I:  To establish the essential and desirable local standards for the quality of 
medicines-related information in discharge summaries in elderly patients from an acute 
hospital using a consensus-based modified e-Delphi technique.  This provided a ‘gold 
standard’ for Phase II of the study. 
 
Phase II:  To measure and evaluate the type and extent of medication-related information 
on the discharge summary to meet the primary objectives.  Also, to determine the level 
of adherence to the ‘gold standards’ obtained from the Delphi study for medication-
related information in the discharge summary and determine the extent to which the GP 
has acted upon the information in the discharge summary in the patient’s primary care 
records. 
 
A non-experimental design was chosen as the principal investigator was measuring the 
medicines-related information on discharge retrospectively and did not require any 
manipulation of the contents of the discharge summary.  Several variables were measured 
and analysed to assess any relationship between the variables and level of adherence to 
the ‘gold standards’. 
 
Phase III:  To determine the extent to which the quality of the medication-related 
information in the discharge summary led to hospital readmission within 30 days of 
discharge.  The study design employed a consensus method using an expert panel to 








Figure 4: The three phases of research to evaluate the quality of medication-related 




1.10.4  Description of thesis chapters 
Chapter 1 of the thesis considers the transitions of care at discharge and implications for 
medication discrepancies.  The issues regarding medicines optimisation for elderly 
patients is considered.  A literature review is undertaken to consider the consequences of 
poor discharge in relation to ADEs, medication discrepancies and readmission to hospital 
due to medication-related issues. The current format and content of a discharge summary 
is considered based on national guidance. 
 
Chapter 2 describes the development of standard setting in the literature and the design 
and application of a modified electronic Delphi study to develop ‘gold standards’ and 
desirable standards for a discharge summary in relation to medication.  The method and 
results of Phase I of the study are considered with a discussion of the results application 
to Phase II. 
 
Chapter 3 is the main part of the pilot study and is a retrospective analysis and evaluation 
of the demographic and medication characteristics of the discharge summaries from the 
study population.  A level of adherence with the ‘gold standards’ is considered for several 
variables that may influence the quality of the discharge summary.  Also, the extent of 
discharge medicines reconciliation undertaken in primary care is investigated. 
 
Chapter 4 is an evaluation of whether any patients who were readmitted to hospital 
within 30 days of discharge from Phase II of the study were due to the quality of 
medication-related information on the original discharge summary.  The narrative 
includes discussion on the use of a consensus method of an expert panel to assess the 
severity and causality of the readmission. 
 
Chapter 5 provides an overview of the themes found to influence the quality of a 
discharge summary in relation to medication and measures that could be considered to 
mitigate medication discrepancies for elderly patient’s post-discharge. Clinical 




Chapter 2: To determine a ‘gold standard’ discharge summary related 
to medication-information (Phase I) 
 
2.1 Introduction 
Chapter one provided an overview of the processes involved in the transition of care at 
discharge, the type and consequence of medication errors at discharge and described 
the current practice at the study hospital. 
 
This chapter describes the development of standard setting in medical practice and the 
design and application of a modified electronic Delphi study to develop a ‘gold standard’ 
for a discharge summary in relation to medication.  The method and results of Phase I of 
the study are considered with a discussion of the results application to Phase II and 
implications for practice, policy and future research. 
 
In healthcare it is important to provide good or quality care that is safe and effective and 
has led to the use of the principles of quality assurance to healthcare.  Quality assurance 
is based upon some fundamental principles, of which one is the principle of adopting a 
standard or standards that should be established and met for a given service or product. 
 
Once a standard has been set for a service or product it is important to ensure that this 
standard is then met to ensure a given level of quality.  Since the 1980s with the concept 
of evidence-based practice, there has been considerable debate about what ‘good’ quality 
healthcare means.  Sackett et al, (1996) described evidence-based medicine as the 
integration of clinical expertise and best external medicine.  In practice, this involves 
considering in a constructive and systematic manner what current published evidence 
presents and combining this with making a considered decision about the care of an 
individual patient.  There is, therefore, a reliance on the judicious use of well conducted 
clinical research to inform ‘good’ healthcare. 
 
In the NHS this led to the routine adoption of medical audit to support the provision of 
quality clinical care (Shaw and Costain, 1989).  The development of medical and 
subsequently clinical audit has led to a requirement for a definition of what either clinical 




include standards (or agreed levels of service), guidelines (recommendations to guide 
decision making) or mandatory guidance where health services must comply (Shaw, 
2015). 
 
Healthcare is often complex and there is often a lack of agreement of standards.  The 
development of the enhanced status of quality standard setting in healthcare based on 
robust clinical research has caused some debate about what a quality standard means.  
Grimshaw and Russell, (1993) proposed that standards of quality define a minimum level 
of acceptable performance or results.  It is important to be clear to define what the terms 
in standard-setting mean so there is clarity of interpretation when the standards are 
reviewed (Donabedian, 1981).  Also, there needs to be recognition that it is not always 
possible to use evidence from quantitative research methods.  In some research areas 
there is either inconclusive evidence or an absence of evidence, for example, in the 
development of consensus guidelines or standards so there is a need to adopt a technique 
to allow for the generation of consensus standards (Wiles et al, 2017). 
 
 
2.1.1 Types of standard setting 
It is therefore desirable when standard setting to consider the components that are 
required to achieve this.  One of the components is that of defining an aspect that requires 
assessment - the criterion, and, the level or target of achievement of that criterion 
(Crombie et al, 1993).  Essentially, criteria assess the quality of care that has been 
received. The criteria should be relevant to the subject area of consideration, clearly 
defined and easily measurable and can be either objective or subjective.  For example, an 
objective criterion includes taking a physical measurement or a defined observation such 
as a blood pressure recording.  Conversely, a subjective criterion uses a clinical judgement 
to assess the quality of care.  Subjective criteria that use clinical judgement allow some 
degree of flexibility as patients with different types of problems can be assessed.  
However, there is also a disadvantage that different observers may come to a different 
conclusion.  A further component of standard setting is that of target setting.  The target 
can be considered as the proportion or level of patients who should meet the criterion 
chosen.  The level of the target should take into consideration factors such as clinical 
importance, practicability and acceptability (Crombie et al, 1993).  In practice the level at 
which the target is set will depend upon a balance between how important the standard 
is and how practical it is to measure it. 
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Standard setting is based upon two different types that is; external and internal standards.  
An external standard is often set by official organisations such as Royal Colleges or other 
national organisations.  Examples of national organisations to define quality include the 
Scottish Intercollegiate Guidelines Network (SIGN) (Petrie et al, 1995).  Also, in England 
the National Institute for Health and Care Excellence (NICE) was established (Rawlins, 
1999).  Both organisations developed systems or processes to review evidence and 
develop authoritative guidelines for clinicians.   
 
Conversely an internal standard is agreed within an audit group.  The criterion, target (and 
exceptions) will therefore be agreed by the group.  In this case the standards will have 
local ownership rather than being imposed.  However, there may be a lack of rigour with 
an internal standard due to a lack of adequate information.  A compromise may be to use 
an external standard, if it is available, and then modify it to consider local circumstances. 
 
The process of standard setting, whether internal or external, relies upon the use of 
accurate information to inform the outcome.  The evidence base for standard setting is 
therefore based on a composite of published literature, evidence from other centres, 
clinical judgement and assessment of current practice (Crombie et al, 1993).  It should be 
noted that in using different centres as a source of evidence or standard setting that there 




2.1.2 Consensus standard setting 
In terms of clinical judgement in some cases there will be no information on which to base 
a target.  This often leads to the need to develop a consensus.  Consensus development 
should not be confused with consensus identification.  Consensus identification often 
involves a group of peers who agree on a group of standards without any consideration 
of how they achieved the target.  In contrast, consensus development involves an 
interaction between groups of people.  In undertaking this, consideration needs to be 
given to how established the group is.  For example, care needs to be taken when there 
are group members who are disruptive, dominant or particularly skilled in leadership as 
they may introduce bias into the process (Ellis and Whittington, 1993).  There are a few 
advantages of using a group to develop consensus in standard setting.  These include the 
ability to have a wide body of opinion and individual group members are more likely to 
60 
 
understand the implications and support its implementation.  Disadvantages of using a 
group include participants being easily persuaded and failing to consider all the relevant 
information. 
 
Consensus techniques are often used when there is a conflict in evidence.  It allows a 
quantitative estimate through a qualitative approach.  Consensus techniques are used to 
allow group facilitation to determine a level of consensus among a group of experts by 
‘aggregation of opinions into refined agreed opinion’ (Campbell and Cantrill, 2001).  These 
consensus techniques include methods such as brainstorming, nominal group technique, 
surveys and Delphi methods.  The nominal group technique is a structured technique 
which involves face-to-face group meetings.  The method of the nominal group technique 
is that members are introduced to the problem or task.  After a period of silence, the 
group leader asks all members to contribute an idea.  Each idea is recorded until all the 
ideas have been exhausted.  Following this there is a process to vote to rank or rate 
independently and anonymously the ideas by each group member and the consensus of 
the group is then the assimilated outcome of the votes (Jones and Hunter, 1995).   
 
 
2.1.3 The Delphi technique of standard setting 
The Delphi technique is often employed when there is no other method that can be used 
where the problem that needs to be solved is not amenable to standard approaches (Ellis 
and Whittington, 1993).  The Delphi technique originated in the United States of America 
(USA) by the Rand Corporation to develop the defence strategy (Dalkey and Helmer, 
1963).  Its application has subsequently expanded since then into other disciplines such 
as science, education, health, social science and quality assurance.  The Delphi technique 
avoids using face-to-face groups by keeping group members separate from each other.  It 
aims to collect, assimilate and refine views made by a notional group of ‘experts’ on a 
specific issue (Ellis and Whittington, 1993).  The Delphi technique has also been widely 
used in medication-related research such as: to define medication wastage (West et al, 
2015), define performance indicators for medicines reconciliation on admission (Aljamal 
et al, 2016) and post-discharge medicines use reviews for elderly patients (Ramsbottom 




2.1.4 Definition of the Delphi technique 
The Delphi technique is defined as a structured, isolated, indirect, multi-stage interaction 
method to determine consensus using repetitive administration of anonymous 
questionnaires, usually across two or three rounds.  There are four features which identify 
the Delphi technique and these are: anonymity, iteration with controlled feedback, 
statistical group response, and expert input (Goodman, 1987 and Cantrill et al, 1996). 
 
The process of the classic Delphi technique has been described as involving several steps 
namely: identifying the research problem, reviewing the literature, choosing a 
methodology, developing criteria, identifying a panel and number of experts, undertaking 




2.1.5 Characteristics of a Delphi technique study 
If the Delphi technique is utilised as the research method to gain a consensus for a given 
problem then it is important to consider the factors that may influence the outcome of 
the study. 
 
The composition and size of the expert panel to undertake the Delphi technique is an 
important consideration.  The panel is usually composed of experts who have knowledge 
and experience of the research problem.  They also have capacity and willingness to 
participate, have time to participate and possess effective communication skills (Wilkes, 
2015).  The researcher must therefore consider what constitutes an expert for their area 
of study before it commences.  Criteria which need to be considered to have an expert 
panel participant include gender, professional experience, education, employment or 
designation (Keeney et al, 2006). 
 
There are no defined acceptable numbers of participants for a panel to carry out a Delphi 
study and varies upon the extent of the issues and resources available (Wilkes, 2015 and 
Powell, 2003). 
 
However, in deciding upon the size and composition of the panel there needs to be a 
balance between having a large size but being difficult to manage with higher drop-out 
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rates versus having a small panel which may introduce bias and not be generalisable (Gill 
et, 2013). 
 
If the panel is comprised of homogenous members ie same professional group then the 
sample may be smaller (10 to 15 people) (Wilkes, 2015).  In clinical studies this provides 
more benefit as panel members are specialist in the area (Jones and Hunter, 1995).  A 
heterogenous group ie panel members with varying perspectives and personalities may 
facilitate a high-quality solution compared to a homogenous group (Powell, 2003).  A 
larger panel will provide more convincing verification whilst a smaller size may require a 
follow-up study to ensure verification (Skulmoski et al, 2007). 
 
The expert panel are often purposively selected to ensure that the participants have an 
awareness and knowledge of the subject matter and may be more motivated to respond 
to the questionnaire.  However, this in itself may also introduce bias, as, only interested 
members may respond to the study (Keeney et al, 2006). 
 
Another consideration when carrying out the Delphi technique is the number of rounds 
or iterations undertaken.  There is no defined number of rounds that should be 
undertaken in a study.  It is often variable and depends upon the reason for the research.  
Most Delphi studies involve two or three rounds (Powell, 2003; Keeney et al, 2006).  In 
deciding the number of rounds to undertake, a pragmatic approach is often taken 
considering factors such as the amount of time available or geography/location of the 
expert panel participants.  This needs to be taken into consideration alongside the balance 
of keeping the number of rounds to a minimum to prevent a reduction in response rates 
(Starkweather et al, 1975). 
 
Before the first questionnaire or round is undertaken there is some value in undertaking 
a pilot questionnaire.  This will support the identification of any ambiguities and ease the 
administration of the study being undertaken (Powell, 2003).  However, there is no 
absolute requirement to undertake a pilot questionnaire when undertaking a Delphi 
study.  In addition, there is also the option to pre-test each subsequent questionnaire 
(Skulmoski et al, 2007). 
 
The first-round questionnaire can be designed to give an initial open response.  A 
qualitative analysis is then undertaken to allow further questionnaires to be developed.  
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Alternatively, more semi-structured or structured questionnaires can be used (Powell, 
2003).  In trying to establish consensus in a clinical setting it may be desirable to construct 
the initial questionnaire based on published literature if this is available.  This is often 
where there is a potential consensus emerging or an idea of the criteria that may need to 
be considered (Duffield, 1993).  Any second or subsequent rounds will then be more 
specific based upon the analysis of the results from the initial round.  The method of 
analysis will often be undertaken by ranking or rating the results to establish a consensus 
opinion (Powell, 2003). 
 
The method or interaction in undertaking a Delphi study can vary.  Clearly the use of pen 
and paper is still a method that is available to a researcher.  However, electronic (e) 
methods are now available that provide many advantages to both the researcher and 
participant.  This is often referred to as an e-Delphi technique.  This provides the ability to 
have a quicker turnaround, easier contact with participants and easier analysis of data as 
distinct advantages (Skulmoski et al, 2007).  The e-Delphi technique can be undertaken by 
email or completion of an online form (Worth et al, 2010; Gill et al, 2013).  A web-based 
e-Delphi technique is a cost effective and simple method for all participants to respond 
from diverse locations.  It also allows direct importation of data for analysis.  There are 
several commercially available web-based survey systems that are easy to set-up with low 
cost.  One of these is SurveyMonkey® and allows the use of predetermined questions to 
be emailed to the panel.  This is a so called ‘reactive Delphi’ technique as it does not utilise 
open statements (McKenna, 1994).  
 
The next consideration in the Delphi technique is data analysis and results reporting.  This 
will depend upon the type of questions used.  So, for example if lists are requested from 
the participants, a qualitative content analysis may be carried out.  A content analysis 
technique can be used to identify themes that have emerged from the initial unstructured 
questionnaire.  A structured questionnaire can then be formulated for the following 
rounds (Powell, 2003; Wilkes, 2015).  Alternatively, a scoring scale such as a Likert scale 
can be used.  This will then allow a measure of the consensus which can be calculated as 
a percentage of responses to present the results found (Wilkes, 2015). 
 
There is a lack of agreement to define when consensus is reached using the Delphi 
technique (Powell, 2003).  The most common definition uses a percent agreement 
(Diamond et al, 2014) with the threshold varying from 55% to 100% (Powell, 2003).  This 
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threshold may be based upon the importance of the research subject (Keeney et al, 2000).  
McIIrath et al, 2010 and McKenna et al, 2002 used a 70% agreement.  Keeney et al, 2006 
used 75%. 
 
In this current study a threshold of consensus was set at ≥80%.  This was based on the 
study by Green et al, 1999.  This study determined the views of GPs information 
requirements which has some similar characteristics to this study in determining GPs 
views (amongst others) of the information requirements of a discharge summary.  A level 
of at least 80% was agreed, based on statistical advice, for consensus.  This consensus, 
however, does not imply that the correct answer has been established but that the panel 
have agreed on a set of questions posed (Keeney et al, 2001). 
 
A further component of any research carried out including the Delphi technique is the 
establishment of the rigour of method.  That is, to ensure that procedures have been 
followed and confounding factors have been minimised.  For quantitative research this 
process of rigour is based on the assessment of reliability and validity.  Reliability being 
the ability to achieve similar results under constant conditions during a study whilst 
validity measures both the generalisability of the results and the confidence placed in 
cause and effect (Hasson and Keeney, 2011).  One of the challenges of the Delphi 
technique (in whatever form) is that there is an absence of precise definitions of the 
methods and this means there is a difficulty to establish what reliability and validity mean 
(Hasson et al, 2000).  Content validity is usually achieved when 70% of respondents agreed 
to inclusion of items (Wilkes, 2015).  Furthermore, there is some issue as to whether the 
Delphi technique is a qualitative or quantitative design.  This has led to the suggestion 
that a measure of rigour for both qualitative and quantitative research be applied to a 
Delphi study (Hasson and Keeney, 2011).  It is often found with questionnaire-type 
research that the response rates can be variable or low.  If the participants in a Delphi 
study have some degree of ownership of the problem then the response rate may be 
improved.  By enhancing the response rate there will be more confidence or rigour in the 
outcome (Keeney et al, 2006). 
 
In summary, the classic Delphi technique or process usually consists of a series of rounds 
that take place.  Initially there is a first round qualitative questionnaire to identify opinions 
of relevant individuals.  The participants are chosen based on the knowledge and 
experience in relation to the subject matter.  The individuals usually remain anonymous 
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for a classic Delphi technique.  The views of the participants can be assimilated under 
several headings and a draft circulated to participants as a questionnaire.  In round two 
the participants identified in round one highlight their agreement with each statement on 
the questionnaire.  The rankings obtained are then summarised and then circulated in a 
revised version of the questionnaire.  This is therefore an iterative process and can be 
repeated if necessary through controlled feedback.  The participants can reconsider their 
responses which may be different from previous rounds.  It is essentially a democratic 
process that aims to facilitate a group opinion or judgement that can be considered 
representative of the participants.  Finally, the rankings are then summarised and 
assessed for degree of consensus.  This therefore constitutes the statistical group 
response component.  The information fed back to the participants through the 
successive questionnaires provides a statistical summary of the group’s views.  This is 
often achieved by a ranking process. 
 
The Delphi technique is therefore a quick and simple method to gain consensus where 
knowledge is incomplete.  It has the advantages of avoiding face-to-face bias and to 
involve larger numbers of individuals than could be otherwise.  Its disadvantages include 
the time taken for the consultation process and potential for a high attrition rate after 
several rounds.  Also, there is a potential to select unsuitable ‘experts’ and provide biased 





Figure 5:  The process for a Delphi study 
 
Figure 5 shows the steps involved in a two or more round Delphi study adapted from 
Avery et al, 2005 and Worth et al, 2010. 
 
In this study the Delphi technique was considered and used for forming a consensus.  It 
was chosen as it enabled a wide group of experts across both primary and secondary care 
to be consulted across a wide geographical area which otherwise would have been 
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difficult to do.  The expert group was multi-professional in nature but interested in the 
problem area.  There may also have been bias by different healthcare professionals or 
dominant views of members if there had been a face-to-face meeting.  So, the nominal 
group technique and brainstorming methods were disregarded. 
 
 
2.2  Method 
In this phase, the objective of setting a local standard for a high-quality discharge 
summary related to medication requirements relies upon certain criteria being met.  
These criteria were used to allow an expression of a quality standard (Grimshaw and 
Russell, 1993).  The criteria that were chosen for the development of standards were 
based upon both published evidence or consensus and local expert opinion (Skulmoski et 
al, 2007).  In this study, standards were obtained from authoritative organisations and 
publications.  However, these standards did not have mandatory status in application and 
no targets were set.  They were, therefore, guidelines with little ability to compare with 
other centres.  In providing the quality standard the criterion used then had a level of 
performance or target allocated to it to determine the level of importance of the 
standards to determine if they were essential or desirable standards using a modified 
Delphi technique. 
 
It was also important to consider local opinion of both secondary and primary care 
healthcare professionals because they may have different perspectives or priorities 
(Yemm et al, 2014). 
 
There is currently a lack of UK national mandated information to be included on a 
discharge summary in relation to medicines.  This is despite several authoritative bodies 
publishing guidance.  The guidance on medicines optimisation issued by NICE builds on 
the previous guidance published by the Royal Pharmaceutical Society and the Academy 
of Medical Royal Colleges which provide a baseline to start from (NICE, 2015b; HSCIC, 
2013; RPS, 2012).  The core elements of a discharge summary recommended by NICE 
include the following: 
 
• Patient and GP contact details; 
• Details of other relevant contacts eg nominated community pharmacy; 
• Known drug allergies and reactions; 
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• Current medicines (including non-prescribed) including name, strength, form, 
dose, route, timing, frequency, duration, how the medicines are taken and what 
they are being taken for; 
• Medicine changes and reasons for them; 
• Date and time of the last dose for weekly or monthly medicines; 
• What information has been given to the patient or carers; and 
• Other necessary information eg when to review, monitoring requirements, and 
support needed for adherence and for specific groups of patients, such as 
children. 
 




2.2.1 Modified electronic (e) Delphi technique 
The e-Delphi technique that was utilised in this study was a modified version of the 
classical Delphi technique to develop consensus.  The modifications included using an 
open-ended question in both rounds and using an on-line rather than paper questionnaire 
(McIIrath et al, 2010 and Aljamal et al, 2016). SurveyMonkey® was used as a tool to decide 
the essential and desirable standards.  This is a free to use readily available tool which 
allows surveys to be conducted quickly and efficiently on- line.  The tool also allows some 
data analysis. 
 
The e-Delphi technique undertaken was a systematic and iterative process administering 
two rounds of surveys to an expert panel. 
 
 
2.2.2 Setting  
The e-Delphi technique carried out was conducted in East Suffolk.  This is a rural county 
in England with a local population of approximately 380,000 people.  The primary 
healthcare service is commissioned and monitored by the Ipswich and East Suffolk Clinical 
Commissioning Group (CCG).  Secondary care or hospital services are mainly provided by 
The Ipswich Hospital NHS Trust (IHT).  This is a local district general hospital with 
approximately 550 beds. 
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2.2.3 Ethical considerations 
The study protocol was discussed with the hospital’s information governance lead and 
research and development manager.  Both were agreed that this study was a survey and 
did not require ethical review as the expert panel members were acting in a professional 
rather personal capacity and confidentiality was maintained throughout the study.  The 
study was conducted in an anonymous way and the responses from the expert panel 
members were not identifiable. 
 
 
2.2.4 Panel of experts  
At the time of this study IHT and Ipswich and East Suffolk Clinical Commissioning Group 
(CCG) had a joint Clinical Quality Improvement Task (CQIT) group consisting of senior 
clinicians and commissioners of both organisations.  The group had the remit to discuss 
quality improvement issues that affected the interface between the acute hospital as 
provider of services to the CCG and primary care users notably local GPs.  One of the issues 
that had been discussed on previous occasions was the low-quality of discharge 
summaries that were being sent to GPs via an electronic method.  Anecdotally the GPs 
had identified deficiencies in the information on transition of care of patients to primary 
care particularly regarding the medication-related information.  The principal investigator 
is chief pharmacist at IHT and a member of CQIT, and, could brief the task group on some 
of the discussions regarding the quality of discharge information.  Support was therefore 
sought following a presentation to the CQIT group for members to participate in the e-
Delphi technique to establish a local standard for a quality discharge summary in relation 
to medication-related information. In addition, members of the local hospital Medicines 
Optimisation Committee were also invited to participate in the survey. 
 
The panel of experts in this study was composed of a relatively homogenous group of 
healthcare-related professionals.  The participants were identified as being key 
stakeholders in the establishment and provision of healthcare services in East Suffolk from 
both primary and secondary care.  The term ‘expert’ used in the context of a Delphi study 
has been described as “clinicians practicing in the field under consideration” (Jones and 
Hunter, 1995).  Therefore, the participants selected in this study were either potential 
users of the service or were involved with the overall management of generation or 
receipt of discharge summaries as part of their daily activities or were regularly involved 
in the review of the quality of discharge summaries.  Therefore, the invited experts 
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consisted of practising GPs and hospital consultants, senior practising pharmacists from 
both the hospital and CCG, senior nurses involved with clinical quality, and executive 
directors with a portfolio for clinical quality.  A patient representative was from the local 




2.2.5 Questionnaire design 
A review of published UK standards in relation to the content of medication-related 
information was undertaken.  It was decided to exclude other international standards 
which have been published due to differences in the delivery of healthcare services in 
other countries outside the UK. 
 
The standards used were those published by the RPS (Picton and Wright, 2012 and RPS, 
2012), Scottish Intercollegiate Guidelines Network (SIGN) (Petrie et al, 1995) Health and 
Social Care Information Centre and the Academy of Medical Royal Colleges- Standards for 
the clinical structure and content of patient records (HSCIC, 2013) and NICE Clinical 
Guideline 5 - medicines optimisation: the safe and effective use of medicines to enable 
the best possible outcomes (NICE, 2015b).  (At the time of the study the PRSB standards 
were not published but have not substantively changed anyway (PRSB, 2017)). 
 
An initial questionnaire was designed using the common themes identified in the four 
published standards.  Seven groups of criteria were established with each group having a 
statement that related to a quality element.  There was also a section at the end for the 
expert panel members to make any other relevant comments on the study.  An initial pilot 
study was carried out with four participants who were a local GP and chairman of the local 
Clinical Prioritisation Group for the Ipswich and East Suffolk CCG, a hospital consultant 
and two senior hospital pharmacists.  The pilot established the content and face-validity 
of the questionnaire and the questions could be answered without further clarification.  
A minimum threshold of consensus at each round was set at ≥ 80% for the criteria (Green 
et al, 1999). 
 
To gain consensus a two-round e-Delphi technique was employed.  The commercial web-




2.2.6  e-Delphi round 1 
The questionnaire was circulated to the participants using an email direct to the panel 
members with a request to complete the questionnaire using a SurveyMonkey® link.  The 
questionnaire consisted of seven sections with a final question requesting open 
comments on any additional issues that the participant felt should be considered 
regarding a quality discharge summary related to medicines.  The expert panel 
participants were asked to rank their level of agreement with the statements indicating 
an appropriate response as either: essential, desirable or not needed.  Participants were 
reminded after several weeks to complete the round 1 questionnaire to increase the 
number of responses. 
 
 
2.2.7  e-Delphi round 2 
The round two questionnaire was amended based on the responses from round one.  
Responses with a score of ≥ 80% agreement were considered as essential and less than 
80% as desirable standards.  The participants were then sent a further email with a 
request to compete a further SurveyMonkey® questionnaire.  The second round consisted 
of four themed sections.  The questions were split into two relating to essential standards, 
one relating to desirable standards and one again requesting for additional comments 
that should be considered as part of the response.  The expert panel participants were 
asked to rank their level of agreement with the statements indicating an appropriate 
response as either: essential, desirable or no preference.  After the initial request for a 
response, a reminder was sent by email to the participants to encourage more responses 
before final analysis was carried out.  It was felt that consensus had been achieved in 




A total of 29 expert panel members were recruited composed of five GPs, 13 consultants, 
five senior pharmacists, two commissioners, three senior nurses and one representative 
of a patient user group.  Table 4 describes the panel of experts invited to participate and 




Table 4:  List of participants for the e-Delphi questionnaire 
Panel of experts - 
designation 
Recruitment source Number of 
participants 
GP CQIT 5 
Consultant CQIT and Medicines Optimisation Committee 13 
Pharmacist CQIT and Medicines Optimisation Committee 5 
Nurse CQIT and Medicines Optimisation Committee 3 
Lay representative Local patient user group 1 
Commissioner CQIT 2 
 
 
Seventeen (58.6%) responses from the participants were generated from round one and 
were analysed using the SurveyMonkey® resource.  Each question was grouped according 
to the criteria presented of being an essential, desirable or not needed quality standard.  
Questions that generated a response of ≥ 80% were considered to reach a consensus as 
being essential and <80% as a desirable standard.  Of the 17 responses, one participant 
chose to disregard all the responses and was excluded so 16 (55.2%) responses formed 
the final assessment. 
 
 
2.2.8.1 Standards for a quality discharge summary - round 1 
The results for round one of the e-Delphi study are shown in Table 5.  The percentage 
reported indicates the level of consensus of the panel members with the number (n) of 
respondents indicated. 
 
Table 5: Results of round 1 of the e-Delphi study 
Description of standard Essential 
standard 
(%)   (n) 
Desirable 
standard  
(%)   (n) 
Not needed 
(%)   (n) 
Total 
(%)   (n) 
Route of administration 100.00%   (16) 0.00%   (0) 0.00%   (0) 100.00%   (16) 
Duration must be specified if it is a 
course 
100.00%   (16) 0.00%   (0) 0.00%   (0) 100.00%   (16) 
Generic name with the dose and 
frequency 
93.75%   (15) 6.25%   (1) 0.00%   (0) 100.00%   (16) 
Strength and form 87.50%   (14) 6.25%   (1) 6.25%   (1) 100.00%   (16) 
If the treatment is long-term it 
should indicate this on the 
discharge summary 
81.25%   (13) 18.75%   (3) 0.00%   (0) 100.00%   (16) 
Record all medicines that were 
stopped during the hospital stay 
81.25%   (13) 18.75%   (3) 0.00%   (0) 100.00%   (16) 
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Description of standard Essential 
standard 
(%)   (n) 
Desirable 
standard  
(%)   (n) 
Not needed 
(%)   (n) 
Total 
(%)   (n) 
Indicate the monitoring or review 
requirements of any medication 
prescribed on discharge 
81.25%   (13) 18.75%   (3) 0.00%   (0) 100.00%   (16) 
Record any adverse reactions to 
medicines or their ingredients 
75.00%   (12) 25.00%   (4) 0.00%   (0) 100.00%   (16) 
Indicate the date and time of the 
last dose where relevant such as for 
weekly or monthly administrations 
75.00%   (12) 25.00%   (4) 0.00%   (0) 100.00%   (16) 
Record the allergy status on 
discharge of the patient 
68.75%   (11) 25.00%   (4) 6.25%   (1) 100.00%   (16) 
If no medicines are prescribed for 
the patient at the time of discharge 
this should be indicated on the 
discharge summary 
68.75%   (11) 31.25%   (5) 0.00%   (0) 100.00%   (16) 
Record why a medicine was 
stopped during the hospital stay 
56.25%   (9) 43.75%   (7) 0.00%   (0) 100.00%   (16) 
Provide a reason for a change to 
admission medication dose ie dose 
increase or decrease 
50.00%   (8) 50.00%   (8) 0.00%   (0) 100.00%   (16) 
Record any problems related to 
adherence of prescribed 
medicines* 
46.67%   (7) 46.67%   (7) 6.66%   (1) 100.00%   (15) 
Provide details of who to contact 
regarding medication queries on 
discharge 
43.75%   (7) 50.00%   (8) 6.25%   (1) 100.00%   (16) 
Indicate what advice has been given 
to the patient, family or carers 
where appropriate related to the 
management of care ie dose 
escalation of steroids 
37.50%   (6) 62.50%  (10) 0.00%   (0) 100.00%   (16) 
Details must be provided of what 
the medication is being used for ie 
the indication 
31.25%   (5) 62.50%   (10) 6.25%   (1) 100.00%   (16) 
Provide information on aids to 
compliance that have been 
provided eg monitored dose aid 
31.25%   (5) 56.25%   (9) 12.5%   (2) 100.00%   (16) 
Provide details of other relevant 
contacts where appropriate eg 
nominated community pharmacy 
18.75%   (3) 62.5%   (10) 18.75%   (3) 100.00%   (16) 
Indicate what written information 
has been given to the patient, 
family or carers where appropriate 
related to the management of care 
eg medication reminder card 
12.50%   (2) 87.50%   (14) 0.00%   (0) 100.00%   (16) 




Three additional comments made by members of the panel are shown in box 1: 
There should be a balance between details and time required to do so.  Whilst in utopia ALL 
details are a must, a junior doctor quite frequently gets haggled by staff to do a "quick 
discharge" and in those circumstances, such deemed high standards cannot be met.  Hence, 
we should have a two-tier system: 1. Essential: allergies, drug reactions, new medications 
and indications, stoppages and indications, duration of treatment, specific instructions etc. 
2. Desirable: everything else.  Hope this helps. 
 
Often the list is incomplete with no indication whether meds have been stopped or simply 
omitted.  Good to indicate as you often do what is new and what has been stopped. 
 
Advice on specials such as liquid products and how/where to obtain formulations where 
these are not the norm, notification of an incident which has occurred and affected the 
patient during their hospital admission, weight and renal function as baseline information 
for the GP if relevant to the medication prescribed (eg enoxaparin), recent warfarin doses 
and INRs to assist the  anticoagulant monitoring service (AMS) team in future dosing, a link 








The results in round one with a score of ≥ 80% indicated a high level of consensus and 
informed round two as being an essential standard and indicated in Table 6. 
 
Table 6:  Essential standards identified from round 1 of the e-Delphi study 
Question % response for 
essential standard 
Include the route of administration 100.00 
The duration must be specified if it is a course 100.00 
Include the generic name with the dose and frequency 93.75 
Include the strength and form 87.50 
If the treatment is long term it should be indicated on the discharge 
summary 
81.25 
Record all medicines that were stopped during the hospital stay 81.25 
Indicate the monitoring or review requirements of any medication 




2.2.8.2 Standards for a quality discharge summary - round 2 
Following the results of round one, a further iteration of the e-Delphi technique was 
carried out.  In the questionnaire that was distributed by email with a SurveyMonkey® 
link, the questions were split into essential and desirable standards.  In round 2, of 29 
individuals originally invited, ten (34.5 %) completed round two.  All the responses were 
anonymous.  The results are indicated in Table 7. 
 
Table 7:  Results of round 2 of the e-Delphi study 
Essential standard Agree Disagree No 
preference 
Total 
Include the route of 
administration 
100.00%   (10) 0.00%   (0) 0.00%   (0) 10 
The duration must be specified if 
it is a course 
100.00%   (10) 0.00%   (0) 0.00%   (0) 10 
Include the generic name with 
the dose and frequency 
100.00%   (10) 0.00%   (0) 0.00%   (0) 10 
Include the strength and form 80.00%   (8) 0.00%   (0) 20.00%   (2) 10 
If the treatment is long-term it 
should indicate this on the 
discharge summary 
100.00%   (10) 0.00%   (0) 0.00%   (0) 10 
Record all medicines that were 
stopped during the hospital stay 
90.00%   (9) 10.00%   (1) 0.00%   (0) 10 
Indicate the monitoring or review 
requirements of any medication 
prescribed on discharge 
90.00%   (9) 10.00%   (1) 0.00%   (0) 10 
 
Desirable standard Agree Disagree No preference Total 
Indicate the date and time of the 
last dose where relevant eg 
weekly or monthly administration 
100.00%   (10) 0.00%   (0) 0.00%   (0) 10 
Record the allergy status on the 
discharge of the patient 
100.00%   (10) 0.00%   (0) 0.00%   (0) 10 
If no medicines are prescribed for 
the patient at the time of 
discharge, this should be 
indicated on the discharge 
summary 
100.00%   (10) 0.00%   (0) 0.00%   (0) 10 
Record any adverse reactions to 
medicines or their ingredients 
100.00%   (10) 0.00%   (0) 0.00%   (0) 10 
Record why a medicine was 
stopped during the hospital stay 
90.00%  (9) 0.00%   (0) 10.00%   (1) 10 
Provide a reason for a change to 
admission medication dose ie 
dose increase or decrease 
90.00%  (9) 10.00%   (1) 0.00%   (0) 10 
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Desirable standard Agree Disagree No preference Total 
Provide details of who to contact 
regarding medication queries on 
discharge 
90.00%  (9) 0.00%   (0) 10.00%   (1) 10 
Record any problems related to 
adherence of prescribed 
medicines 
70.00%   (7) 0.00%   (0) 30.00%   (3) 10 
Provide information on aids to 
compliance that have been 
provided eg monitored dose aid 
70.00%   (7) 0.00%   (0) 30.00%   (3) 10 
Indicate what written information 
has been given to the patient, 
family or carers where 
appropriate related to the 
management of care eg 
medication reminder card 
60.00%   (6) 0.00%   (0) 40.00%   (4) 10 
Indicate what advice has been 
given to the patient, family or 
carers where appropriate related 
to the management of care eg 
dose escalation of steroids 
60.00%   (6) 0.00%   (0) 40.00%   (4) 10 
Details must be provided of what 
the medication is being used for 
ie the indication 
50.00%   (5) 20.00%   (2) 30.00%   (3) 10 
Provide details of other relevant 
contacts where appropriate eg 
community pharmacy 
40.00%   (4) 0.00%   (0) 60.00%   (6) 10 
 
Three comments from unknown participants are shown in box 2. 
Please remember that if an increased amount of information is required on an e-TTA the 
form will take longer to fill in. 
 
Some of the questions would depend on the drug being prescribed. eg monitoring and 
review, if it is standard treatment such as blood pressure tablets or statin, I would expect 
the recipient to have this knowledge, if shared care this would have been already been 
discussed.  It would be where the drug and/or indication is unusual that I would expect this 
to be supplied.  There is also a responsibility for the recipient to clarify anything they are 
unsure about. 
 
If any information is handwritten it needs to be legible.  Also, the name of the signature and 
the name of the consultant team needs to be clear, not just initials and scribbles.  If a 
standard proforma is used, which has standard dose, say for unlicensed medication, the 
form should not be adapted and counter signed. (suggest as midazolam gel). 
 
Box 2: Additional comments made by the respondents in a free text section of the e-Delphi 
questionnaire   
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The results of the second round when compared to the first round essential and desirable 
standards are summarised in Table 8 with codes for each standard for reference.  It can 
be observed from the results in Table 8 that there is an increase in the percentage score 
from round one to round two of the e-Delphi technique for all the essential and desirable 
standards except for the inclusion of the strength and form score.  In this case there is still 
a consensus level of 80%. 
 
Table 8:  Comparison of the consensus results from round 1 to round 2 
Standard Essential result: 
agree (%)   round 1 
Essential result: 
agree (%)    round 2 
Code 
Include the route of administration 100 100 E1 
The duration must be specified if it 
is a course 
100 100 E2 
Include the generic name with the 




Include the strength and form 87.5 80 E4a, E4b 
If the treatment is long-term it 
should indicate this on the 
discharge summary 
81.25 100 E5 
Indicate the monitoring or review 
requirements of any medication 
prescribed on discharge 
81.25 90 E6 
Record all medicines that were 
stopped during the hospital stay 
81.25 90 E7a 
Standard Desirable result:  
agree (%)   round 1 
Desirable result: 
agree (%)   round 2 
Code 
Record any adverse reactions to 
medicines or their ingredients 
75 100 D1 
Indicate the date and time of the last 
dose where relevant eg weekly or 
monthly administration 
75 90 D2 
If no medicines are prescribed for 
the patient at the time of discharge 
this should be indicated on the 
discharge summary 
68.75 100 D3 
Record the allergy status on the 
discharge of the patient 
68.75 100 D4 
Record why a medicine was stopped 
during the hospital stay 
56.25 90 D5a 
Provide a reason for a change to 
admission medication dose eg dose 
increase or decrease 
50 90 D6 
Record any problems related to 
adherence of prescribed medicines 







This is the first study that has described the use of a modified e-Delphi technique to 
describe a consensus gold standard of a discharge summary for medication-related 
information using an expert panel.  Also, it is the first attempt to use the national 
published standard statements such as those developed by the RPS (2012), the Academy 
of Medical Royal Colleges (HSCIC, 2013), SIGN (2012) and NICE Clinical Guideline-
Medicines Optimisation (NICE, 2015b) to produce a set of locally developed consensus 
standards. Based on the agreed consensus level, 20 standards were identified, seven of 
which were classified as essential and 13 as desirable standards.   The essential standards 
identified therefore represent the gold standards. 
 
In this study the classical Delphi technique was modified by including an open-ended 
question and using an on-line rather than a paper-based questionnaire.  The use of on-
line or electronic (e) method facilitated anonymity between the expert panel members 
which is one of the characteristics of a Delphi study (Hsu and Sandford, 2007). 
 
Standard Desirable result:  
agree (%)   round 1 
Desirable result: 
agree (%)   round 2 
Code 
Provide details of who to contact 
regarding medication queries on 
discharge 
43.75 90 D8 
Details must be provided of what the 
medication is being used for ie the 
indication 
31.25 50 D9 
Indicate what advice has been given 
to the patient, family or carers where 
appropriate related to the 
management of care eg escalation of 
steroids 
37.5 60 D10 
Provide information on aids to 
compliance that have been provided 
eg monitored dose aid 
31.25 70 D11 
Provide details of other relevant 
contacts where appropriate eg 
community pharmacy 
18.75 40 D12 
Indicate what information has been 
given to the patient, family or carers 
where appropriate related to the 
management of care eg medication 
reminder card 
12.5 60 D13 
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Consensus was achieved if a score of ≥ 80% respondents agreed with the standard 
statement in the rounds of the Delphi study.  It was decided to divide the standards into 
essential and desirable with any results ≥ 80% being an essential standard and results 
<80% being a desirable standard after round one.  This was done in recognition that it is 
not always possible to ensure that all medication-related information can be included in 
the discharge summary.  The differentiation between essential and desirable standards 
allowed consideration of the core information that the GP requires and allows 
prioritisation of medical staff time when completing a discharge summary to focus on 
providing the information most valuable to the GP.  This approach was supported by a 
comment made by a panel member from one of the Delphi rounds and the e-prescribing 
toolkit (2007). Also, a recent study by Fitch et al, (2017) carried out in a UK hospital 
evaluated the quality of information of discharge summaries sent to GPs after hip 
fractures.  The GPs reported that some information was essential whilst others that it was 
beneficial or desirable and supports the approach taken in this study. 
 
All the essential standards apart from E4 (include the strength(E4a) and form(E4b)) had 
either an increase or no change in the level of consensus from round one to round two.  
This suggests that the panel experts reached agreement on what essential information is 
needed for a discharge summary. 
 
The essential standards E1 (route of administration), E3a (generic name), E3b (dose) and 
E3c (frequency specified), E4a (strength), E4b (form) and E7a (record of medicines 
stopped) were all specified in the five key nationally published standards 
recommendations (RPS, 2012; SIGN, 2012; HSCIC, 2013, PRSB, 2017 and NICE, 2015b).  
The standard E2 (duration) was specified in four of the five key nationally published 
standards.  These findings would confirm that there is agreement locally with national 
standards despite published national standards lacking an evidence base.  Interestingly, 
in this study standards E5 (if the treatment is long term) and E6 (indicate monitoring or 
review requirements) are not listed in the national recommendations.  This has a potential 
impact on clinical practice as this study reflects the opinions of local experts and 
practitioners and reflects a real-life experience.  This preliminary study should therefore 
be carried out on a wider scale to increase the reliability and validity to increase 




Essential standard, E4a (strength) and E4b (form) had a lower level of agreement in round 
two dropping from 87.5% to 80%.  The reason for this may be due to the reduced number 
of respondents in round two who felt this was an essential standard, decreasing from 14 
to 8, and any small difference in number of responses would have a large effect on the 
result. 
 
Also, some respondents may have felt that both the strength and form are implicit from 
the description on the discharge summary and not an essential information requirement.  
For example, for most oral medicines the relationship between the dose and strength is 
not essential for the GP to know, as the dose may be the same as the strength or a multiple 
of the strength. 
 
A consensus of ≥80% for consensus was agreed as per Green et al, (1999) so the inclusion 
of E4a and E4b as an essential standard was still justified.  This data is also supported from 
some key national recommendations which includes the strength and form as part of the 
core content of a discharge summary (SIGN, 2012; RPS, 2012). 
 
There were two standards that scored 75% level of agreement after round one ie D1-
recording any adverse reactions to medicines or their ingredients, and, D2-indicate the 
date and time of the last dose where relevant eg weekly or monthly administration.  They 
both had a high level of agreement on the second round (100% and 90% respectively) and 
would be considered as an essential standard if the threshold for consensus was reduced.  
Other published Delphi studies have used a lower threshold than 80% (Aljamal et al, 2016) 
and this would have influenced the final results.  None of these standards are listed in the 
four key national publications and this supports their exclusion as essential standards in 
this study. 
 
Interestingly the standards, D6 (reason for a change in medication, 50%) and D4 (allergies, 
68.75%) had a low level of agreement after round one and were classified as desirable 
standards rather than essential.  These standards were listed in all four of the national 
resources.  It is unclear why the expert panel members in this study did not classify these 
as essential standards.  It may be that the respondents felt that the changes in medication 
would be self-explanatory from the overall discharge summary narrative or the allergies 
are already known from other sources of information.  This would be an interesting area 
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to follow-up in a larger study.  Many of the other desirable standards would be considered 




The essential and desirable standards were agreed based on published resources from 
national organisations.  The local experts included practising senior doctors and 
pharmacist experts’ representative of secondary and primary care reflecting real-world 
knowledge and practice. This approach therefore strengthens the face-validity of the 
study. 
 
The process used followed a structured, recognised procedure to reach a consensus.  
Opinions of all the panel members could be expressed in an anonymous manner and 
represented a clinically relevant view.  None of the standard statements was considered 
inappropriate by the expert panel members.  Using an on-line questionnaire facilitated 
access to responses and analysis in a manageable and straightforward manner.  




2.3.2 Limitations of Phase I  
The main limitation of Phase I was that the number of respondents decreased from 16 
(55.2%) in round one to 10 (34.5%) in round two.  The results from round two may 
therefore not represent the views of all the expert panel members, which impacts on the 
validity of the study. 
 
The use of an on-line questionnaire assumes that panel members should have ready 
access to their email accounts to be able to respond to the questionnaire.  It is not known 
if this was the case for the participants for all rounds of the study and may account for the 
reduced response rate in round two.  A reminder email was sent to panel members after 
a few weeks of initial circulation to encourage completion of the questionnaire and 
improve the response rate.  A recommendation has been made to try and motivate panel 
members to ensure that response rates are as high as possible (Hsu and Sandford, 2007).  
It is recommended for a future development that the reliability and validity of the 
standards should be reassessed by using a larger number of panel members and using a 
different healthcare system(s) over a wider geographical area. 
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Panel members were purposely recruited and briefed by the principal investigator in 
advance of the study which may have introduced some bias as they were already engaged 
with the study, as opposed to any members recruited without a briefing who may have 
given different responses. 
 
A larger sample size and being carried out in more settings would provide more 
confidence and generalisability of the standards.  The adoption of an e-Delphi study across 
multi-sites would also be a more credible evidence-base to influence the 
recommendation to improve the quality of discharge summaries in the future by adoption 
of these findings. 
 
The question for essential standard E7a ie record all medicines that were stopped during 
the hospital stay, should have also stated medicines started (E7b).  This was an oversight 
and further analysis assumed that the panel members would have answered this in the 
same way as when a medicine had been started as it is an action of similar significance.  
In a similar manner the questionnaire asked for the expert panel member to indicate a 
reason for a change in medication but not whether they wanted to see a change in 
medication indicated on the discharge summary. 
 
It is acknowledged that the use of the Delphi technique may not reflect a true consensus 
but rather a compromise position (Yousuf, 2007) and reflect the opinions of participants 
in this study (Keeney et al, 2001).  This is a further justification to carry out a larger study 
to provide greater generalisability of the results. 
 
The setting of the Delphi study was based around a single non-teaching hospital in a rural 
county in England.  The size (29 panel members) and composition of the expert panel met 
the criteria as stated by Wilkes (2015) for a Delphi study.  The members were all specialists 
with an interest in the subject matter.  However, the expert members may have been 
biased and not represent the views of all GPs or hospital consultants with varying levels 
of experience.  
 
Many of the essential standards identified in the study reflect national published 
standards and a larger study would increase the reliability, generalisability and validity of 




This preliminary study therefore forms the basis of further research.  Furthermore, the 
membership of the expert panel included only one lay person and so the views and 
perspectives of patients on the content of a quality discharge summary in relation to 
medication was limited.  This is a limitation of the study in terms of considering the views 
of patients or carers themselves.  Indeed, the PRSB in their recent report on an e-discharge 
standard for electronic systems state that any local implementation should involve 
patients and carers to ensure that the content is expressed in an understandable and 
person-centred manner (PRSB, 2017).  There is an opportunity to proactively include 
patients in future studies about the value and needs of a ‘gold standard’ discharge 
summary in relation to medication. 
 
 
2.3.3 Implications for practice, policy and research 
This preliminary e-Delphi study provides a method to obtain consensus based on UK 
published literature and local expert opinion for a ‘gold standard’ discharge summary for 
medication-related information.  The implications are that this should influence both local 
and national practice and policy.  The adoption of both local and national ‘gold standards’ 
would contribute to improving the quality of care to patients.  The differentiation 
between essential and desirable standards provides a pragmatic assessment of what the 
core requirements of a discharge summary are when resources and time are limited in 
everyday clinical settings.  However, by defining the desirable standards this provides 
guidance if time and resources are available.  These details could be included in the 
discharge summary by others and not just the doctor eg pharmacist or nurse. 
 
This study also informs the need for the consistent adoption and application of a ‘gold 
standard’ for discharge summaries in relation to medication in the UK.  This includes the 
recommendation to include the essential ‘gold standard’ elements into the design and 
content of HEPMA functionality across the UK.  This will reduce any latent failures in the 
production of discharge summaries by designing the electronic templates to include the 
standards and to potentially make them mandatory to complete (see also Chapter 5).  
 
The concept of a ‘gold standards’ of essential and desirable standards develops the ethos 
of quality improvement in healthcare.  There is the ability to develop comparisons 
between, and within, organisations to facilitate hospital performance indicators for 
quality of discharge information.  This could be used between commissioners and host 
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organisations as part of a quality improvement initiative or as a performance 
management tool. Future research could focus on seeking to identify gaps in practice and 
to encourage training and process re-design to address any deficiencies found.  
 
It would also be an area of future research to assess the generalisability and applicability 
of ‘gold standards’ to other types of healthcare settings which may have their own 
discharge requirements that are different to a standard acute hospital eg mental health 
hospital or children’s hospital. 
 
The consensus of the local standards also allowed Phase II of the study to be carried out 
measuring the level of adherence with the gold standards to give a measure of the quality 
of discharge summaries in relation to medication-related information.   
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Chapter 3: Adherence to ‘gold standard’ discharge summary in 
elderly patients discharged from hospital (Phase II study) 
 
3.0 Chapter overview 
In chapter two, Phase I of the study described the modified e-Delphi technique used to 
produce the essential or ‘gold standards’ for a discharge summary related to medication. 
The essential standards found are shown in table 9. 
 
Table 9:  Essential standards identified in Phase I of the e-Delphi study 
Essential standard Code 
Route of administration E1 
Duration if a course E2 
Generic name stated E3a 
Dose stated E3b 
Frequency stated E3c 
Strength specified E4a 
Formulation E4b 
Duration of long term specified E5 
 Monitoring or review required specified E6 
Record of medication stopped E7a 
Record of medication started E7b 
 
 
A measure of the level of adherence to the local essential or gold standards and desirable 
standards from the hospital discharge summary established from Phase I for medication-
related information was carried out.  Primary objectives were to describe and categorise 
the type and extent of medication-related information in the discharge summary.  To 
determine the extent to which the GP has acted upon the information in the discharge 
summary in the patient’s primary care records.  Also, to consider whether there are any 
variables that may influence the quality of the discharge summary and measure how 
many patients were readmitted within 30 days after discharge for Phase III of the study. 
Elderly patients’ discharge summaries who were discharged from care of the elderly 
wards at the study hospital were retrospectively reviewed for demographic and 
medication-related information.  
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Where reference is made to methodology or results obtained from this study it will be 
referred to as ‘current study’. 
 
 
3.1 Method  
3.1.1 Setting 
The pilot study was carried out by collecting data of patients ≥65 years of age, discharged 
from care of the elderly wards at The Ipswich Hospital NHS Trust, a local district general 
hospital which serves the population of East Suffolk, with approximately 550 beds.  
Patients discharged from this hospital and based in Suffolk were followed up with their 
local GP records. 
 
 
3.1.2 Pilot study 
A standardised data collection form was developed based upon the essential and 
desirable standards identified from Phase I of the study.  A pilot study of the data 
collection tool was carried out to assess content and face validity of collecting data for the 
medication-related details of the discharge summaries for coding and content analysis.  
Two senior clinical pharmacists reviewed six patients to test the data collection form for 
ease of use and applicability (see Appendix 1).  The form was modified to include the type 
of the doctor or prescriber writing the discharge summary and to re-format the details of 




3.1.3 Sample selection 
The patient sample comprised of patients discharged from a care of the elderly ward at 
the study hospital and were over the age of 65 following an emergency admission.  
Patients were included in the study if they had been an inpatient for more than 48 hours 
or if they had been an inpatient for less than 48 hours but had all their medication 
prescribed on the discharge summary.  The discharge policy at the study hospital is that 
all medicines should be prescribed for a patient on discharge if they are an inpatient for 
more than 48 hours.  The patient’s discharge summary was located on the hospital 
electronic health records called Evolve®.  Additionally, after 30 days the patient’s GP 
records were accessed to ascertain the quality of information related to medicines in the 
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GP records using SystmOne®.  Patients who had died within 30 days of discharge were 
also excluded from the study sample.   
 
SystmOne® is a commercial software package often used in primary care by GP practices 
with an electronic health record function.  Patient data can be shared securely across 
services including between GP practices and hospitals, providing details of medicines that 
a patient has been prescribed.  This is a crucial patient safety service as it enables clinicians 
to be able to access patient clinical information 24 hours a day.  The principal investigator 
was already familiar with the use of SystmOne®. 
 
Patients from the study hospital were identified by the principal investigator using a 
software package called Medeanalytics®.  Medeanalytics® is a commercial information 
technology system that allows analysis of data including hospital discharge data.  Random 
searches were generated on the Medeanalytics® system of patients discharged from 
identified care of the elderly wards at the study hospital over a six-month period from 
January to June 2016.   
 
Figure 6 illustrates the process for identifying the sample population of patients in Phase 
II of the study, and also, the subsequent data collection and analysis of patients who have 









3.1.4 Data collection 
Retrospective data was collected manually on a standardised data collection form 
previously piloted using a combination of both patient demographic data of the sample 
population and collecting the medicines-related information on the discharge summary 
aligned to the essential and desirable standards from Phase I of the study.   
 
Phase II was a pilot study to establish some of the approaches when undertaking a study 




The data collected was composed of both pre-populated data including the ward, date of 
admission and date of discharge, as well as the medication-related information that had 
been manually inputted.  Data was collated using Microsoft Excel® and analysed using the 
Statistical Package for Social Sciences (SPSS) Windows version 24. 
 
The discharge summary of all the patients in the study identified the main diagnosis that 
was found as part of the inpatient episode of care.  This was subsequently coded 
according to the International Statistical Classification of Diseases and Related Health 
problems, 10th revision (ICD-10): 2015 classification and is the recognised medical 
classification list created by the World Health Organisation (WHO) and contains codes for 
diagnoses (WHO, 2017). 
 
 
3.1.5 Co-morbidity profile 
The type of other conditions or co-morbidity profile of the study patients was collected.  
This was collected to gain an understanding of the level of ill health and can be used to 
calculate the Charlson Co-morbidity Index.  Data was collected direct from the description 
on the discharge summary of the co-morbidities listed by the discharging doctor.  These 
were not verified but taken as reflecting the co-morbidities known during the patient’s 
current inpatient admission.   
 
 
3.1.6 Charlson Co-morbidity Index (CCI) 
The CCI is a predictive tool used to estimate an individual’s likely survival based on several 
parameters including their co-morbidities.  For example, for a score of four there is a 
probability of 52% mortality one year after hospital admission, whilst a score of five or 
more would give an 85% risk of mortality one year after hospital admission (Hall et al, 
2004).  The CCI calculator is available as a Microsoft Excel tool from the publication from 




3.1.7 Ward of discharge 
The wards chosen for the study sample were known as care of the elderly wards at the 
study hospital.  These are all in the medicine and therapies division and all have a 
nominated lead consultant. 
 
 
3.1.8 Day of discharge 
The day of the discharge was coded from the date indicated on the discharge summary 
although it is recognised that on some occasions this may be the next working day after 
discharge.  The agreed policy for discharge at the study hospital is for the patient to be 
issued a paper copy of the final discharge summary at the point of discharge from the 
hospital Patient Administration System (PAS).  However, in some cases, particularly at 
weekends, the final discharge on the PAS may occur later than the actual discharge and 
indicate a different day of discharge.  It is known by the principal investigator that this 
only occurs occasionally. 
 
 
3.1.9 Length of stay 
The length of stay was calculated from the date of admission and compared with the date 
of discharge related to the inpatient episode of care indicated on the final discharge 
summary following the episode of care.  Part days were counted as one day. 
 
 
3.1.10 Demographic details 
Data collected from the discharge summaries of the study group was composed of pre-
populated data including the patient demographic details and name of the lead 
consultant.  Also, the clinical narrative describing the main diagnosis, secondary diagnosis 
or co-morbidities, relevant investigations and results and the name and grade of the 
person who prepared these details on the discharge summary were reviewed.  The date 
of completion and details of the medication verification by a pharmacist are also included.  
The consultant indicated on the discharge summary is the lead consultant who was 
responsible overall for the patient during their inpatient stay and is automatically 




3.1.11 Prescriber preparing discharge summary 
The discharge summary that was generated provides an electronic signature of the doctor 
or non-medical prescriber undertaking the activity and their grade or designation. 
 
The discharge summary produced on the Evolve® system requires clinical information to 
be inputted manually by a clinician.  This is most commonly a doctor but may in some 
cases be a specialist nurse with prescriber status and authority.  In the UK the medical or 
doctor career structure is defined by the General Medical Council (GMC) and was 
reviewed in 2005 (BMA, 2017).  Once a medical graduate completes medical school (four 
to five years) they will enter a two-year foundation programme namely FY1 (Foundation 
Year 1) which replaced the previous pre-registration house officer year.  They then move 
onto FY2 (Foundation Year 2) which was previously known as the Senior House Officer 
(SHO) grade working in a hospital environment.  Following completion of these two years 
the doctor has full GMC registration.  This is then followed in hospitals with three to seven 
years of Specialist Training (ST) dependant on the speciality and these are then referred 
to as ST1, ST2, ST3 etc, noting the number of years of specialist training undertaken.  The 
doctor may then receive a certificate of completion which then allows them to work as an 
independent practitioner either as a consultant or GP.  There are also doctors who have 
achieved a level of training that they stay working at.  These are referred to as staff grade, 
trust grade or non-consultant doctors.  These are collectively known as non-career grade 
doctors (NCGD) and coded as such in this study.  NCGD doctors have no on-going training 
requirement. 
 
For the purposes of the current study the following codes were used for the prescriber 
type and are defined in Table 10. 
 
Table 10:  Definitions of types of prescribers writing the discharge summary 
Prescriber type Definition 
Nurse Nurse registered with the Nursing and Midwifery Council and has 
undertaken an accredited prescribing course. 
FY1 Foundation Year 1 
FY2 Foundation Year 2 
ST1 Specialist Training Year 1 
ST2 Specialist Training Year 2 
ST3 Specialist Training year 3 
Consultant Consultant 
NCGD Non- Career Grade Doctor 
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3.1.12 Hospital readmission  
Patients in the study were followed up at least 30 days after discharge to determine if 
they were readmitted for any reason.  This was carried out by examining the hospital 
electronic PAS to establish readmission or not.  All patients were included in this data 
collection aspect at this stage irrespective of the reason for readmission.  Patients were 
excluded if they had attended the Accident and Emergency department or other similar 
acute admission/assessment service but not admitted. 
 
 
3.1.13 Pharmacy-led medicines reconciliation (PMR) on admission 
The presence of a pharmacy-led medicines reconciliation service was measured. This is 
when an approved pharmacy staff member (pharmacist or accredited pharmacy 
technician) undertakes medicines reconciliation (MR) during the patient’s episode of care.  
This is ideally undertaken within 24 hours of admission.  This activity ensures there is a 
reconciliation or check of the patient’s medicines prior to admission compared to those 
prescribed whilst an inpatient and aims to reduce the number of unintentional medication 
discrepancies as an inpatient.  This data was collected by reviewing the study patients’ 
health records, which includes the inpatient medication chart.  This medication chart is 
annotated by a member of pharmacy staff on the front if they carry out a MR activity so 
there is evidence of whether a PMR has been carried out and when this occurred.  The 
medication chart will also provide evidence if any unintentional discrepancies were 
identified as part of the MR service and whether they were acted upon. 
 
 
3.1.14 Allergy status on discharge summary 
The information related to allergy status on the discharge summary was coded by 
whether the data was entered or not and if a description was given or not if applicable.  
The discharge summary has a field which is generated automatically titled 
‘Allergies/Adverse Drug Effects’ and was coded whether data was entered or not.  The 
abbreviation ‘NKDA’ stands for No Known Drug Allergy and would be coded that the 




3.1.15 Discharge medicines 
The numbers and types of medicines on the discharge summary was taken directly from 
the discharge summary on the Evolve® system which keeps all previous discharge 
summaries as part of the patient’s electronic health record whilst an inpatient in hospital. 
 
The classes of medicines were coded according to the World Health Organisation (WHO) 
classification.  This utilises the Anatomical Therapeutic Classification (ATC) and the 
Defined Daily Dose (DDD) as the measurement units and has been established as the 




3.2 Ethical approval and considerations 
The leads for research and information governance for the study hospital agreed opinion 
that ethical review of the study was not required because it met the criteria of a service 
evaluation.  The study was given clinical approval in April 2015 by the local CQIT group of 
senior clinicians and officers of the study hospital and local CCG.  The hospital information 
governance lead was also consulted about the need for consent to access the patients’ 
GP records or summary care record (SCR).  It was confirmed that as this was part of normal 
clinical practice at the hospital as part of the medicines reconciliation processes, that 
consent was not required.  Data was kept confidential and under the secure control of the 
principal investigator.  If during the data collection period the principal investigator found 
a medication discrepancy that was unintentional on the discharge summary that could 
affect patient safety and care, they would contact the patient’s GP to notify them of any 
discrepancies so that they could assess if any further action needed to be taken. 
 
 
3.3 Calculation of adherence level to the gold standards  
To provide a measure of the level of adherence or performance to the essential or ‘gold 
standards’ a calculation was undertaken based on previously published methodology.  
 
Aziz el al, (2016) carried out a retrospective audit of adherence with the national 
standards for patient discharge information in Ireland.  The adherence was broken down 
into three main categories namely; patient demographic and discharge information, 
medication information, and adherence relating to therapy change information.  
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Adherence was assessed in a binary ‘yes/no’ response.  Thus, a discharge summary was 
considered completely compliant if a ‘yes’ or ‘N/A’ was recorded for each selected 
criterion or element.  The score was calculated by summing the number of elements that 
were rated as compliant (including non-applicable criteria) divided by the number of 
applicable elements for each discharge summary; multiplied by 100.  In a similar study 
Hammad et al, (2014) undertook a study to measure the compliance or adherence for 
discharge information.  This study used the National Prescribing Centre (NPC) minimum 
dataset of information that is required to be transmitted to primary care.  The estimation 
of adherence of the discharge summary to the NPC dataset was undertaken using a 
scoring system.  Discharge summaries scored one point when a criterion was successfully 
fulfilled.  Two points were scored for each criterion not fulfilled.  Discharge summaries for 
patients with no medication history or where no medicines were changed, initiated or 
discontinued were scored only against the applicable criteria.  In a similar manner to the 
study by Aziz et al, (2016) the NPC minimum dataset criteria were broken down into three 
categories; patient admission and discharge information, medication information and 
therapy change information. 
 
In this current study the essential standards identified in the modified e-Delphi 
component considered only the medication-related elements of the discharge summary.  
This contrasts with the previously reported studies.  A comparison undertaken identified 
that the following essential and selected desirable standards can be categorised into the 
following two groups as per Aziz et al, (2016) and Hammad et al, (2014) and is shown in 
Table 11.  
 
Table 11:  Categories of the essential and selected desirable standards  















Long term treatment E5 
Monitoring or review requirements E6 
Therapy change Record of stopped (or started) medication (*) E7a, E7b 
Reason stated for a medication stopped (or 
started) 
D5a, D5b 





(*) Denotes the inclusion of medicines started as well as stopped on the discharge 
summary (E7b).  This standard was not included in the original dataset for the e-Delphi 
study but it is expected that the same response would have been obtained for newly 
started medicines. 
 
In Table 11, reasons for changes in medicines has been included as standards that have 
been considered in other studies and it would be worth considering in this study (Aziz et 
al, 2016; Hammad et al, 2014). 
 
The method adopted by Aziz et al, (2016) was adapted and utilised to estimate the extent 
of adherence with the essential standards for the discharge summaries in the study and 
therefore a measure of the gold standard.  So, for each essential standard that was met a 
score of one was recorded.  If the essential standard was not applicable this was excluded 
from the total score possible.  A total score was calculated for each of the essential 
standards met.  All the medicines should meet the criteria for a score to be assigned.  For 
example, if only four out of six medicines that were applicable had long term treatment 
denoted on the discharge summary then no score was given for this standard.  An overall 
percentage adherence was calculated based on the standards being met against those 
that were applicable for all the essential standards or the ‘gold standards’.  An overall 
adherence score was also calculated for the additional desirable standards indicated in 
Table 11 ie the standards that relate to reasons for a medicine being stopped, started or 
changed.  These were included to allow some comparison with other published studies 
(Aziz et al, 2016; Hammad et al, 2014). 
 
 
3.4 Data analysis and plan 
A data analysis plan was developed to include demographic, patient and medication 
variables.  
 
Data analysis of the sample patients was composed of descriptive statistics to summarise 
and describe the results of the medication-related content of the discharge summaries.  




The analysis was undertaken to determine if there was an association between the 
influence of various variables, see section 3.13, and the quality of the discharge summary 
adherence score using a probability (p) value of ≤0.05.  Where multiple variables are 
compared a more stringent level of p was applied of 0.01. 
 
Analysis for comparing differences between sets of data was undertaken using the 
following to test an association with the variables: 
 
The mean and standard deviation describe data that is normally distributed.  The 
independent samples t-test (to test the probability that the samples come from a 
population with the same mean value), Analysis of Variance (ANOVA) (to compare the 
means of more than two groups that come from the same population) eg length of stay 
and the Pearson’s correlation (r) were used when looking for an association between 
variables eg number of medicines started and number of medicines discharged on. 
 
The median and interquartile range (IQR) describe the data where the sample size is 
smaller or where there is non-normal distribution eg number of co-morbidities and also 
other non-parametric tests such as the Mann Whitney U test (to test if there is a 
significant difference between two sets of data from two different sets of subjects) eg 
influence of therapeutic classes and the adherence score,  the Chi-square test (X²) to test 
the association between two categorical values eg ADE and gender and the Kruskai-Wallis 





3.5.1 Summary of results 
A summary of the results to describe the demographic details and essential and desirable 





Table 12:  Summary of the results 
Details  Description Result 
Demographic and medication 
 Total number of patients 155 
 Mean age (years)   83.17(+/- SD 8.22) 
 Total number of medicines prescribed  1470 
 Mean number of medicines per patient   9.48(+/- SD 3.99) 
 Median number of medicines   9 (IQR 7-12) 
 Mean length of stay (days)   13.17(+/- SD 12.62) 
 Median length of stay (days)  10 (IQR 5-18) 
Essential standard                                                                                                              (%) 
E1 Route of administration 1465/1470   (99.7) 
E2 Duration if a course 96/96   (100) 
E3a Generic name stated 1370/1470   (93.2) 
E3b Dose stated 1463/1470   (99.5) 
E3c Frequency stated 1465/1470   (99.7) 
E4a Strength specified 88/1470   (6.0) 
E4b Formulation specified 74/1470   (5.0) 
E5 Duration of long term specified  1374/1470   (93.5) 
E6 Details of monitoring or review required specified 44/155   (28.4) 
E7a Record of medication stopped 70/155   (45.2) 
 GP records not updated of medicines stopped 19/130   (14.6) 
E7b Record of medication started  131/155   (84.5) 
 GP records not updated of medicines started  17/335   (5.1) 
Desirable standard 
D1 Details of Adverse Drug Event specified 21/155   (13.5) 
 GP records not updated of Adverse Drug Events  12/33   (36.4) 
D2 Details of date and last dose given 34/155   (21.9) 
D3 Details of no medication prescribed Not applicable 
D4 Allergy status specified 119/155   (76.8) 
D5a Reason for medication stopped  98/130   (75.4) 
D5b Reason for medication started 284/335   (84.8) 
D6 Reason for a change to medication 23/45   (51.1) 
 GP records not updated of medicines with a 
change in dose 
4/45   (8.9) 
D7 Details of adherence problems stated  5/155   (3.2) 
D8 Contact details given of whom to contact  3/155   (1.9) 
D9 Reason or indication specified  287/1470   (19.5) 
D10 Details of verbal advice provided  1/155   (0.6) 
D11 Details of compliance aids provided 56/155   (36.2) 
D12 Other relevant contacts provided 55/155   (35.5) 
D13 Details of written information provided 4/155   (2.6) 
 Overall adherence score for essential/gold 
standards (SD) 
64.63   (9.25) 
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3.5.2 Demographic and medication characteristics 
The study sample of 155 patients had a mean age of 83.17 years, (median age 85 years), 
and median of four co-morbidities due to the non-normal distribution. Sixty four (41.3%) 
were male (see table 13). 
 
The mean number of medicines was 9.48 per patient with a tendency for male patients 
to be on more medicines than females (mean 10.06 for male compared with 9.08 for 
female patients).  There was no statistical difference using the independent samples t-
test (t=-1.52) for the number of medicines and gender (p=0.130).  A total of 1,470 
medicines were prescribed on the discharge summaries with 644 (43.8%) for male 
patients. 
 












Patients Frequency (%) 155   (100) 64   (41.3) 91   (58.7)  
Age (years) Mean   (SD) 83.17   (8.21) 83.02 (7.84) 83.29  (8.51) 61-99 
Number of co-
morbidities 
Median 4 (IQR 2-5) 4 (IQR 2-5) 3 (IQR 2-4) 0-10 
Charlson Co-morbidity 
Index (CCI) 
Median 6 (IQR 4-7) 6 (IQR 4-7) 6 (IQR 4-7) 0-11 
Total number of 
medicines at discharge 
Frequency   (%) 1470   (100) 644   (43.8) 826   (56.2)  
Number of medicines 
per patient at discharge 
Mean   (SD) 9.48   (3.99) 10.06 (4.20) 9.08   (3.80) 1-22 
 
 
3.5.3 Diagnosis type and co-morbidities of patients  
The types of main diagnosis and co-morbidities for the patients in the study were 
classified using the International Statistical Classification of Diseases and Related Health 
Problems (10th Revision) (ICD-10) and grouped into the most common diseases and is 




Table 14:  Main diagnosis of patients in the study 
Primary diagnosis of patients Number (%) 
Diseases of the Respiratory system 50   (32.2) 
Diseases of the Circulatory system 24   (15.5) 
Syncope and Collapse 20   (12.9) 
Diseases of the Genitourinary tract and system 17   (11.0) 
Infectious diseases 9   (5.8) 
Diseases of the Nervous system 8   (5.2) 
Diseases of the Blood 4   (2.6) 
Diseases of the Digestive tract 4   (2.6) 
Diseases of the Musculoskeletal system 4   (2.6) 
Endocrine, Nutritional and Metabolic disorders 3   (1.9) 
Mental and Behavioural disorders 3   (1.9) 
Neoplasms 3   (1.9) 
Other 6   (3.9) 
 
 
The most common diagnoses in the patient group were diseases of the respiratory system 
32.2% (n=50) of which pneumonia accounts for 14.8% (n=23).  Also, circulatory system 
15.5% (n=24), syncope and collapse 12.9 % (n=20) and respiratory tract infection 10.3% 
(n=16). 
 
A total of 552 co-morbidities were recorded for the 155 patients with a range of 0 to 10.  
The median number of co-morbidities was four for all patients (IQR 4-7), four for male 
patients (IQR 4-7) and three for female patients (IQR 2-4).  
 
Figure 7 shows the skewed distribution of the number of co-morbidities versus 
percentage of patients.  This is because the study sample is a pre-selected elderly group 






Figure 7:  Distribution of number of co-morbidities versus percentage of patients in the 
study (n=155) 
 
The types of associated co-morbidities for the 155 patients in the study were also 
classified using the ICD-10 WHO definitions and the results are indicated in Table 15. 
Table 15:  Profile of the associated co-morbidities  
Profile of associated co-morbidities Number of occurrences  
(%) 
Diseases of the Circulatory system 204   (36.9) 
Endocrine and Nutritional disorders 63   (11.4) 
Diseases of the Musculoskeletal system and Connective tissue 61   (11.1) 
Diseases of the Respiratory system 39   (7.2) 
Diseases of the Genitourinary system 38   (6.9) 
Mental and Behavioural disorders 38   (6.9) 
Diseases of the Nervous system 33   (6.0) 
Miscellaneous eg electronic cardiac device 18   (3.3) 
Neoplasms 17   (3.0) 
Diseases of the Eye 16   (2.9) 
Diseases of the Digestive system 13   (2.3) 
Diseases of the Ear 5   (0.9) 
Diseases of the Skin and Subcutaneous tissue 4   (0.7) 
Diseases of the blood 3   (0.5) 
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3.5.4 Charlson Co-morbidity Index results 
The median Charlson Co-morbidity Index (CCI) was six (IQR 4-7 ) for all patients, for male 
patients six (IQR 4-7) and female patients six (IQR 4-7).  This represents a cohort of study 
patients with a high likelihood of death within one year.  There is a bi-modal distribution 
as 23 (14.8%) of patients have a CCI score of zero. 
 
The frequency of patients against CCI score is indicated in Figure 8. 
Figure 8:  The Charlson Co-morbidity Index (CCI) score versus the frequency of number 
of patients (n=155) 
 
 
3.5.5  Ward of discharge 
Most patients (26.4%) were discharged from ward W6 because at that time of the current 
study this ward was operating as a pre-discharge ward.  Patients were medically fit for 
discharge and waiting for social care packages to be set up, and therefore were waiting 
for discharge on this ward.  It is interesting to note that when the ward of discharge is 
broken down by gender that more females are discharged from W6 compared to males.  
It was felt important to report on the ward of discharge to ensure there was no skew in 
the data due to differences in the medical teams that were responsible for these areas. 










Number of male 
patients (%) 
Number of female 
patients (%) 
W1 24   (15.5) 11   (7.1) 13   (8.4) 
W2 20   (12.9) 8   (5.2) 12   (7.8) 
W3 26   (16.8) 19   (12.2) 7   (4.5) 
W4 20   (12.9) 9   (5.8) 11   (7.1) 
W5 24   (15.5) 6   (3.9) 18   (11.6) 
W6 41   (26.4) 11   (7.1) 30   (19.3) 
Total 155   (100) 64   (41.3) 91   (58.7) 
 
 
3.5.6 Day of discharge 
The day of discharge may be a factor that affects the quality of discharge information. 
Only 6.5% (10) of the patients were discharged over the weekend.  This may explain the 
higher number of patients discharged on Monday (28.4%) and Tuesday (17.4%) due to the 
pressure to discharge patients following admission as an emergency over the weekend. 
 
 
The profile of the number and percentage of patients discharged by day of the week is 
shown in Table 17. 
 
Table 17:  Number of patients discharged according to the day of discharge  
Day of discharge Number of patients discharged (%) 
(n=155) 
Monday 44   (28.4) 
Tuesday 27   (17.4) 
Wednesday 25  (16.1) 
Thursday 23   (14.8) 
Friday 26   (16.8) 
Saturday 7   (4.5) 





3.5.7  Length of stay 
The mean length of stay was 13.17 days and median length of stay was ten days (IQR 5-
18) with a minimum of one day for one patient (this patient was included in the dataset 
as all the medication was included on the discharge summary) and a maximum of 84 days 
for one patient.  The median length of stay for males was seven days (IQR 4-19) and 10 
days for females (IQR 5-18).  There was no significant difference between male and female 
length of stay using the Mann Whitney U test (U=2651.5) and p=0.343. 
 
Figure 9 shows the non-normal distribution of length of stay for the study group. 
 
Figure 9: Distribution of length of stay versus the number of patients (n=155) 
 
 
3.6  Preparation of the discharge summary 
 
3.6.1  Prescriber types 
Most of the discharge prescriptions were written by a junior doctor at Foundation Year 
Level 1 (FY1) (43.9%) and Foundation Year level 2 (FY2) (27.7%) (total 71.6% for both).  
Only six (3.9%) of the discharge summaries were written by a consultant.  No discharge 
prescriptions were written by a pharmacist.  The non-career grade doctors (NCGD) 
account for 17.4% of all discharge summaries written.  The NCGD are permanent, unlike 
junior doctors at FY1 and FY2 levels.  The skewed distribution of the types of prescribers 
who prepared the discharge summary against the percentage of discharge summaries is 





Figure 10: Type of prescribers generating a discharge summary against the percentage of 
the total written (n=155)  
 
 
3.7 Readmission to hospital within 30 days of discharge 
Of the 155 patients in the study, 31 (20%) of patients were readmitted within 30 days for 
a variety of reasons, 17 (54.8%) were female and 14 (45.2%) male.  The demographic 
details of these patients are shown in Table 18. 
 
Only six (3.9%) of the 31 readmissions were potentially due to medication ie four female 
and two males.  Two of the discharge summaries were written by a FY1 level doctor, two 
by ST1 level and two by NCGD doctors.  All patients had a pharmacist verification and five 
had a pharmacy-led MR undertaken.  This part of the analysis will be explored in more 




Table 18:  Demographic details of patients readmitted 
Details of patients readmitted within 30 
days of discharge (n=155) 
Result (%) Potential number of patients  
readmitted possibly due to 
medication (%) 
Age range (years) 61-96  
Number of patients readmitted 31 (20) 6 (3.9) 
Male patients readmitted (%) 14 (45.2) 2 (1.3) 
Female patients readmitted (%) 17 (54.8) 4 (2.6) 
Median number of co-morbidities 4 (IQR 2-5) - 
Median number of medicines  8 (IQR 6-12) - 
 
 
3.8  Pharmacy service and medication-related information 
3.8.1  Pharmacy-led medicines reconciliation (PMR) on admission 
Pharmacy staff at the study hospital carried out 140 MRs of the 155 patients during their 
inpatient stay ie 90.3% occurrence rate.  The time of MR in relation to admission was not 
recorded.  The MR would have been carried out by a pharmacist or a MR trained 
competent pharmacy technician and so the quality of the MR undertaken was the same 
as the competency standard is the same for both sets of staff.  This would be irrespective 
of when it was undertaken.  Also, that any unintentional discrepancies were identified 
and acted upon.  The number of PMR activities per ward is shown in Table 19.  There is 
little variation between the wards in the study apart from ward W6 which was a pre-
discharge ward at the time of the study. 
 





W1 W2 W3 W4 W5 W6 
Yes 140 
(90.3) 
22 18 22 15 22 41 
 
 
3.8.2 Pharmacist verification  
A procedure that is carried out prior to discharge is the clinical verification or validation 
of the discharge summary medication component for accuracy by a pharmacist.  This 
ensures that any unintentional discrepancies are corrected prior to the actual discharge 
of the patient.  This verification can be carried out electronically and remotely in the 
dispensary or on the ward of discharge.  The number of discharge summaries that were 
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verified for accuracy by a pharmacist prior to discharge was 148 (95.5%).  Of the seven 
(4.5%) patient discharge summaries that were not verified by a pharmacist, no patients 
were readmitted for a medication-related reason. 
 
 
3.8.3 Profile of types of discharge medicines on discharge 
The total number of medicines in the study at discharge is 1,470.  The median number 
was nine (IQR 7-12) and the mean was 9.48 (SD=3.99) with a range 1 to 22.  Figure 11 
illustrates the distribution of the number of medicines on the discharge summary against 
the frequency of this occurring. 
 
 





The breakdown of the frequency of therapeutic classes of medicines is indicated in Table 
20 using the WHO ATC/DDD classification. 
 
Table 20:  Occurrence of therapeutic classes of medicines on the discharge summary 
Classes of medicines on the discharge 
summaries 
Number of medicines in class (n=1470)   (%) 
Alimentary tract and metabolism 338  ( 23.00) 
Nervous system 324   (22.04) 
Cardiovascular system 311   (21.15) 
Blood and blood forming agents 140   (9.53) 
Drugs for Respiratory disorders 105   (7.14) 
Antibacterial agents 61   (4.15) 
Hormonal preparations 61   (4.15) 
Musculoskeletal system agents 41   (2.79) 
Ophthalmology agents 28   (1.90) 
Urological agents 25   (1.70) 
Dermatological agents 24   (1.63) 
Miscellaneous agents 7   (0.48) 
Anti-neoplastic agents 5   (0.34) 
 
 
Some of the therapeutic classes of medicines are at an increased risk of causing adverse 
effects in elderly patients (Tangiisuran et al, 2010).  This is because the medicines may 
have a low therapeutic index or have a greater risk of side-effects due to increased 
sensitivity in the elderly population.  These classes include agents used for treating 
dementia and Parkinson’s disease which are included in the nervous system class 
(22.04%), agents used for cardiovascular disease such as diuretics which account for 
21.15% of the medicines and anti-thrombotic agents which account for 9.53% of agents 
in the blood agents class.  This means that the agents causing the highest potential risk of 
an ADE are amongst the common medicines prescribed in this patient group. 
 
 
3.9  Results for essential or gold standards  
The following section of results are broken into the various essential standards E1 to E7 
with sub-groups results where they have implications for clinical practice and future 
policies and procedures.  These essential standards would form the basis of a gold 




3.9.1  Essential standards: Medicine route (E1) name (E3a) and dose (E3b) with 
frequency (E3c) 
Following the Phase I study establishing the essential standards for a quality discharge 
summary, there were four essential standards that should be clearly stated.  These are 
that the generic name of the medicine, the dose, the frequency and the route of 
administration are all specified on the discharge summary.  The percentage adherence for 
these standards is shown in Table 21.  The total number of medicines in the study was 
1,470.  There was a high adherence score for standards E1 and E3a, E3b and E3c which 
provides confidence to the GP that basic information is likely to be received. 
 
Table 21:  Percentage adherence of essential standards E1 and E3 
Code Essential Standard Number Adherence 
(%) 
E1 Total number of medicines with route 
specified 
1,465/1,470 99.7 
E3a Total number of medicines with generic 
name 
1,370/1,470 93.2 
E3b Total number of medicines with a dose 
specified 
1,463/1,470 99.5 





3.9.2  Essential standard: Medicines duration if a course (E2) 
In some cases, it is important that the duration of medicine treatment is specified on the 
discharge summary to prevent inappropriate long-term prescribing or extended courses 
of treatment.  In 69 (44.5%) patients there was a medicine where the duration needed to 
be specified.  This accounts for 96 medicines and in all cases, this was appropriate and 
there was also a reason given for the duration so there is 100% adherence for this 
standard.  Forty-five of the patient’s details of the duration was in relation to an antibiotic 
course.  The frequency of occurrence of the other reasons for the duration being specified 
was very low and included reducing doses of steroids for six patients and vitamin D 




3.9.3 Essential standard: Medication with strength specified (E4a) 
Clinically, in some cases, it is important to know the strength of the medicine prescribed 
on discharge in addition to the dose and is an essential standard in this current study.  It 
was found that only 51 (32.9%) patients had any details of the medication strength 
indicated on the discharge summary out of 155.  This was for a total of 88 out of 1,470 
medicines or 6.0% of the total.  The most common medicines that had the strength 
specified on the discharge summary were: nine patients for eye drops, 18 patients who 
were on an inhaled medicine and seven patients were for medicines used for Parkinson’s 
disease.  The details for the frequency and number of strengths specified on the discharge 
summary is given in Table 22. 
 
Table 22:  The number of medicines with strength on the discharge summary against 
frequency  
Number of medicines with strength on the 
discharge summary per patient 
Frequency of strengths 
stated (n= 1,470)   (%) 
1 25   (1.7) 
2 32   (2.2) 
3 27   (1.8) 
4 4   (0.3) 
 
 
3.9.4 Essential standard: Medication with formulation details specified (E4b)  
In a similar manner to the requirement in some cases to specify the strength of a medicine 
on the discharge summary, it is also essential to specify the formulation of the medicine 
prescribed.  A total of 74 medicines had the details of the formulation specified on the 
discharge summary out of 1,470 or 5.0% of the total.  Details of the characteristics of the 
formulation details frequency of occurrence is given in Table 23.  
 
Table 23:  Details of the formulations stated on the discharge summaries 
Number of formulations 




1 39 39 
2 13 26 
3 3 9 





There were 55 patients who had details of the formulation specified on the discharge 
summary.  The most common details that were mentioned regarding the formulation 
were as follows: 
• 19 (25.7%) formulations were in relation to either liquid or dispersible 
preparations 
• 17 (23.0%) formulations were related to medicines with extended release 
characteristics eg modified release 
• 7 (9.5%) were for various patch formulations. 
 
 
3.9.5 Essential standard: Duration of long term treatment specified (E5) 
One of the essential standard requirements was to indicate if the medication prescribed 
on discharge is for long term use.  It was found that 153 (98.7%) of 155 patients had the 
duration of treatment specified as long term for at least one medicine on the discharge 
summary.  In the two cases that did not have long term treatment specified, these were 
justifiable.  One case was for a patient with end of life medication predominately and the 
other patient was only on a course of antibiotics.  However, further analysis of the 153 
patients who did have long term treatment specified on the discharge summary 122 
(79.7%) of these patients’ discharge summaries had all the medicines listed as being long 
term.  This means that 31 (20.3%) of these patients did not have one or more of their 
medicines specified as being for long term use however these may have been prescribed 




3.9.6  Essential standard: Monitoring or review requirements specified (E6) 
Another essential standard was related to the requirement to indicate if any monitoring 
or review requirements related to medication are indicated on the discharge summary.  
Forty-four (28.4%) patients had a monitoring or review statement on the discharge 
summary related to medication.  There were several monitoring or review statements 
specific for each patient on the discharge summaries reviewed.  However, ten patients 
had monitoring statements related to reviewing the urea and electrolyte results and five 
of the patients had a statement to monitor the blood pressure after discharge in relation 




3.10 Essential Standards related to changes in medicines 
An essential and important cluster of standards determined from Phase I of the study was 
related to the documentation on the discharge summary of the medicines that were 
changed during the inpatient episode of care.  That is medication that was stopped, 
started or a dose was changed during the inpatient episode of care.  Figure 12 indicates 
the potential outcomes on the content of the discharge summary following medication-
related actions during the inpatient episode of care (assuming the medication was written 
on the discharge summary). 
 
Figure 12:  A schematic to illustrate the potential outcomes on the content of discharge 
summaries of medication-related changes during admission 
 
 
3.10.1 Essential standard: Medication stopped during the inpatient admission (E7a) 
The number of patients with medicines that were stopped was 70 (45.2%) as shown in 
Table 24.  The rest of the patients either did not have any medicines stopped during the 
inpatient episode of care or was not specified on the discharge summary.  An important 
aspect of this is whether the medication that is stopped during the hospital admission is 
then updated and documented in the patient’s GP medical records.  It was found that 60 
patients who had medication stopped during the inpatient stay and was indicated on the 
discharge summary had their GP records subsequently updated.  In the case of ten 




Table 24:  Details of patients where medication was stopped 
Medication stopped during inpatient episode on discharge 
summary  
Number of patients 
(n=155)   (%) 
Yes 70   (45.2) 
       GP records updated if medication stopped 60   (39.0) 
No record of reason for stopping medication 14   (9.0) 
Number of patients with no update of stopped medicines on 
GP records 
10   (6.4) 
Not indicated 85   (54.8) 
 
 
3.10.2 Desirable standard: Reason for medication stopped (D5a) 
This desirable standard is included in this section as it is related to medication being 
stopped and keeps all the results together in one section. 
 
Of the 70 of patients who had medication stopped and indicated on the discharge 
summary during the inpatient admission, this accounted for 130 medicines in total.  This 
represented a mean of 1.86 medicines per patient (SD = 1.16 and standard error of mean 
0.138) and a median of 1.5 medicines stopped (IQR 1-2) and with a range from 1 to 7.  
There were 98 of the 130 medicines with a reason indicated on the discharge summary 
(75.4%). 
 
The number of patients with medicines stopped against gender is shown in table 25 
although gender may not be a risk factor for developing an ADR in the elderly (Tangiisuran 
et al, 2012). Chi-square test of gender versus medicines stopped confirms a lack of 
association between gender and medicines stopped in this current study (X² 0.083 and 
p=0.978) 
 
Table 25:  Number of patients with medicines stopped by gender. 
 Male Female Total 
Number of patients with medicines stopped 29 41 70 
Number of patients with no medicines stopped 50 35 85 
 
 
The mean age of patients with medication stopped was 83.93 years old (SD=7.89) 




Of the 70 patients who had medication stopped during their episode of care, 51 (73%) 
were over 80 years old.  The Charlson Co-morbidity Index (CCI) of the 70 patients who had 
medication stopped as an inpatient found that 46 (65.7%) of these patients have a score 
of 6 or above indicating patients who have a risk of 85% mortality within one year.  This 
would indicate that these patients are more likely to be more frail or vulnerable to 
medication-related harm and ADEs. 
 
Of the 70 patients who had a medication stopped, 14 did not have a reason for stopping 
the medication specified on the discharge summary or 20% of those who had medication 
stopped (Table 24).  The reasons for stopping medication were variable but well 
documented.  Additionally, of the 70 patients who had medication stopped on the 
discharge summary 10 patients did not have the GP records updated for 19 medicines 
(1.3% of all medicines).  The 19 medicines that were not updated in the GP records after 
being stopped out of 130 stopped during the inpatient episode of care is shown in Table 
26. 
 
Table 26:  Details of medicines not updated in the GP records that were stopped during 
the inpatient stay 
Patient ID (n=10) Medicine stopped Comment 
A32 ramipril Low blood pressure 
A79 furosemide No reason 
A80 bendroflumethiazide Low blood pressure 
A95 amitriptyline No reason 
A98 methotrexate, losartan, amlodipine, 
adalimumab 
No reason 
A103 furosemide, bisoprolol No reason 
A113 amlodipine, ibandronic acid No reason 





Poor renal function 
Low blood pressure 
A128 pantoprazole Not needed 
 
 
For the 19 medicines out of 130 that were stopped, where the GP records were not 
updated, (14.6% of medicines stopped) ten out these (53.7%), were for cardiovascular 
medicines and four (21.0%) were for musculoskeletal medicines.  These results suggest 
that patients with cardiovascular conditions are at more risk of taking medication post-
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discharge from hospital when they should not be.  This is a cause for concern as this co-
morbidity increases the CCI score and may increase the risk of medication-related harm 
(Hall et al, 2004). 
 
Ten of the 19 (52%) medicines not updated on the GP records did not have a reason for 
stopping documented on the discharge summary. 
 
For the 14 patients where there was no reason for stopping the medication on the 
discharge summary, five did not have their GP records altered.  One of the patients who 
had no reason for the medicines stopped on the discharge summary (Furosemide 
stopped) and no update on the GP’s records was readmitted due to medication but little 




3.10.3 Essential standard: Medication started during the inpatient admission (E7b) 
In a similar manner to medicines that are stopped during the admission, details of 
medicines that are started is also considered an essential standard.  It was found that 131 
(84.5%) of the 155 patients had a medicine started and noted on the discharge summary 
and accounts for 335 medicines.  Most patients had one or two medicines started during 
the admission and accounts for 78 (50.3%) of the total number of patients in the study.    
 
There was no association between the number of medicines commenced and gender (Chi-
square test (X²) 1.942 and p = 0.163; see Table 27). 
 
Table 27:  Number of patients with medicines started, by gender 
 Male Female Total 
Number of patients with medicines started 51 80 131 
Number of patients with no medicines started 13 11 24 
 
 
However, there was a significant relationship between number of medicines started and 
the number of medicines the patient was discharged on (p=0.000) using the Pearson 
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correlation (r= 0.347) which is to be expected as the patients in this total study group are 
already on a median number of nine medicines. 
 
 
3.10.4 Desirable standard: Reason for medication started (D5b) 
This desirable standard is included in this section as it is related to medication being 
started and keeps all the results together in one section.  
 
120 patients of the 131 patients with a medicine started had a reason stated for starting 
the medication. This means that 11 patients (or 7.1% of the total population) did not have 
a reason documented on the discharge summary.   
 
There were 335 medicines started in total and of these 284 (84.8%) had a reason 
documented on the discharge summary. Figure 13 shows the skewed distribution of 
number of medicines started and documented on the discharge summary compared with 








The number of patients who did not have the details about the medicines started during 
the admission put on the GP records was 23 (14.8 %) excluding patients who were on 
antibiotic courses.  However, of these 23 patients, seven were for simple acute analgesia 
ie paracetamol; four were for night sedation or agitation ie zopiclone and haloperidol and 
not expected to be for continuation after discharge, and two were for self-limiting 
conditions ie cyclizine for vomiting.  This leaves 10 patients (6.5% of the total of patients) 
who did not have a record made in the GP records after the medicine was started during 
the inpatient episode of care.  Details of the medications that were not documented in 
the GP records after starting is shown in table 28. 
 
 
Table 28:  Details of medication not documented in the GP records that were started 
during the inpatient admission  
Patient ID (n=10) Medication started Comment 
A33 fresubin, omeprazole None given 
A36 movicol Constipation 
A57 lactulose Constipation 
A68 movicol Constipation 
A85 fresubin, prednisolone None given 
A108 furosemide, bisoprolol, spironolactone None given 
A118 citalopram Depression 
A119 prednisolone, gylcopyrronium inhaler, 
spironolactone 
Steroid course 
A122 buprenorphine patch, senna None given 
A150 hydroxocobalamin None given 
 
 
In total 17 medicines were not updated on the GP records or 5.1% of the number of 
medicines started.  Seven out of the 17 medicines were for medicines affecting the 
alimentary tract and metabolism (41.2%) and four medicines were for the cardiovascular 
system (23.5%). 
 
Ten of the 17 (59%) medicines that were started but not documented on the GP records 
did not have any reason indicated on the discharge summary.  Table 29 gives a summary 




Table 29:  Summary of patients with medication started  
Patients with medication started during inpatient 
episode on discharge summary  
Number of patients 
(n=155)   (%) 
Yes 131   (84.5) 
No record of reason for starting medication 11   (7.1) 
Patients with no update of medication started on GP 
records 
10   (6.5) 
Not indicated 24   (15.5) 
 
 
3.11  Desirable standards of a discharge summary related to medication 
The locally agreed consensus content of a high-quality discharge summary also 
considered the desirable standards related to medicines and thirteen were identified. 
 
 
3.11.1  Desirable standard: Documentation of adverse drug events (ADEs) (D1) 
A record of an ADE was made for 21 (13.5%) of the 155 patients in the study.  Thirty-three 
ADEs were recorded.  Twelve patients had one ADE documented, six patients had two 
ADEs documented and three patients had three ADEs recorded on the discharge 
summary.  Of the 21 patients who had an ADE recorded on the discharge summary, eight 
did not have their GP records updated in terms of a description of the ADE or 5.2% of the 
total number of patients.  None of the patients were readmitted due to medication-
related issues.   
 
No association was found between ADE and gender using the Chi square test (X² = 0.0256, 
p = 0.875) in this study although women may suffer more ADEs than men (Rademaker, 
2011). 
Details of the eight patients and the 12 medicines with an ADE not noted on the GP 
records are indicated in Table 30.  There were therefore 12 out of the 33 ADEs 
documented on the discharge summary not noted on the GP records or 36.4%.  For two 
of the patients, the ADE was included in the clinical narrative of the discharge summary 
rather than listed on the ADE section of the discharge summary following the inpatient 
episode of care.  Five of the 12 (42%) medicines with an ADE not documented in the GP 
records were cardiovascular medicines and again identifies that patients on 
cardiovascular medicines are at greater risk of low quality medication information on the 
discharge summary.  
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Table 30:  Indicating the patients with an adverse drug event (ADE) not documented in 
the GP records 
Patient ID 
(n=8) 
Medication with ADE Details of ADE Medication stopped 
noted on discharge 
summary 
A9 sodium valproate Parkinson’s symptoms Yes 
A12 irbesartan Acute Kidney Injury Yes 
simvastatin Acute Kidney Injury Yes 
A51 mirtazapine Hyponatraemia Yes 
bendroflumethiazide Hyponatraemia Yes 
diltiazem Bradycardia Yes 
A56 haloperidol Parkinson’s symptoms Yes 
A59 fluoxetine Ecchymosis Yes 
clopidogrel Thrombocytopenia Yes 
A72 amitriptyline Drowsiness In narrative only 
A148 nitrofurantoin Skin rash In narrative only 
A149 bendroflumethiazide Hyponatraemia Yes 
 
 
3.11.2 Desirable standard: Details of date and last dose when relevant (D2) 
A desirable standard was whether there were details specified on the discharge summary 
of the date and last dose when a medicine was prescribed where it is important to be 
aware of these details.  For example, a bisphosphonate medicine, administered once a 
week on a specified day for the prevention of osteoporosis or an opioid patch for pain 
control applied once or twice a week. 
 
In the study cohort of 155 patients, 34 (21.9%) patients had a medicine where the date 
and last dose is relevant.  The breakdown of the types of preparations where the dates of 
the last dose were stated, and the frequency is shown in Table 31.  In some patients there 
was more than one medicine where this condition was met.  This desirable standard was 
well documented in this cohort of elderly patients. 
 
Table 31:  Types of medicines or situations where date of last dose is needed 
Types of medicines or situations where date of last dose is needed Frequency 
Weekly bisphosphonate 15 
Two or three times a week opiate patch 8 
Monthly administration 2 
Twice a week alfacalcidol 2 
Weekly vitamin D 3 
vitamin B12 injection 4 
Other eg reducing dose 2 
119 
 
3.11.3  Desirable standard:  Details of no medication prescribed (D3) 
In this current study there were no patients who were discharged without any medication 
and so for this cohort of patients this standard is not applicable. 
 
 
3.11.4  Desirable standard: Allergy status (D4)  
The number of patients who had allergy status documented on the discharge summary 
was 119 (76.8%).  Of these 119 patients where the allergy status was documented 115 
(96.6%) had a description of the allergy type on the discharge summary.  Forty-nine 
(31.6%) of the allergy descriptions were documented as ‘NKDA’ or ‘No Known Drug 
Allergy’ (n=155). 
 
Of the 36 patients who had no allergy status written on the discharge summary 24 (66.7%) 
were written by doctors at either FY Level 1 or 2 
 
 
3.11.5  Desirable standard: Reason for a change in dose of medication (D6) 
There were 31 patients (8 male and 23 female) of 155 (20% of the total number of 
patients) who had one or more dose changes of their medication indicated on their 
discharge summary.  A breakdown of the number of patients and number of dose changes 
is illustrated in Table 32.  In total there were 45 dose changes for the 31 patients. 
 
Table 32:  Number and frequency of dose changes per patient 
Number of dose changes per patient Number of patients (%) (n=155) 
1 21   (13.5) 
2 6   (3.9) 
3 4   (2.6) 
 
 
Twenty-eight of the patients who had a dose change in one or more medicines 
documented on their discharge summary had their GP record updated.  However, there 
are three (1.9% of the total number) patients who did not have their GP records updated.  
Details of the three patients who did not have their GP record updated after a change in 




Table 33:  Details of patients with a dose change during the inpatient admission with no 
update to the GP record 
Patient ID Medication with dose change Comment 
A16 furosemide Increase to 40mg twice a day 
A66 dexamethasone For brain tumour 
A108 furosemide and bisoprolol None 
 
 
For the three patients with no dose change updated in the GP records this affected four 
medicines.  Three (75%) of these medicines were cardiovascular medicines. 
 
Of the 45 medicines with dose changes indicated on the discharge summary, 23 had a 
reason on the discharge summary (51.1%).  Four of the 45 medicines or 8.9% where there 
was a dose change was not documented in the GP records.  However, only 10 had a 
specific reason for a change.  The other comments related to whether the change was an 
increase or decrease in the dose.  Compliance with this standard was therefore 23/45 or 
51.1%.  If a stricter interpretation is taken there was a compliance of 10/45 or 22.2% with 
a specific reason documented on the discharge summary of a change in dose.  Sixteen 
patients did not have a reason for the dose change documented on the discharge 
summary. 
 
Table 34 gives a summary of the patients who had a dose change on the discharge 
summary. 
 
Table 34:  Summary of patients who had a dose change on the discharge summary 
Patients with a dose change on the discharge summary Number (n=155)   (%) 
Yes 31   (20) 
     GP records updated 28   (18) 
     No record of reason on discharge summary 16  (10) 
     Patients with no update on the GP records 3   (1.9) 
Not indicated 124   (80 
 
 
The number of patients who had a medication started, stopped and changed on the 
discharge summary was 13 (8.4%) whilst the number of patients with a medication that 
was started and stopped on the discharge summary was 61 (39.4%).    
121 
 
3.11.6  Desirable standard: Details of adherence problems (D7) 
Only five (3.2%) of the 155 patients had details related to adherence indicated on the 
discharge summary.  In all five of the patients, a compliance device was supplied on 
discharge.  Comments that were mentioned on the discharge summary included one 
patient who was confused and had an accidental overdose, whilst a second comment was 




3.11.7  Desirable standard: Details of who to contact on discharge summary (D8) 
The requirement to provide details of who to contact on the discharge summary was a 
desirable standard.  For this standard evidence of specific reference of a contact was 
considered and not just the name of the verification pharmacist or prescriber.  Only three 
discharge summaries (1.9%) of the 155 patients indicated a point of contact if there were 
any details required about the medication.  These were two cases of details of the 
compliance device supplied (monitored dose system) and one providing details of the 
community pharmacy that was going to dispense the medication after discharge. 
 
 
3.11.8  Desirable standard: Medication with reason for use or indication (D9) 
Of the 155 patients, 126 (81.3%) had at least one medicine with the indication written on 
the discharge summary. 
 
A breakdown of the most common indications recorded on the discharge summary was 
as follows (Table 35). 
 
Table 35:  Most common indication on the discharge summary 
New medicines 118 (76.1%) of patients had a new medicine with 
indication out of 155 patients 
Antibiotics 23 (14.8%) out of 155 patients 
Medicines for constipation 10 (6.5%) out of 155 patients 
 
 
The total number of medicines with the indication specified was only 287 (19.5%) out of 
the total of 1,470 medicines on discharge.  273 of the indications were for new medicines 
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or 95.1% of all medicines with an indication stated on the discharge summary.  Table 36 
illustrates the frequency of indications stated on the discharge summary compared with 
the number of medicines and number of discharge summaries. 
 
Table 36:  Frequency of indication written on the discharge summary compared with the 
total number of medicines with indication stated and number of discharge summaries this 
occurred on. 
Frequency of indications 
stated on the discharge 
summary 
Total number of medicines 
with indications stated 




1 45   (3.1) 45 
2 90   (6.1) 45 
3 42   (2.9) 14 
4 44   (3.0) 11 
5 15   (1.0) 3 
6 36   (2.5) 6 
7 7   (0.4) 1 
8 8   (0.5) 1 
 
 
3.11.9 Desirable standard: Details of advice given on the discharge summary (D10) 
There was only one case or 0.6% of patients where there was any indication given on the 
discharge summary of verbal advice given to the patient.  However, no actual details of 
advice were specified. 
 
 
3.11.10 Desirable standard: Details of compliance aids (D11) 
Fifty-six (36.2%) of the 155 patients had details of the compliance aid specified on the 
discharge summary.  These were all for compliance devices or monitored dose systems 
(MDS) and specified the fact that a patient was either using a device or details of the 
device and the community pharmacy where the medicines were dispensed from.  The 




3.11.11 Desirable standard: Details of other relevant contacts (D12) 
This desirable standard relates to whether there was any mention of other contacts who 
may be involved with the medication aspects of the discharge.  For 55 of patients (35.5%) 
details were included of other relevant contacts.  In all cases these were related to the 
place of dispensing of a compliance aid or monitored dose system (MDS).  The 




3.11.12 Desirable standard: Details of written information (D13) 
Details of written information related to medication were only specified for four patients 
or 2.6% of 155 patients.  Two of these were related to the provision of a medication card 
that was issued to the patients.  One patient’s discharge summary stated details of a 
relative that administers insulin to the patient and the other remaining discharge 
summary gave details about the introduction of allopurinol for the treatment of gout after 
the acute episode of gout was over. 
 
 
3.12 Overall adherence scores 
3.12.1 Overall adherence scores for the essential/gold standards  
Using the method adapted from that described by Aziz et al, (2016), the overall adherence 
score of the discharge summaries for the essential standards is 64.63 %.  Table 37 provides 
the overall adherence characteristics for the essential or ‘gold standards’. 
 
Table 37:  Overall results for level of adherence to the essential standards 








There are 14 patients who have an adherence score of ≥ 80% (9% of patients) and 15 




3.12.2  Overall adherence scores for the additional essential standards 
Overall adherence scores were also calculated for the standards of the study that were 
not identified as being essential but were considered in the studies by Aziz et al, (2016) 
and Hammad et al, (2014) and shown in Table 38 and based on the number of medicines 
involved.  These essential standards related to medicines that were changed, started or 




Table 38:  Overall adherence scores for the therapy change standards by the number of 
medicines 
Group n/N % 
Medication changed with a reason on discharge summary 23/45 51.1 
Medication stopped with a reason on the discharge summary 98/130 75.4 
Medication started with a reason on the discharge summary 284/335 84.8 
 
 
If the scores are included for the therapy changes then the overall adherence score is 
67.05 %. 
3.13 Influence of variables on adherence to the gold standards 
A number of variables were selected to test the association that the quality of discharge 
adherence score was not associated with hospital readmission within 30 days of 
discharge. The following variables were chosen because: 
(a) Gender and age range - some evidence suggests that women suffer more ADRs 
than men and therefore a patient with MRH may be associated with gender and 
the quality of the discharge summary (Rademaker, 2001) whilst increasing age 
may affect ADRs due to physiological changes (Tangiisuran et al, 2010). 
 
(b) The number of medicines and certain conditions or co-morbidities have been 
found to be associated with an ADR in patients 65 years or older (Onder et al, 
2010) as well as length of stay and therapeutic class of medicine (Tangiisuran et 
al, 2012) and therefore included as variables in this study. 
 
(c) The level of experience of the doctor writing the discharge summary may be 
important as they may be unaware of the discharge requirements of a GP (Yemm 
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et al, 2014) and may have a major input into the level of quality of the discharge 
summary. 
 
(d) The process of medicines reconciliation and related verification of a discharge 
summary may have the ability to influence the accuracy and quality of a discharge 
summary and are included as variables (Sentinel Event Alert, 2006). 
 
(e) Readmission has been found in up to 23% cases to be due to ADRs (Davies et al,  
2010) and therefore may be related to the quality of the discharge summary.  The 
use of a compliance aid was included as a variable as it may be a proxy for patients 
who require additional assistance with their medication and so may be more 




3.13.1 Influence of gender 
The variable of gender was considered to see if there is any association with the ‘gold 
standard’ adherence score. From univariate tests the mean percentage adherence was 
calculated and is shown in Table 39.  
 
Table 39:  Gender and mean adherence score in relation to the gold standards 
Gender Mean adherence 
(%) 
SD n 
Female 64.96 8.17 91 
Male 64.15 10.65 64 
 64.63 9.25 155 
 
 
There was no association between gender and the quality of the discharge summary in 





3.13.2 Influence of age range 
The patients in the study were all over 65 years of age but it was of interest to establish if 
the age range of the patients influenced the adherence score for the ‘gold standards’.  
From univariate analysis using the mean scores of the percentage adherence with the gold 
standards in relation to age range was calculated (Table 40).  Using the Mann Whitney 
test no association was found between the youngest age group (61-71 years old) and the 
oldest group (≥92 years of age), (U= 210.5 and p= 0.191). 
 
Table 40:  Age range and mean adherence score in relation to the gold standards 
Age range (years) n Mean adherence (%) SD 
61-71 19 62.35 7.20 
72-81 42 64.67 9.26 
82-91 69 64.84 10.36 
Over 92 25 65.67 7.35 
All 155 64.63 9.25 
 
 
3.13.3 Influence of number of medicines 
A variable that may influence the adherence to the ‘gold standard’ was that of the number 
of medicines on the discharge summary.  From univariate analysis it was found that there 
was little variation in the mean adherence score against the number of medicines (Table 
41). 
 
Table 41:  Number of medicines on the discharge summary and mean adherence score in 
relation to the gold standards 





1-5 66.46 2.07 21 
6-9 64.78 1.44 59 
10-15 63.08 1.19 65 
>15 64.47 3.31 10 
Overall 64.63 1.20 155 
 
 
There was no association between the number of medicines on the discharge summary 
and the adherence score for the quality of the discharge summary in relation to the 
essential/gold standards using the Kruskai Wallis test (value = 17.177. p = 0.641).  
127 
 
3.13.4 Influence of therapeutic classes 
The main therapeutic classes found in the study were anti-thrombotic agents, anti-
dementia agents, diuretics, diabetes agents and agents used for Parkinson’s disease. 
These are all potentially agents that can cause medication-related harm in the elderly. 
 
The mean overall level of adherence with the ‘gold standards’ was calculated using 
univariate statistics and compared with the therapeutic class of a high-risk medicine 
(Table 42).  There was no association between highest performing therapeutic agents, 
anti-dementia agents, and adherence score using the Mann Whitney test (U= 685 and p= 
0.452) or for the lowest performing agents, anti-thrombotic agents (U= 2610.5, p = 0.291). 
 
Table 42:  Overall mean adherence score with gold standards compared with certain 
therapeutic classes of medicines 
Therapeutic class Mean adherence 
(%) 
SD Number of 
patients (n) 
Anti-thrombotic 63.99 9.71 92 
Anti-dementia 66.96 8.78 11 
Diuretics 64.61 9.11 50 
Diabetes 65.90 8.57 24 
Parkinson’s disease 65.82 10.17 20 
All medicines 
(overall) 
64.63 9.25 155 
 
 
3.13.5 Influence of type of prescriber 
The type of prescriber who produced the discharge summary was considered. From 
univariate analysis the mean adherence scores for the ‘gold standards’ were calculated in 
relation to prescriber type (Table 43).  In comparing the most senior prescribers ie 
consultants with the most junior prescribers ie FY1, there is no association with the 




Table 43:  Prescriber types and mean adherence score in relation to the gold standards 





Nurse 0 70.00 0.00 1 
Foundation Year 1 1 64.09 9.60 68 
Foundation Year 2 2 66.15 8.70 43 
Speciality Training (ST) 1 3 70.60 17.87 3 
ST2 4 57.57 9.36 5 
ST3 5 70.00 14.14 2 
Consultant 6 61.85 13.16 6 
Non-Career Grade 
Doctor (NCGD) 
7 64.18 6.67 27 
Overall compliance All 64.63 9.25 155 
 
 
3.13.6 Influence of pharmacist verification 
The influence of the intervention of a pharmacist verification of the discharge summary 
was also considered.  From univariate analysis the mean scores of the percentage 
adherence against pharmacist verification was calculated (Table 44).  However, this is 
insufficiently powered, as the number of discharge summaries without a pharmacist 
verification was too low. 
 
Table 44:  Pharmacist verification and mean adherence score in relation to the gold 
standards 
Pharmacist validation n Mean adherence 
(%) 
SD 
No 7 60.00 13.88 
Yes 148 64.84 8.99 
 
 
3.13.7 Influence of pharmacy-led medicines reconciliation 
The mean scores of the percentage adherence with the gold standards in relation to 
pharmacy-led medicines reconciliation (PMR) was calculated to establish if a PMR 
contributed to the adherence score (Table 45).  The Mann Whitney test found no 
association between PMR and the quality of the discharge summary adherence score (U= 




Table 45:  PMR and mean adherence score in relation to the gold standards 
PMR n Mean adherence 
(%) 
SD 
Yes 140 64.56 9.25 
No 15 62.20 9.57 
Overall 155 64.63 9.23 
 
 
3.13.8 Influence of patients readmitted 
Phase III of the study considers the likelihood of the level of the quality of the discharge 
summary contributing to a patient’s readmission.  Using univariate analysis, the mean 
scores of the adherence with the ‘gold standards’ in relation to patients readmitted (for 
any reason) was calculated (Table 46).  No association was found between patients 
readmitted and the adherence score for the quality of the discharge summary using the 
Mann Whitney test, (U= 1636 and p= 0.197). 
 
Table 46:  Patients readmitted and mean adherence score in relation to the gold standards 
Patient readmitted n Mean adherence (%) SD 
Yes 31 66.66 9.33 
No 124 64.17 9.20 
 
 
3.13.9 Influence of length of stay 
The length of stay is a variable that may influence the adherence score to the ‘gold 
standards’ so from univariate tests the mean scores of the percentage adherence with 
the ‘gold standards’ in relation to patient’s length of stay was calculated (Table 47).  Using 
the ANOVA test statistic (F=0.84, df= 3) found a p value of 0.475 so there was no 
relationship with the quality of the discharge summary and length of stay. 
 
Table 47:  Length of stay and mean adherence score in relation to the gold standards 
Length of stay 
(days) 
n Mean adherence 
(%) 
SD 
1- 7 71 65.29 10.13 
8-14 33 62.57 9.68 
15-28 39 65.50 7.95 




3.13.10 Influence of compliance aid 
Of the 56 patients with a compliance aid the overall adherence score with the gold 
standards was 65.36% (SD 7.60) compared with 64.63% for overall adherence.  From the 
Mann Whitney test no association was found between patients who used a compliance 
aid and adherence score, (U= 2596.5 and p= 0.510).  This group was chosen because 
patients who require a compliance aid may be considered at higher risk of a medication 




3.14 Discussion  
The main finding of Phase II of the pilot study was that the overall adherence to the ‘gold 
standards’ (E1 to E7 essential standards) was 64.63%, reflecting the quality of discharge 
information in relation to medication using the essential standards identified by 
consensus in Phase I.  This is important and provides preliminary evidence of the use of a 
modified e-Delphi technique based on published recommendations and local expert 
opinion to identify the essential components of a discharge summary and measure how 
well this is being adhered too.  
 
The results provide evidence of the level of adherence to the individual standards and 
demonstrates a marked variation in meeting the standards ie duration if a course (E2) is 
100% whilst formulation being specified (E4b) is 5%.  The following discussion will 
consider the results and implications for clinical practice, policy and future research. In 
addition, a comparison will be made with other published studies to identify where there 
is a common issue or new issue that needs to be considered. 
 
This is the first study where the relationship between the classification of the therapeutic 
classes used in the discharge summary have been considered that could determine the 
risk of readmission due to the low quality of discharge information.  Whilst no relationship 
was found in this study, there are indications that some therapeutic classes may pose 
greater risk than others and due diligence should be exercised when completing the 
discharge summary for these classes eg cardiovascular medicines.  Some of these themes 
will be explored more fully in Chapter 5 and this preliminary pilot study provides a 




The essential standards, E1 to E3 and E5, could be considered as essential and core 
standards.  That is, they provide the basic information to the GP of the medication 
information on the discharge summary ie route, duration (if a course or long term), 
generic name, dose and frequency.  These standards all had an adherence score of > 90%.  
In comparison the essential standards for strength being specified and formulation were 
very low at 6% and 5% respectively.  One of the reasons for this could be that the design 
of the discharge summary template at the study hospital forced the prescriber to 
complete standards E1 to E3 and E5 whereas there was no requirement to specify the 
strength and formulation on the discharge summary.  The implications for this are 
discussed in Chapter 5.  However, the consequence for clinical practice is the excellent 
adherence to the core essential standards will improve communication to the patients GP 
and reduces the risk of a medication error.  
 
The essential standard requiring the strength and formulation to be specified (E4a and 
E4b) scored poorly with only 6% and 5% adherence respectively.  Although these 
standards were considered essential it is not needed for all medicines. Shah et al, (2016) 
reported adherence of 60.3% for formulation but did not give a reason for this.  It may 
have been related to the design of the discharge template used in each hospital studied.  
For many oral medicines the dose and strength is implicit so that the GP does not need to 
know the strength of the preparation eg paracetamol tablets.  It will only be of importance 
if there is an ambiguity of the dose or there is more than one strength of a preparation 
that could be prescribed.  This may explain why only certain types of medicines had the 
strength specified eg eyedrops, inhalers where more than one strength exists.  Also, the 
poor score for formulation again may be due to it being implicit with the dose instructions 
eg modified release preparations.  The implications for clinical practice are that the 
prescriber and verification pharmacist need to ensure that the discharge summary is 
clearly and accurately annotated with the strength and formulation details if it is clinically 
relevant to do so.  Doctors will often not be familiar with the strengths and formulations 
available and this is likely to be a task for the pharmacist. 
 
The adherence score for essential standard of details of monitoring or review required 
(E6) was only 28.4%.  This may be a result of the prescriber’s either not concerned 
clinically that the GP needs to undertake any specific monitoring post-discharge or not 
being aware of the importance of this standard for the GP.  Junior doctors are often not 
aware of the discharge information requirements of a GP (Yemm et al, 2014).  This cohort 
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of patients are all elderly often with multi co-morbidities and polypharmacy and this 
should be an area of priority when designing a training package for junior doctors on 
producing a ‘gold standard’ discharge summary.  The expert panel in Phase III identified 
this as an important standard to reduce the likelihood of a readmission as it provided 
advice to the GP on what needs to be followed up post-discharge.  In a recent study in 
Ireland a GP survey of what they considered to be important also included information on 
follow-up and supports the increased emphasis on completing this aspect of the discharge 
summary (Murphy et al, 2017). 
 
A cluster of essential and desirable standards of interest are those related to where there 
has been a change in the medication ie stopped (E7a), started (E7b) and a reason specified 
on the discharge summary for it being stopped (D5a), started (D5b) or changed (D6).  In 
this current study these standards were inconsistently applied.  Details of medicines 
stopped was only provided in 45.2% and started in 84.5% of cases.  It was not always clear 
in the discharge summary whether the medication had been stopped or started if it was 
not clearly documented on the Evolve® discharge summary.  This may contribute to a 
medication discrepancy post-discharge.  In this current study 14.6% of medicines stopped 
and 5.1% of medicines started were not reconciled on the GP records post-discharge. 
Shah et al, (2016) found that for medicines that were stopped/started or had a dose 
change 12.5% were not actioned within seven days of the receipt of the discharge 
summary.  There was a trend for cardiovascular medicines to be omitted on the GP 
records for medicines started and stopped in this current study.  This was also evident in 
patients with a high CCI score and therefore is a concern that patients who are at most 
risk have low-quality information on their discharge summaries and poor discharge 
medicines reconciliation.  Costa and Byon, (2018) found that for every medication 
discrepancy post-discharge, the odds of being readmitted within 90 days increases by 
32%.  A clinical implication is that elderly patients with a high CCI score need to be 
prioritised to have a gold standard discharge summary produced, as they may be more 
liable to medication-related harm post discharge.  It is increasingly being recognised that 
de-prescribing of medicines is important to optimise safe prescribing (Barnett and Jubraj, 
2017).  Hence, if a medication is intentionally stopped it is important that the GP is 
informed about this and acts upon the recommendation.  A larger study, if undertaken, 




In the study hospital site, the inpatient drug administration record has a section for each 
medicine to annotate the status on the chart according to the ‘ENID’ classification.  This 
means that doctors and pharmacy staff can indicate on the record if the medication is: 
Existing, New, Increased or Decreased at any stage of the inpatient episode of care.  When 
the electronic discharge summary is completed the prescriber and/or the verifying 
pharmacist can indicate the status of therapy for each medication directly from the 
inpatient prescription.  This process may contribute to the higher number of medicines 
started that have a reason specified on the discharge summary (D5b), in this current study 
of 84.8%, because the status can be taken from the record on the chart at the point of 
producing the discharge summary.  This study has better results compared with the 
studies by Uitvlugt et al, (2017) of 72%; Aziz et al, (2016) of 51.5%; Hammad et al, (2014) 
of 34.8%; and Shah et al, (2016) of 49%.  There are also similar results for reasons for a 
medicine stopped (D5a) of 75.4% in this current study compared with 20% in the study by 
Hammad et al, (2014) and 57% by Shah et al, (2016).  
 
In this study ADE documentation was considered a desirable standard (D1).  Only 21 
patients (13.5%) had an ADE documented on the discharge summary.  A limitation of this 
study was that the patient’s full medical records were not analysed to establish if an ADE 
occurred during the inpatient stay but was not documented.  The finding that eight 
patients out of 21 did not have an ADE documented on the GP records representing 12 
medicines with an ADE is a concern.  Whilst the number of ADEs is small (1.4% of the total) 
the high ratio of ADEs not documented in the GP record (36.4%) increases the potential 
for future medication-related harm to the patient.  There would be no record of the ADE 
in the primary care records.  This standard would be an interesting area of future study to 
understand why the GP records were not updated and to assess the level of risk of ADEs 
occurring if not documented in the GP records.  There was a small tendency for 
cardiovascular medicines causing an ADE (five or 42% of the total omitted) to be omitted 
from the GP records and this reinforces the need to prioritise patients on cardiovascular 
medicines to obtain a high-quality gold standard discharge summary. 
 
The allergy section was only completed for 76.8% of patients (desirable standard, D4).  
This is consistent with the results of Shah et al, (2016) who reported allergy status 
documented in 75.8% of cases and may reflect why it is a desirable standard.  This is a 
further example of the design of the discharge summary template influencing the 
performance.  In the study hospital the allergy section is separate to the medication 
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section and is not mandatory to complete so it can be easily ignored by the prescriber 
who may not have time to compete the discharge summary fully.  There is therefore 
potential to improve this standard either through electronic template re-design or 
empowering other healthcare staff eg nurses, pharmacy staff to ensure this section is 
completed prior to final discharge of the patient. 
 
There was little evidence of any value being placed on either verbal advice being provided 
(D10, 0.6%) or written information provided (D13, 2.6%) and this agrees with that found 
in a systematic review by Wimsett et al, (2014).  In this review little value had been put 
on the importance to provide advice to patients, verbally or written about medication at 
discharge and this is a neglected area of patient care that requires further study and 
emphasis in clinical settings. 
 
This does not mean it did not occur but was not documented.  Interestingly, at the study 
hospital, patients can be given a bespoke ‘medication card’ which lists all the medicines 
the patient is taking, when to take them and any side-effects to be aware of.  There was 
no evidence of the study patients receiving these cards and it may be worth exploring 
their use again as there is value in using them (Costa and Byon, 2018).  Often elderly 
patients are on complex medication regimens and there is evidence that the more 
complex the medication regimen is it 
 may lead to medication discrepancies at home so that any intervention to support patient 
understanding of the medication regimen should be encouraged (Costa and Byon, 2018). 
 
A secondary objective of the study was to consider the level of PMR and pharmacist 
verification prior to discharge.  In both cases there was a high score with 90.3% of patients 
receiving a PMR prior to discharge and 95.5% of patients having a pharmacist verification 
of the discharge summary prior to discharge.  This compares well with the audit carried 
out by Shah et al, (2016) which found only 49% of discharge summaries had been verified 
by a pharmacist and this may reflect difference in policy between hospitals and the 
sample of patients in each study.  Whilst both results are encouraging there is still some 
caution with this data.  There is evidence that despite a PMR being undertaken during 
admission, not all unintentional discrepancies identified are been acted upon prior to 
discharge.  Cornu et al, (2012), found that the acceptance rate for pharmacist’s 
interventions was only 72.3% and only corrected in 55.6% of cases.  Also, pharmacists are 
not available 24 hours a day and will not be able to screen all discharges (Cornish et al, 
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2005).  It is therefore a limitation of the study that there was no reconciliation undertaken 
between the medication that the patient was admitted on and that on discharge.  If a 
further study was undertaken it would be useful to do this to strengthen the study 
methodology.  Furthermore, a larger study may be able to determine if the absence of 
pharmacist verification of the discharge summary affects the quality of the discharge 
summary particularly patients who are discharged out of hours or at weekends when 
pharmacists may not be available.  It may be necessary for pharmacy managers to 
consider a delay in sending the final discharge summary to the GP to ensure that a 
pharmacist verification has taken place to improve the accuracy of the discharge summary 
as recommended by Yemm et al, (2014) although this was not identified in this current 
study due to the lack of power to detect an effect. 
 
A further secondary objective was to determine if any patient, medication or service 
variable influenced the level of adherence to the essential standards.  
 
In this current study whilst many variables were considered and analysed there was a lack 
of association of the total adherence score for the gold standards and gender, number of 
medicines, therapeutic classes, type of prescriber, influence of pharmacist verification, 
influence of PMR, age range, length of stay and requirement for a compliance aid.  The 
reasons for the lack of association are likely to be multi-factorial.  For some of the essential 
standards identified the performance was determined predominantly by the inherent 
design specification of the electronic discharge summary template.  For some variables 
the level of performance was high such as PMR (90.3%) and pharmacist verification prior 
to discharge (95.5%) and so any effect of the absence of the intervention would be difficult 
to detect with the small sample size.  It is recommended that this preliminary pilot study 
should be undertaken with more patients and in more settings to increase the power, 
reliability, validity and generalisability. 
 
Although undertaken in a different healthcare setting (Norway) an audit evaluated the 
quality of medication information in discharge summaries and variables associated with 
the level of quality (Garcia et al, 2017).  The method used to calculate adherence was 
different to that used in this current study and was based on that described by Hammad 
et al, (2014).  Garcia et al, (2017) reported lowest adherence scores for generic name and 
indications for medicines use whilst in this current study generic names (E3a), had a high 
score (93.2%) and indications (D9) a low score of 19.5%.  These differences may be due to 
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the different processes to prepare a discharge summary between Norway and the UK 
where the discharge prescription is written by hand in Norway.  Males had a higher score 
than females in the Norwegian study, but, this was not found in this current study.  It was 
postulated that this may be due to differences in the information supplied on admission 
between genders. In this current study the mean age of patients was older (83 years) 
compared with 65 years in the Norway study and may also be a confounding factor.  These 
findings support the need for further research of the effects of these variables in larger 
studies. 
 
A recent study in the USA has suggested that the complexity of the medication regimen 
may be an important factor resulting in medication discrepancies at home and a further 
study could look at measures of medication complexity as a variable on the quality of the 
discharge summary (Costa and Byon, 2018).   
 
Interestingly the level of adherence to the discharge summary was not influenced by the 
number of medicines the patient was discharged on or the length of stay in this current 
study.  It may be expected that the higher number of medicines a patient is on the lower 
the adherence score.  This reason for the lack of association may be because patients 
were under the care of an elderly care medical team that knew the patient and could 
complete a high-quality discharge summary and the high level of pharmacist verification 
prior to discharge.  However, only 14 (9%) of patients had an adherence score of ≥80% in 
the current study and so there is room for improvement.  It is worth noting that the scores 
for the strength and formulation essential standards were very low and reduced the 
overall adherence scores but demonstrated that further work is needed to improve the 
gold standard adherence levels. 
 
Despite the lack of clear variables that influence the quality of a discharge summary for 
medication-related information, the method and approach used can be developed for 
further, larger research studies. 
 
 
3.14.1 Comparison with other studies 
Several studies have considered the adherence to a standard for discharge summaries 
related to medicines and are worth considering as they are either based in England or 
Ireland and reflect current practice in the UK ie Aziz et al, (2016); Hammad et al, (2014); 
and Shah et al, (2016) and a comparison with this study is shown Table 48. 
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Demographic details     
Number of discharge summaries 155 198 3,444 1,454 
Median age of patients 85 63 66 72 
% male patients 41.3 50.3 49.1 47.0 
Median number of medicines 9 NR 5 NR 
Adherence results (%)     
Duration stated (E2) 100* 87.8 35.9 72.5 
Generic name specified (E3a) 93.2 97.8 NR 97.9 
Dose stated ((E3b) 99.5 98.3 87.5 92.2 
Frequency stated (E3c) 99.7 98.6 89.6 98.8 
Reason for medication stopped specified 
(D5a) 
75.4 NR 20.0 57.0 
Reason for medication started specified (D5b) 84.8 51.5 34.8 49.0 
Reason for change specified (D6) 51.1 63.7 20.5 39.0 
Key: 
NR = Not Reported 
*    = Duration specified if for a course 
 
There is generally good adherence to the core essential standards with results 
consistently at or above 90% for generic name, dose and frequency (E3a to E3c).  This 
would suggest that these standards are embedded into the discharge processes.  There is 
considerable variation in adherence to the duration standard (E2).  In this study standard 
E2 relates to duration if it is a course.  In the studies by Aziz et al, (2016) and Hammad et 
al, (2014) no definition of what this standard means was provided whereas Shah et al, 
(2016) define this standard as instructions for ongoing use/supply stated, which is more 
useful.  A difference in results might be expected if there is differentiation between a 
specific course of treatment versus long term treatment.  This is important for clinical 
practice as the GP needs clarity on the anticipated duration of treatment (Aziz et al, 2016). 
 
What is apparent for all studies is the poor adherence to the standards relating to 
documenting reasons for medication changes varying from 20.5% in the study by 
Hammad et al, (2014) to 63.7% in the study by Aziz et al, (2016) and 51.1% in this current 
study.  There are also discrepancies in the adherence for reasons for medicines stopped 
and started indicated on the discharge summary.  It has been suggested that the low 
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adherence for these may be due to being missed due to human error (Hammad et al, 
2014).  Whilst this is a possibility, it suggests that there is a lack of awareness of the 
importance of this type of information by hospital staff for the GP. 
 
The results of this study and the other published studies provides evidence that there is 
still an urgent need to improve the quality of discharge information relating to medication 
changes to reduce the potential for any medication-related harm post-discharge. 
 
The overall adherence score for the essential standards in this study was 64.63%.  If the 
standards for therapy changes were included, then, the adherence score would be 67.05% 
which is still below the ideal level eg >80%.  In the study by Aziz et al, (2016) the overall 
adherence score to the standards was of a similar order, 77%.  The method recommended 
in the study by Aziz et al, (2016) was used and adapted in this study and supports the use 
of this method for further larger studies. 
 
A further study was recently carried out in a 550-bed teaching hospital in Holland 
investigating the level of adherence to the Dutch healthcare guidelines for medication-
related information in discharge letters (Uitvlugt et al, 2017).  Two hundred and eighty-
eight patients were included in the study with a mean age of 62 years and 46% were male.  
In total 1,432 (53%) of 2,696 medications were documented incorrectly in the discharge 
summary.  In 453 (16.8%) cases there was absence of either the drug name or dose.  There 
was no differentiation between the drug name or the dose of the medication.  This 
contrasts with the results in this current study and others.  In this current study the generic 
name was documented in 93.2% of medicines and demonstrates the difference where 
there are different processes, health systems and electronic systems.  Also, 28% of new 
medicines were started without a reason mentioned on the discharge summary 
compared with 15.2% in this current study. 
 
There has been recognition that the content of discharge summaries is a critical source of 
information in the transition of care from hospital to primary care services (Van Walraven 
and Rokosh, 1999).  Clearly, one of the most important components of the discharge 
summary is that related to medication and has been cited as often being missing (Belleli 
et al, 2013).  This has prompted several audits to assess the level of performance in 
relation to medication-related incidents in the discharge summary.  McMillan et al, (2006) 
found that there were 1.42 errors per discharge summary for medical patients discharged 
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from hospital.  Tan et al, (2014) carried out an audit of discharge summaries of medication 
changes and follow-up expectations with a method like this current study so a useful 
comparison can be made.  The study was based in a 607-bedded teaching hospital in 
Australia.  Patients were eligible if they were discharged directly from an acute 
assessment unit.  Basic demographic data, hospital length of stay and admission and 
discharge medications were recorded.  The specific criteria of the audit were in relation 
to information on medication changes and of follow-up.  A comparison between the study 
by Tan et al, (2014) and this current study is shown in Table 49. 
 
Table 49:  Comparison of the audit results by Tan et al, (2014) and this study 
Dataset Tan et al, (2014) Current study 
Number of patients 219 155 
Mean Age (years) 73 83 
Mean number of medicines 7.8 9.48 
Common classes of medicines (%):   
Alimentary tract 24.2 23.0 
Nervous system 23.2 22.0 
Cardiovascular system 11.3 21.0 
Anti-infectives 28.0 4.0 
MR (%) 93 90 
Indications (%) 50.0 19.5 
 
 
The study by Tan et al, (2014) gave remarkably similar results to this current study despite 
being based in a different country with a different healthcare system and ward setting 
(acute assessment unit versus care of the elderly wards).  In the Australian study only 50% 
of the patients with a medication change had documentation relating to indications for 
these changes and follow-up expectations.  It was felt that the reason for the low 
percentage was that discharge summaries were often completed by junior medical staff 
who may not have been directly involved in the patients’ care.  In Norway, Garcia et al, 
(2017) also found that there was a low adherence score for indications stated. 
 
In this current study the level of adherence with indications of 19.5% compared with 50% 
in the Tan et al, (2014) and, 11% in the Shah et al, (2016) studies. It is difficult to explain, 
as it would be expected that the junior doctors being elderly care ward-based have 
greater knowledge about the patient when they prepare the discharge summary and 
improve the quality of medication-related information. It could be that there was greater 
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emphasis working in an acute assessment unit on medicines compared with working in a 
care of the elderly ward.  This may be of relevance in clinical practice in that the type of 
ward in which the discharge summary is prepared may have an influence on the quality 
of medication-related information on the discharge summary.  
 
It has also been found that elderly patients may not understand intended medication 
changes or new medicines post-discharge (Ziaelan et al, 2012).  
 
So, future research could look at the effect of both the differences between ward 
specialities and adherence to the gold standards and the effect of interventions to 
improve patients understanding of their medication at discharge that could reduce post-
discharge medication errors.  
 
The successful application of the modified e-Delphi technique to develop gold standards 
for a discharge summary has been demonstrated in this preliminary pilot study and could 
be further developed for a larger multi-site study.  The method of calculating the total 
adherence scores could also be used in a larger study to validate the method.  Whilst no 
association was found between the gold standard adherence score and a variety of 
variables, this would be worth exploring in a larger, multi-site study.  
 
Whilst the small study sample size and the use of only one site/speciality for the data 
collection with a single electronic discharge process limits the generalisability of the 
result, this preliminary pilot study does provide a template for further research.  
 
 
3.15  Limitations of Phase II of the study 
The study was conducted in a single site district general hospital in a rural area of England 
which limits the generalisability of the results to other types of hospitals which may 
operate in a different manner.  Whilst the cohort of patients selected were elderly the 
study population may not be representative of the population of elderly patients in 
England.  Also, whilst the wards selected to recruit patients were identified as care of the 
elderly wards, they may not reflect a typical population of elderly patients within the 




The data collection period for the audit of adherence with the discharge standards was 
only over a six-month period and was carried out between January to June 2016 and may 
not be representative of all types of discharge over a longer consecutive period as well as 
practice changing since 2016. 
 
The sample size was small of 155 patients and therefore is a pilot for a larger sample size 
and study.  No attempt was made to record the reconciliation of the pre-admission 
medicines with the medicines at discharge.  This means that medicines omitted due to 
intentional and unintentional reasons may not have been recorded on the discharge 
summary.  However, most of the discharge summaries were subject to a PMR and 
pharmacist verification of the discharge summary prior to discharge to minimise any 
transcription errors at discharge.  These two interventions would reduce any 
unintentional discrepancies between the pre-admission medicines and the discharge 
medication.  However, there is evidence that not all pharmacist interventions after MR 
are acted upon prior to discharge (Cadman et al, 2017). 
 
This current study only considered patients who were admitted as an emergency and it 
may be there are differences between emergency and elective admissions that influences 
the quality of the discharge summary that warrants a further study.  Hammad et al, (2014) 
found slightly higher adherence for discharge information for emergency admissions for 
medication changes compared with elective admissions.  This was not possible to consider 
in this study due to time constraints, but, the method could be used for other types of 
admissions.  It is worth noting that the quality of outpatient medication information is 
also poorly studied and may be another interesting area to consider for a future study.  
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Chapter 4: Relationship between the quality of discharge 
information related to medication and readmission to hospital of 
elderly patients (Phase III) 
 
4.1  Overview 
In chapter three, Phase II of the study provided a result for the overall adherence to the 
‘gold standards’ of a discharge summary of 64.63%. Whilst there was a lack of association 
with the variables the method employed provides a basis for a larger, multi-site study.  
 
Phase III of the study was to evaluate whether the quality of medication-related 
information (MRI) in the discharge summary had any impact on the likelihood of a 
readmission to hospital due to medication within at least 30 days of discharge of elderly 
patients.  The hypothesis being that a poor-quality discharge summary related to 
medication information may cause or contribute to a hospital readmission. 
 
Various studies have been undertaken to assess the extent of either the severity or 
likelihood of a medication error occurring (Hartwig et al, 1991; Sakowski et al, 2008; and 
Dean and Barber, 1999).  For example, there has been considerable interest in the ability 
to predict or quantify the severity of medication-related harm (MRH) due to medication 
errors or adverse drug reactions (ADR).  In this study the application of methodology used 
in the assessment of likelihood of medication-related harm occurring will be used so it is 
important to consider the basis of the research method utilising published studies related 
to MRH and/or ADRs. 
 
The basis of the assessment or measurement of severity of the medication error can vary 
depending on the study type and measuring patient outcomes (Hartwig et al, 1991) or 
processes (Sakowski et al, 2008).  Any method that is employed must be valid, reliable 
and practical to measure.  A method that adopts a patient outcome approach is likely to 
have high validity ie be a real measure of the severity but may have practical limitations 
especially if the data is undertaken through observations (Dean and Barber, 1999). 
 
If an observation-based study is employed, then it can be split into two types.  The first 
type is when an observer is aware of the error as it occurs such as during drug 
administration.  This type of observation may cause ethical concerns as an error may occur 
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or be about to occur which requires the observer to make an intervention.  So, in this type 
of study the actual patient outcome may not be known (Ridge et al, 1995).  The other type 
of observational study involves a retrospective analysis.  This may make it difficult to 
identify any clinical effect due to a delay in recognising cause and effect (Dean and Barber, 
1999).  An alternative option therefore is to consider assessing the severity based on a 
potential patient outcome and will not be susceptible to subjective measures. 
 
An important study that provided a basis for this current study was carried out by Dean 
and Barber in 1999.  This study described a reliable and validated method to score the 
severity of medication errors based on potential patient outcomes.  They adopted the so-
called generalisability theory to assess how the number of judges, the judge’s professional 
groups and the number of scoring occasions affected the severity scores.  Generalisability 
theory allows the estimation of the size of measurement error from multiple sources 
(Shavelson et al, 1989; Cor and Peeters, 2015).  So, if there is an assessment of the severity 
of a medication error the main sources of variation included will be due to differences in 
the judges or expert panel members, when the error occurred and so on.  If these 
variances are quantified, then a method to reduce unwanted sources of variance can be 
found. 
 
Dean and Barber (1999) asked thirty healthcare professionals or judges to score 50 
medication errors in terms of potential patient outcomes on a visual analogue scale from 
0 to 10.  The errors were minor, moderate or severe in nature.  They found that a reliable, 
validated method of scoring the severity of a medication error that did not require 
knowledge of patient outcomes requires at least four judges.  Also, the reliability and 
validity were not affected by the professions or the number of times on which the error 
occurred.  
 
The principles of the study by Dean and Barber (1999) were then applied in this study to 
develop a method to rate the causality and severity of a patient being readmitted to 
hospital due to medication.  The causality being related to the poor quality of medication-





Medication errors or MRH may result in admission to hospital particularly in elderly 
patients (Tangiisuran et al, 2010).  The consequences can lead to increased morbidity, 
mortality and increased health care costs (Pirmohamed et al, 2004).  It is therefore 
desirable to be able to target clinical interventions to reduce the likelihood of an adverse 
event.  This has led to the concept of risk reduction models being used in healthcare to 
predict ADEs in elderly patients due to their increased risks.  A recent systematic review 
of predictive risk models for ADEs in hospital for inpatients found that two studies had 
demonstrated good validation, model development and reasonable performance and 
could be developed for future clinical application (Falconer et al, 2018).  These two 
predictive risk reductions models were by Trivalle et al, (2011) and Tangiisuran et al, 
(2014).  
 
In the Trivalle et al, (2011) model the focus was only on medication as a risk factor, whilst 
the model described by Tangiisuran et al, (2014) was based on five clinical variables and 
called the BADRI (Brighton Adverse Drug Reaction Risk) model.  This model is for 
predicting adverse drug reactions in elderly people during their hospital stay.  The study 
included all patients aged ≥ 65 years admitted to a UK teaching hospital.  Patients were 
screened and identified for a potential ADE and each event was further assessed to 
determine the relationship between the medications prescribed and suspected ADR.  This 
was carried out using the Hallas algorithm where each ADR was classified as being either: 
definite, probable, possible or unlikely/doubtful.  In doing this various pre-determined 
criterion had to be satisfied or not (Hallas et al, 1990).  Additionally, to strengthen the 
methodology, an assessment of the causality of each event was rated by the reviewer 
using a six-point Likert scale described by Morimoto et al, (2004). 
 
The six-point scale consists of: 
1. Little or no confidence 
2. Slight to moderate confidence  
3. ˂50 percent confidence but a close call 
4. ˃ 50 percent confidence but a close call 
5. Strong confidence 
6. Virtually certain 
 
Many variables were then collected for each patient in the BADRI study.  Following 
multivariate analysis five clinical variables were found to identify an ADR risk for elderly 
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patients.  These five variables were: hyperlipidaemia, number of medicines ≥ eight, length 
of stay ≥12 days, use of antidiabetic agents and high white blood cell count on admission.  
Each variable is given a score of one making it simple to adopt in clinical practice.  
However, in terms of applicability to this current study the BADRI study was related to 
inpatient events rather than events causing readmission. 
 
In a more recent study a risk prediction model to identify elderly patients at risk of MRH 
following hospital discharge has been described (Stevenson et al, 2016).  This is the PRIME 
study (Prospective study to develop a model to stratify the Risk of Medication-related 
harm in hospitalised Elderly patients), a multi-centre prospective observational study, 
following patients eight weeks after discharge to determine if they have experienced 
MRH.  If the MRH was unclear this was reviewed by an ‘End Point Committee’ for a final 
decision.  The process by which MRH was estimated utilised the Naranjo algorithm 
(Naranjo, 1981).  
 
This algorithm is used as a method for estimating the probability of an ADR.  In the PRIME 
protocol the Naranjo algorithm is used as a guide as some of the questions in the 
probability scale are not all relevant. 
 
In this current study some of the methods in the BADRI and PRIME studies will be applied 
to assess whether the elderly patients in the cohort were readmitted due to the quality 
of MRI on the original discharge summary.    
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4.2 Study design  
 
 
Figure 14:  Flow diagram to illustrate the design and process for Phase III  
 
Figure 14 shows the design and process for Phase III.  Patients who have been readmitted 
due to potential MRH are assessed by an expert panel.  This panel assess the causality and 




4.3.1 Data collection  
The electronic hospital discharge summaries (Evolve®) were screened by the principal 
investigator for all 155 patients described in Phase II of the study at least 30 days after 
discharge to ascertain if they were readmitted to hospital or not.  All patients who were 
readmitted into hospital were then identified.  Patients were excluded if they were seen 
in the emergency department or an assessment clinic eg frailty clinic, after discharge and 
not admitted within 30 days after hospital discharge. 
 
The patients who were identified after screening as being readmitted for whatever reason 
were then reviewed to ascertain if the cause could be medication-related or not.  This was 
undertaken initially by the principal investigator by examining all the readmission 
discharge summaries.  For example, some of the readmissions were due to a completely 
different reason not related to the original primary diagnosis following their first 
admission.  Two senior pharmacists (clinical pharmacy manager and emergency 
admissions senior pharmacist) then validated these screened patients for further 
assessment by the expert panel for causality of readmission.  The expert panel meeting 
was carried out in March 2017. 
 
 
4.3.2 Setting and recruitment of expert panel 
Phase III of the study was set in the same acute hospital as Phase I and Phase II described 
in Chapters 2 and 3.  The expert panel was purposely recruited to obtain a consensus view 
on whether the readmission was due to medication and could potentially be caused by 
the quality of MRI in the original discharge summary.  The principal investigator is also the 
chief pharmacist at the study site and made personal contact via email to senior 
consultants and senior pharmacists who had either an interest in the study subject due to 
their speciality or had expressed support for the study being undertaken. 
 
 
4.3.3  Assessment of readmission causation 
The expert panel members were given an anonymised version of the original discharge 
summary sent to the patient’s GP.  This discharge summary had been previously 
generated on the hospital electronic discharge system- Evolve®.  The expert panel 
reviewed the discharge summary and was then given a further anonymous discharge 
summary relating to the same patient’s readmission within 30 days of the first discharge 
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episode.  The panel then used a modified version of the criteria for assessment of hospital 
readmission form used in the PRIME study to give a decision on the likelihood and 
causality of the quality of the discharge information related to medication influencing the 
patient’s readmission to hospital (Stevenson et al, 2016 and Stevenson, personal 
communication, 2017)- see Table 50.  The form used was adapted from that described in 
the PRIME study protocol, the six-point Likert scale of assessment of causality described 
by Morimoto et al, (2004) the Hallas algorithm (Hallas et al, 1990) and cognisant of the 
National Patient Safety Agency (NPSA) risk model matrix for risk managers where the 
likelihood of an event is rated against the consequence (NPSA, 2008). 
 
Table 50:  Criteria used for assessment of likelihood and causality of readmission due to MRI 
Criteria for assessment of 
readmission due to MRI 
Expert panel response 










˂50 percent confidence but a close call 
˃50 percent confidence but a close call 
Strong confidence 
Virtually certain 











Unable to evaluate 
Was the readmission related to the 





˂50 percent confidence but a close call 












This assessment was adapted from that used by Stevenson et al, (2016) in the PRIME 
protocol.  The following annotations refer to the original source of information and 
subjected to minor modification (see Appendix 2). 
 
Key: 
(a) From Stevenson et al, 2016 - PRIME study protocol 
(b) From Morimoto et al, 2004 
(c) From Hallas et al, 1990 
 
The degree or level of severity in the assessment was taken from that described by 
Morimoto et al, 2004.  Table 51 provides some clinical examples of how to apply the 
different levels of MRH severity due to MRI. 
 
Table 51:  Severity categories for consequences of possible MRH with examples 
Definition of severity Examples 
Fatal Patient died due to the incident 
  
Life threatening Patient transferred to ITU 
Respiratory failure requiring intubation 
Mental status change: patient falls and gets intracranial 
haemorrhage 
Tongue swelling/anaphylactic shock due to medication 
  
Serious Gastrointestinal bleed 
Altered mental status/excessive sedation due to medication 
Increased creatinine due to medication 
Decrease in blood pressure, patient feels lightheaded 
Allergic reaction: shaking chills/fever 
Additional visit to clinic for treatment or additional medication   
Significant Rash 
Diarrhoea due to antibiotics 
Nausea and vomiting due to medication 
Any significant event that is identified by the patient but not 
requiring a change in therapy 
 
Adapted from: Morimoto et al, 2004. 
 
In this study it is based on one site only and a single meeting of an expert panel was 
possible.  The principal investigator did not participate in the assessment process but 





4.4.1 Recruitment of expert panel  
At the study hospital the expert panel consisted of two senior pharmacists and six senior 
consultants and the principal investigator as facilitator.  The expert panel composition is 
shown in Table 52. 
 
Table 52:  Composition of the expert panel for Phase III of the study 
Profession Title Speciality (n) 
Pharmacist Clinical pharmacy manager (band 8b) All areas (1) 
Pharmacist Senior pharmacist (band 8a) Emergency Medicine (1) 
Doctor Consultant Elderly Medicine (2) 
Doctor Consultant Diabetes &Endocrinology (2) 
Doctor Consultant Respiratory Medicine (1) 
Doctor Consultant Haematology (1) 
 
 
The expert panel in the study all met together and there was good agreement amongst 
all the participants about the criteria for readmission and there were no disputes. 
 
 
4.4.2  Results of selection of readmission cases 
Thirty-one of the 155 patients were readmitted into hospital or 20% of the total of study 
patients within 30 days of discharge.  The demographic details of these patients can be 
found in section 3.7 and table 18.  The reasons for the subsequent readmission were then 
reviewed to ascertain whether there was any potential association with medication.  
Seven patients were initially identified who could have had an association between 
medication and a readmission into hospital.  The principal investigator undertook this 
initial review, and this was independently validated by two senior clinical pharmacists 
(clinical pharmacy manager and emergency admissions senior pharmacist) independently 
ie all pharmacists looked at the reasons for readmission alone. 
 
Independent review by the principal investigator and two senior pharmacists: 
• Seven patients identified due to possible medication-related readmission 





Figure 15:  Flow diagram of the results of the expert panel assessment of causality and 
likelihood of readmission (Phase III). 
 
Figure 15 shows the results of the expert panel assessment of causality and likelihood of 
readmission and MRH due to the quality of MRI in the discharge summary.  This was 
undertaken by reviewing the original and readmission discharge summaries and then 
rating the readmission based on a modification of the PRIME study (Stevenson et al, 2016) 




4.4.3 Results of assessment by the expert panel 
Details of the six patients who were readmitted within 30 days of discharge possibly 
caused by MRH is shown in Table 53.  There were four females and two males with an 
average age of 83 years and an average number of 10.5 medicines per patient.  The level 
of the preventability of the readmission was assessed by the expert panel based on the 
clinical narrative in the discharge summary.  For example, if a patient was discharged on 
too high a dose of insulin and was readmitted with hypoglycaemia then the preventability 
was considered as definite as the dose was too high. 
 
Table 53:  Showing some details of the six patients who were readmitted following 
discharge within 30 days 
Patient 
ID 








A23 F 92 Congestive Heart Failure 7 8 
A29 F 88 Congestive Heart Failure 7 11 
A39 M 69 Postural Hypotension 5 8 
A79 F 92 Acute Myocardial 
Infarction 
8 13 
A114 F 88 Urinary Tract Infection 9 11 
A154 M 89 Collapse 8 12 
 
 
The results of the expert panel consensus view are presented in Table 54.  These results 
demonstrate that of the six patients who were readmitted into hospital within 30 days 
two had a doubtful, two had a probable and two had a definite association with a 
medication-related readmission.  Two of the patients had a strong-MRH (one ‘definitely’ 
and one ‘probably’ causing readmission) and one a ‘virtually certain’ (‘definitely’ causing 
readmission) likelihood of suffering MRH.  Only one of these was thought to be a ‘>50% 
but close call’ (‘probable’ cause of readmission) and one ‘slight/moderate’ (‘probable’ 
cause of readmission) relationship to the quality of MRI on the discharge summary.  So, 
two (1.3% of total) may be associated with the quality of MRI on the discharge summary.  
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have been due to 
lack of 
Fludrocortisone 
that had been 
recommended in a 
frailty clinic visit 












and not related to 
discharge 
information. 
Possibly Little/ no 
confidence 
Serious 
A114 Probable Strong Other Readmission due 
to hypoglycaemia 
after too high a 
dose of Insulin on 
previous discharge. 
Possibly ˃50% but 
close call 
Serious 
A154 Doubtful Slight/ 
moderate 
Other Bisoprolol stopped 
for low blood 












In this preliminary study the number of patients who were readmitted within 30 days of 
the initial discharge due to medication was only six and therefore not subject to further 
statistical analysis.  Of these six patients, only two patients were identified by the expert 
panel as having either a ‘slight/moderate’ or ‘˃50% but a close call’ confidence level that 
the readmission was related to the quality of the discharge summary information and 
assessed as ‘probably’ being caused by medication.  In one case there was a lack of 
documentation after a follow-up assessment to commence fludrocortisone to treat 
postural hypotension and so was not directly related to the initial discharge summary.  In 
the other case the patient was readmitted with hypoglycaemia after too high a dose of 
insulin was prescribed on the original discharge summary with no review specified.  In 
both cases the consequences were considered serious and both were deemed as possibly 
preventable. 
 
Nevertheless, despite the low number of patients identified from Phase III of the study 
there are still aspects of the study that have clinical implications on policy and practice 
and provide a basis for future research. 
 
The expert panel convened for Phase III was composed of practising clinicians of six senior 
consultants and two senior pharmacists relevant to the study subjects (Jones and Hunter, 
1995).  This demonstrated that the panel members felt that the study was clinically 
relevant and could influence future practice.  This would suggest that for any future 
research senior medical and pharmacy staff should be used as expert panel members.  It 
may also be interesting for future research to look at other specialities with larger patient 
numbers to establish if there are any specific clinical requirements that could reduce 
readmission in these areas.  Examples include oncology, paediatrics, surgery and mental 
health.  For example, a recent study was carried out in orthopaedic surgery on the quality 
of discharge information for patients who have had hip surgery (Fitch et al, 2017).  GPs 
highlighted information for the management of osteoporosis as an issue they wanted 
information on.  In a similar manner, a recent study of the quality of discharge summaries 
from mental health hospitals has identified that psychiatric doctors in mental health 
hospitals may not be as competent with prescribing non-psychotropic agents compared 




The expert panel made several qualitative observations regarding the practice of 
producing the discharge summary in relation to medication and generally how this 
influences the quality of the information.  The senior consultants had mainly a medical 
background and speciality.  They commented that some of the patients readmitted within 
30 days of the initial discharge were not all medically stable for discharge although they 
were medically fit.  There was some view that this was in part due to the bed pressures of 
the hospital and the need to discharge patients to release beds for emergency admissions.  
It was also noted that of the six patients readmitted, FY1 or 2 doctors only wrote two of 
the original discharge summaries.  There was, therefore, an apparent lack of association 
with experience and training on the completion of a discharge summary and readmission 
due to MRI and requires a further study to understand why. It may be due to be lack of 
adequate training despite length of experience, human error or poor competency.  
 
There was no correlation between the gold standard adherence overall score and 
readmission’s, but this measure may not be sensitive to detect standard specific issues 
that may pose more risk of impacting upon readmission than others.  There may be subtle 
issues that influence a readmission such as lack of advice to the GP on the monitoring 
required post-discharge eg insulin.  Advice on monitoring post-discharge would include 
what to do, for example, if a patient’s medication had been temporarily stopped on 
admission or a further dose titration was required.  A further mixed-method study could 
be undertaken to establish hospital doctors’ understanding and application of the ‘gold 
standards’ for a discharge summary for GPs and patients in a similar manner to the study 
from Yemm et al, (2014).  This discussion will be explored further in Chapter 5. 
 
The local policy of producing the electronic discharge summary as the patient’s admission 
progresses was also recognised as a potential reason for a poor-quality discharge 
summary as any subsequent changes in medication may not have been made prior to 
submission of the final discharge summary if a verification, by a pharmacist at the point 
of discharge had not been undertaken.  However, in this study all six patients readmitted 
had pharmacist verification of the initial discharge summary.  There were also 
inaccuracies in the clinical narrative that was sent to the GP as there was no one who had 
responsibility for overall checking of the content of the discharge summary prior to 
sending to the GP.  There was recognition that there was often insufficient advice for the 
GP on the monitoring and management of the patient after discharge.  There was also an 
acceptance by the expert panel members that there are groups of patients that are 
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particularly affected by this.  For example, in the study hospital patients with congestive 
heart failure may have limited access to a heart failure nurse specialist in the community.  
There is, therefore, a need to follow-up patients closely after discharge who have had a 
change in their medication following a hospital admission if no nurse is available to do 
this.  This is evident if diuretics eg furosemide or agents used to control heart rate eg 
bisoprolol are altered, as there is a risk of relapse after discharge.  This was observed in 
this small study in two of the patients - one with congestive heart failure whose diuretics 
were increased on the original admission and was subsequently readmitted with a fall.  In 
this patient there was a definite association between the readmission being due to 
medication but not the MRI whilst the other patient, who had their bisoprolol stopped for 
low blood pressure, was subsequently readmitted with atrial fibrillation.  In this case there 
was ‘little/no confidence’ that this was related to MRI on the discharge summary.  
 
This reinforces the finding from Phase II that patients who are on cardiovascular 
medicines may be more at risk of poor quality medication-related information on the 
discharge summary than others.  This supports the finding from a study of mental health 
patients that there are more errors with psychotropic agents rather than non-
psychotropic agents suggesting that there may be a relationship between therapeutic 
classes and speciality of medical staff producing the discharge summary (Keers et al, 
2015).  This has implications for clinical practice as there appears to be little published 
evidence of the quality of discharge information related to therapeutic class types and 
speciality and identifies an area of future research (Keers et al, 2015). 
 
There was also strong consensus amongst the expert panel that the quality of the 
discharge summary should clearly highlight the differences between the medicines on 
admission and discharge and give a clear justification for a change in treatment.  There 
should also be a consideration to anticipate the future needs of the patient.  Often after 
an acute episode treatment is reviewed and stopped or altered but after discharge, there 
is a need to review this decision as there is a potential for the original problems to recur, 
such as heart failure or atrial fibrillation.  These and other issues will be considered in 




4.5.1 Limitations of Phase III 
The small sample size and single geographical setting clearly limit the validity and 
generalisability of the review of readmissions due to medication-related information on 
the discharge summary.  It would have been beneficial to broaden the membership of the 
expert panel to include GP’s and patients to gain a wider perspective.  The time of 
following patients up after discharge for readmission within 30 days could be extended to 
a longer period - 90 days or even a year to establish if readmissions which may not be 
apparent immediately after discharge may occur later and have a latent effect not 
detected within 30 days.  
 
 
4.5.2 Implications for policy, practice and future research 
Even a small number of elderly patents readmitted due to MRH after a poor-quality 
discharge summary may have implications on clinical practice and policy.  Whilst this is 
outside the scope of this thesis, a recent costing statement published by NICE (2015c) 
provides some idea of the scale of potential financial savings.  NICE predicts that a 
reduction in avoidable medicine-related admissions may save commissioners up to £530 
million per year in England.  Whilst that due to poor quality of medication-related 
information would be lower, it would be an interesting area to consider as part of a larger 
multi-site research study. 
 
Clearly, a further larger study following up patient’s post-discharge for longer periods, eg 
90 days or longer, may provide further evidence of the incidence of readmission and 
causality to the quality of MRI on the discharge summary and improve reliability and 
validity (Costa and Byon, 2018).  
 
An implication for practice is that there may be value in a local expert panel meeting on a 
regular basis to review the quality of MRI on the discharge summaries for patients 
readmitted due to medication as a quality improvement project to improve practice and 
reduce future medication errors.  
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Chapter 5: General discussion 
 
5.0  Discussion overview 
In chapter four, Phase III of the study found no relationship between the quality of the 
discharge information related to medication and readmission to hospital of elderly 
patients. However, the method employed can be used to carry out a larger, multi-site 
study. 
 
This study is the first recorded use of a modified e-Delphi technique to produce the 
essential standards of a discharge summary in relation to medication-information.  The 
concept of a ‘gold standard’ content of a discharge summary for medication was 
considered.  The level of adherence to the ‘gold standards’ in this study was found to be 
only 64.63%.  The notion of a risk prioritisation score for a ‘gold standard’ discharge 
summary for medication-related information is proposed.  The study provides a basis to 
undertake more comprehensive, multi-site collaborative research that could be used to 
develop a national consensus for ‘gold standard’ discharge summaries for medication-
related information. 
 
Despite recognition of the importance of a high-quality transfer of information from 
hospital to primary care, there is still a paucity of evidence on the adoption and value 
placed on interventions to ensure a high-quality discharge summary is produced 
(Unnewehr et al, 2015). 
 
Elderly patients may suffer medication-related harm such as ADEs and/or hospitalisation 
after discharge.  One of the aims of this study was to consider whether the quality of the 
discharge summary in relation to medication is associated with readmission to hospital.  
Whilst the results in this study were too small to detect an effect with only two patients 
probably having a readmission associated with the quality of medication information on 
the discharge summary, it is worthwhile considering some of the themes that have arisen 
from the study and their implications on future clinical practice, policy and research 
recommendations.  
 
In considering these themes it is worth first considering the underlying approaches to 
human error theory and how these can be applied to this study.  James Reason (2000), in 
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his seminal work on the models and management of human error as applied to 
healthcare, provides a good basis to work from.  Reason postulated that most adverse 
events involve a combination of so-called active and latent failures.  Active failures are 
the failure of an act by people who are in direct contact with the patient or system.  
Examples of these active failures include slips, lapses, mistakes and procedure deviations.  
Conversely, latent failures are those that arise by correct action of an inappropriate or 
incorrect plan.  They often arise from decisions made by designers or policy makers and 
can translate into error producing conditions such as understaffing or inexperience or 
weaknesses such as unworkable procedures or poor design features.  It is with these 
principles of error that a thematic discussion around some of the issues regarding the 
quality of the discharge summary in relation to medication will be considered, the 
application of human error theory where applicable, and strategies about how to reduce 
the risks to patients will be considered.  The main themes, therefore, are related to: types 
of disease and medicines causing ADRs, discharge medicines reconciliation, design of 
electronic transfer of medication-related discharge information, education and training, 




5.1  Themes that ensure best practice in producing a ‘gold standard’ discharge 
summary 
 
5.1.1  Types of disease and medicines causing adverse drug reactions 
An area of interest in terms of identifying elderly patients who may be at increased risk of 
hospital readmission is in relation to their diseases and medicines used to treat these.  
Medication errors due to the type of disease or medicines may derive from active failures 
such as slips or lapses or latent failures due to lack of familiarity by the prescriber.  
 
Chu and Pei (1999) found that certain diseases such as chronic obstructive pulmonary 
disease, end stage renal failure, malignancy and congestive heart failure were associated 
with an increased risk of readmission in elderly patients.  In this current study most of the 
patients had a primary diagnosis of either respiratory (32.2%) or cardiovascular disease 
(15.5%).  Thus, it could be argued that it may be worth targeting patients with certain 
diseases and/or medicines such as cardiovascular disease or agents to ensure that the 
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content of the medication-related information on the discharge summary is optimised 
(see later section on risk minimisation stratification tool).  In this current study ten out of 
19 medicines stopped on discharge were not updated in the GP records, four medicines 
started out of 17 medicines not updated on the GP records and five of the 12 medicines 
where an ADE was not documented on the GP records were for cardiovascular medicines. 
 
Anecdotal evidence from the expert panel members in Phase III of the study highlighted 
that it was important to document clearly in the discharge summary patients who 
required monitoring by the GP post-discharge.  For example, patients on diuretics who 
had congestive heart failure, emphasising the need to prioritise this group of elderly 
patients.  In this current study only 44 (28.4%) patients had any type of monitoring 
specified on their discharge summary.  This highlights that the monitoring or review 
standard (E6) requires improvement.  This may be achieved by raising awareness to 
hospital medical staff of the importance to specify this on the discharge summary and/or 
make this a mandatory requirement as part of redesigning the discharge summary 
template. 
 
A risk factor for early hospital readmission in elderly patients is the type of medicine.  Chu 
and Pei (1999) found that 5% of emergency readmissions were due to medication-related 
adverse effects.  More recently in a UK study, 20% of patients were readmitted to hospital 
within one year of discharge (Davies et al, 2010).  Anti-platelet or anti-thrombotic 
medicines and loop diuretics were the most common medicines causing an ADR.  In a sub-
group analysis of patients who were readmitted within 28 days of the original admission 
23% experienced an ADR- related readmission.  These figures were higher than previously 
reported at 5-10% (Nivya et al, 2015) and 13% (Dalleur et al, 2017) of readmissions due to 
ADRs.  Interestingly, Dalleur et al, (2017) also found that 48.6% of readmitted patients 
were due to diuretics, analgesics or anti-thrombotics.  This suggests that doctors should 
be careful when prescribing these classes of agents on discharge summaries. 
 
In this current study, 31 (20%) patients were readmitted, with only six potentially due to 
a medication.  There was limited adherence to the ‘gold standard’ discharge summary for 
patients on anti-thrombotic drugs (63.99%) and diuretics (64.61%) compared with the 
overall adherence score of 64.63%. These agents are identified as being a higher risk of 
causing an ADR so there is still room for improvement.  The relationship with the discharge 
being that if the quality of the discharge summary is not optimised for high risk medicines 
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that elderly patients will be at a greater risk of readmission.  This raises the question do 
certain medicines present a higher risk to the elderly and should these be prioritised when 
preparing a ‘gold standard’ discharge summary?  This could form the basis of one of the 
main aims of a larger, multi-site research study. 
 
 
5.1.2  Discharge medication reconciliation (DMR) 
The transition of care from secondary to primary care, following an acute hospital 
episode, can be a vulnerable time with a risk of ADEs occurring following discharge (Armor 
et al, 2016 and Forster et al, 2003).  These may result from discrepancies between the 
patient’s post-medication regimen and the hospital discharge summary and be the result 
of an active failure (Coleman et al, 2005).  The process of medicines reconciliation (MR) 
reduces the likelihood of medication errors occurring at care transition points (Kwan et 
al, 2013).  Most of the work on MR in England has been undertaken in relation to 
admission MR (AMR) typically within 24 hours of admission.  The premise being that the 
earlier an MR review is carried out after admission the less likely it is for the patient to 
suffer MRH due to an unintentional discrepancy between the prescribed medicines as an 
inpatient and pre-admission medication (NICE, 2007).  In comparison, discharge 
medicines reconciliation (DMR) is less well-studied and is a more complex task, compared 
with an AMR (Wong et al, 2008). 
 
DMR involves reviewing pre-admission medications, changes made during hospitalisation 
(medicines stopped, started and dose changes) and comparing them with the discharge 
prescription ensuring that all medications are appropriately continued, resumed or 
discontinued (O’Riordan et al, 2016).  A flow chart has been published by the National 
Prescribing Centre in England to highlight the process of medicines reconciliation on 
patient discharge from secondary care to primary care highlighting optimal and sub-
optimal practice (NPC, 2015).  A recent systematic review of DMR identified that the 
median number of discrepancies found was 60% with an average of between 1.2 and 5.3 
discrepancies per patient.  This highlights the importance of DMR to improve patient 
safety (Michaelsen et al, 2015). 
 
In this current study an attempt was made to establish whether there was evidence of 
reconciliation in primary care by accessing the patient’s SCR.  In terms of medication that 
was stopped during the admission, 10 (6.4%) patients had no update of stopped 
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medicines in their GP records.  These were predominantly in patients over 80 years of age 
with a Charlson Co morbidity Index score of six or above.  For these 10 patients there were 
19 medicines.  
 
Ten out of the 19 medicines, not updated on the GP records, did not have a reason for 
stopping indicated on the discharge summary.  In a similar manner for medicines started, 
10 (6.5% of total) patients did not have any documentation in the GP records for 17 
medicines.  Ten (59%) of these medicines had no comment on the discharge summary.  
For medicines where there was a change in dose of the medication on the discharge 
summary, there were only three patients that did not have their GP records updated for 
a total of four medicines.  Of these medicines, two had no reason stated on the discharge 
summary.  In a large collaborative audit of the quality of medication-related information 
in England when transferring patients from secondary care to primary care with DMR in 
primary care, 12.5% of patients did not have a DMR within seven days of the GP receiving 
the discharge summary for medicines that were started/stopped or changed, which is of 
a similar order to this current study if we assume that the lack of evidence of reconciliation 
in primary care is due to it not being undertaken (Shah et al, 2016). 
 
These results demonstrate that unintentional discrepancies after discharge may occur.  It 
is likely that the poor quality of the discharge summary contributes to poor reconciliation 
in primary care.  O’Riordan et al, (2016) explored discharge prescribing errors post-
discharge.  In the study, 83 patients’ discharges were analysed at least 10 days after 
discharge.  They found that 36 (43.4%) patients had a post-discharge medication error 
with 32 affecting the patient.  Unintentional prescription of an intentionally stopped 
medication and unintentional omission of active medication were cited amongst those 
medication errors most likely to persist after discharge.  These medication errors were 
also found in this study and are examples of both active and latent failures.  This reinforces 
the requirement to put measures in place to optimise the accuracy and content of the 
discharge summary regarding medication prior to discharge. 
 
The verification of the discharge summary by a pharmacist prior to discharge may improve 
the accuracy and quality of the discharge summary (Abdel-Qader et al, 2010) and was also 
carried out in this current study although no relationship was found.  Alternatively, 
pharmacists may prepare the discharge summary and prevent ADEs (Onatade et al, 2017; 
Tong et al, 2017).  This has implications on future practice as there may be insufficient 
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pharmacists to either verify or write all discharge summaries.  A further interesting study 
would be to compare the quality of the discharge summary between those that had been 
verified or written by a pharmacist and those that had not.  In this current study 95.5% of 
patients’ discharges were verified by a pharmacist so no comparison could be made. 
 
A recent study of frail elderly patients over 75 years of age, who were referred for an 
electronic medicines reconciliation service undertaken by a pharmacist prior to discharge 
found that serious medication errors were detected prior to discharge and that the use of 
an information sheet may prevent additional errors at home (Agud et al, 2016).  There is, 
therefore, a need to undertake further studies to assess the impact of DMR at discharge 
or post-discharge by a pharmacist to ascertain if the quality and accuracy of discharge 
information can be improved.  Indeed, the principal investigator has been in discussion 
with the local GP lead for prescribing of piloting the role of a pharmacist, based in the 
hospital, to ensure that the discharge summary that is sent to the GP is accurate and then 
undertakes the DMR in primary care on behalf of the GP practice to improve safety.  This 
has implications for a change in the way that the DMR is traditionally undertaken moving 
the role from primary care services to an interface role.  
 
Jani et al, (2017) undertook an analysis of discharge summary reconciliations for 1,454 
patients in England.  The reason for initiation of new medicines was documented in only 
half of the 79% of patients where at least one new medicine was started.  In this current 
study however, 91.6% of the patients who had new medicines started had a reason stated 
on the discharge summary.  Whilst the sample size is a lot smaller in this current study 
one of the reasons for this could be attributed to the design of the discharge template.  In 
the study hospital the electronic discharge summary template has the facility to add a 
reason for the medicine.  Whilst this is not a mandatory field this may be why this 
improves the quality of the discharge summary in this setting and reduces latent errors. 
 
Furthermore, Jani et al, (2017) found that any intentional changes to the primary care 
records after discharge were undertaken by the GP (51.5%), CCG or practice pharmacist 
(6.6%) or receptionist (5.6%).  It is important to ensure that the content of the discharge 
summary is clear and easy to interpret as the reconciliation maybe undertaken, albeit in 
small numbers, by a non-healthcare professional.  This demonstrated that GP practices 
need clear processes on how information provided on discharge summaries is managed 
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once received.  There is a need to define who has the responsibility to review medicines 
on the discharge summary and who should action changes on the GP prescribing system. 
 
If the quality of the discharge summary is high, then this will support the DMR in primary 
care following agreed procedures. 
 
A relatively recent service development that is related to the quality of information about 
medicines and clinical practice is that of a post-discharge medicines use review (DMUR) 
service.  In the UK it is recognised that improved discharge information is a key part of 
reducing unintentional medication changes, patient harm and hospital readmissions (RPS, 
2012; Pherson et al, 2014).  There is some evidence in the UK that community pharmacists 
can identify and resolve medication errors post-discharge (Nazar et al, 2015).  Elderly 
patients may benefit from this service and a targeted DMUR service may reduce 
healthcare costs and improve patient safety (Ramsbottom et al, 2018).  In the study by 
Ramsbottom et al, (2018) 20 patients over the age of 65 discharged from a hospital had a 
DMUR within 28 days of discharge.  Whilst the number of patients was low, 17% of 
interventions involved medicines reconciliation to resolve discrepancies between pre-
admission and discharge medications that were intentional.  Clearly if a community 
pharmacist undertakes a DMUR then having access to a high-quality discharge summary 
will reduce the likelihood of unintentional discrepancies, reduce risk and make the DMUR 
more straightforward. 
 
Electronic (e) discharge referral systems between hospital and community pharmacists 
are currently being rolled out across the NHS in England with support from some 
Academic Health Science Networks.  The e-referral services consist of web-based 
platforms such as PharmOutcomes® (Pinnacle Health Partnership LLP (PHP), 2018) or 
Refer to Pharmacy® (ELHT, 2018) which allow a secure method of electronic transfer of 
information related to medicines between hospital and the patient’s community 
pharmacy (Nazar et al, 2016).  Whilst initial evidence of uptake has been low (30.5%) by 
community pharmacists after referral from hospital this is now increasing (personal 
communication, Dines-Allen, 2018) and there is early evidence that this may result in 
lower rates of readmission and reduced length of stay in hospital (Nazar et al, 2016).  In 
the e-referral study most of the patients referred were elderly and had cardiovascular or 
respiratory disease.  Eighteen percent of the referrals made were related to the issue of 
a new medicine, 7.3% due to a change in dose and 7.0% due to medication stopped in the 
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hospital.  The study highlighted deficiencies in the e-referral process to a community 
pharmacist of the lack of quality information related to medication and therefore 
demonstrates once again the need for ‘gold standard’ information on the discharge 
summary to optimise patient safety and reduce hospital readmissions.  A further study is 
currently underway to develop a consensus for referral criteria of hospital inpatients for 
follow-up by a community pharmacist and there is an opportunity to further develop a 
national ‘gold standard’ package of measures to improve discharge information to 
support this referral and follow-up process (personal communication, Nazar, 2018). 
 
The schematic below indicates a conceptual framework for the flow of information 
related to medication and the complexity of ensuring that patient safety is maintained at 
the key points of transition of care (Figure 16). 
 
 
Figure 16:  A schematic of a conceptual framework for the flow of medication-related 
information at the transitions of care for a patient 
 
The conceptual framework in figure 16 shows the flow of medication related information 
at transitions of care, interventions that can influence the quality and accuracy of the 





1. Information sources related to medication at the points of transition of care in 
hospital and community in relation to admission and discharge. 
2. Interventions carried out at the points of transition of care in hospital and the 
community such as AMR, DMR, verification of the discharge summary and transfer 
of information. 
3. The purpose and potential outcome to the patient from the interventions carried 
out to determine the quality and accuracy of MRI and patient hospital 
(re)admission. 
 
The proposed conceptual framework regarding the flow of medication-related 
information considers the inter-relationship between the patient journey on transitions 
of care between hospital and the community settings and interventions that may have a 
positive or negative outcome for the patient.  It is interesting to consider that 
interventions have traditionally focused on healthcare professionals such as pharmacists 
and doctors.  However, further quality improvement initiatives should involve patients 




5.1.3  Design of electronic transfer of medication-related discharge information 
The usual way of communicating hospital discharge information to the patient’s GP in the 
UK has been by handwritten methods.  This typically consisted of a review and 
transcription of the inpatient prescription to another paper document sometimes 
referred to as the immediate discharge letter (IDL).  The IDL may be followed up by a more 
comprehensive discharge summary.  Nowadays the IDL is commonly also the final 
discharge summary sent to the patient’s GP.  The paper document is usually based on a 
template with the potential to add relevant medication for discharge.  The discharge 
summary may have been clinically verified by a pharmacist prior to discharge and sending 
to the patients GP.  More recently, developments in information technology (IT) have 
allowed the introduction of electronic transmission of discharge summaries although 
uptake is still variable.  In 2013 a recommendation was made for standardisation of 
electronic discharge summaries in the EU but the vote by the UK to leave the EU may 




Despite recommendations being made for the ‘gold standard’ content of a discharge 
summary in relation to medication by several organisations as previously discussed the 
actual adoption of this standard has been variable (RPS, 2012; SIGN, 2012; NICE, 2015b; 
HSCIC, 2013 and PRSB, 2017).  
 
Clearly, adopting a well-designed electronic (e)-discharge system of transfer of discharge 
information offers the potential to improve the efficiency and accuracy of medication-
related information going to the patient’s GP and reduce latent errors (Lehnbom et al, 
2014; PRSB ,2017; Blain, 2011 and Mills et al, 2017b). 
 
Interestingly, if the e-discharge summary is poorly designed then the benefits can be lost 
and lead to confusion about medication information (Sarzynski et al, 2017).  Also, a 
HEPMA system generating an e-discharge summary does not always mean that it 
guarantees reconciliation with the medication the patient is discharged on (Tan et al, 
2018). 
 
The PRSB standards recommend that implementation guidance should be provided about 
how to present medication information in the electronic discharge summary safely 
although there is a lack of actual guidance (PRSB, 2017). 
 
There are also fundamental differences in the design of HEPMA and GP prescribing 
systems that will need to be considered in future system design and integration.  An 
example of this is the difference between ‘dose-based’ prescribing in hospital versus 
‘product-based’ prescribing in GP practices.  In hospital the dose is not dependent on the 
product strength and this was demonstrated in this current study where only 6% of 
medicines had the strength specified on the discharge summary.  The challenge will be 
for an integration between HEPMA and GP prescribing systems so there will be a common 
terminology and recognition between the two so that these variations will be considered 
on the electronic transfer of information (PRSB, 2017).  
 
Despite UK policy to promote and implement HEPMA systems within the NHS, uptake is 
still variable.  A recent report from a Department of Health convened Short Life Working 
Group on reducing medication-related harm found that only 35% of acute trusts were 
reporting roll out of HEPMA where greater than 80% of inpatient prescriptions were 
written digitally and less than 12% of mental health organisations in November 2017 
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(Department of Health, 2018).  This important report has recommended the need to 
accelerate roll-out of HEPMA in England.  However, this is not without some caution as 
poor design of HEPMA may contribute to latent failures and different types of medication 
errors. 
 
An example of this is the need to regularly review and update national guidance to inform 
best practice.  An e-prescribing toolkit is available to assist hospitals to install and use 
HEPMA (e-prescribing, 2007) and specifies essential delivery priorities to implement 
including a section on the general requirements of a system for discharge.  These 
requirements are shown in Table 3 in Chapter 1 but are shown here for ease of reference 
and compared with those found from the modified e-Delphi study carried out and other 
recommended standards (Table 55).  Interestingly, the e-prescribing toolkit does not 
include a reason for the medicine ie indication (D9) which was found in the desirable 
standards in this study and route of administration (E1) which was an essential standard 
identified in this study.  
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Table 55:  Comparison of discharge summary core contents 

















Patient details ✓ ✓ ✓ ✓ ✓ ✓ NS 












✓ ✓ ✓ ✓ ✓ ✓ ✓(E3a) 




✓ ✓ ✓ ✓ ✓  ✓(D9) 
Dose strength ✓ ✓ ✓  ✓ ✓ ✓(E4a) 




✓ ✓ ✓ ✓ ✓ ✓ ✓(E3c) 
Route ✓ ✓ ✓  ✓  ✓(E1) 
Duration of 
treatment 
(stop date or 
review) 




days of supply 









 ✓ ✓ ✓  ✓ ✓(D11) 
Allergies and 
conditions 




  ✓    ✓(E6) 
 
D = Desirable standard 
E = Essential standard 
NS = Not Studied 
 
There is, therefore, good congruence between the standards of content of a discharge 
summary related to medication and that recommended by the RPS, (2012); SIGN, (2012); 
170 
 
Academy of Royal Colleges; HSCIC, (2013), PRSB, (2017), HIQA, (2013), NICE, (2015b) and 
e-prescribing toolkit, 2007. 
 
However, there are some subtle differences as shown in Table 55.  This current study 
identified that review and monitoring were essential standards whereas the quantity 
supplied was not identified as being an issue.  This may be because GPs are familiar with 
the local arrangements for quantities to supply on discharge but wanted more practical 
advice on how to monitor the patient post-discharge.  It is worth noting that despite the 
recommendations to employ HEPMA in UK hospitals, that the e-prescribing toolkit, with 
the general requirements of the discharge summary, was last updated in 2007 and needs 
to be reviewed.  Furthermore, the low uptake of HEPMA in the UK has been compounded 
by the introduction of a wide-range of products that have been developed by both UK and 
non-UK suppliers.  Mozaffar et al, (2014) found there were 17 different systems available 
in the English market but only half were designed and developed by UK based suppliers 
and potentially more aware of the systems use in the NHS.  There are also several 
specialised HEPMA products in use eg chemotherapy, intensive care and mental health.  
This reflects a diverse range of suppliers, functions and uses.  Consequently, there is a lack 
of standardisation of definitions and distribution of functionality across, and within, 
systems and means there are latent safety risks with these products which include the 
risk of medication error.  Mozaffar et al, (2017) carried out a qualitative study of the 
implementation and adoption of HEPMA in six English hospitals to explore unintended 
consequences of errors introduced.  The study identified themes associated with patient 
safety which included inadequacy of system design.  Whilst this current study did not 
focus on system design in relation to the content of a discharge summary, there is 
recognition that either a HEPMA derived discharge summary or standalone e-discharge 
summary need to integrate in some way with the GP primary care system and incorporate 
the gold standards for discharge medication information. 
 
Several other initiatives have been considered for improving e-discharge information with 
varying success.  Maurice et al, (2014) introduced an electronic prompting system to assist 
with entry of the correct information on a discharge summary, although, in this case it did 
not improve the quality of discharge information.  Whilst in Norway there was limited 
effect of using a structured medication report prepared by a pharmacist in addition to the 
normal electronic discharge summary (Holdhus et al, 2018). 
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A more locally-owned approach to system design was that employed by May-Miller et al, 
(2015).  This consisted of a quality improvement project to improve the quality of 
discharge summaries in a hospital that used two different electronic discharge systems.  
Using the Academy of Medical Royal Colleges standards for discharge they designed a new 
template that was compliant with these standards (HSCIC, 2013).  The median compliance 
with the standards improved from 67.9% to 75.7% and provided an example of how to 
embed best practice standards in the design of an electronic discharge system which can 
improve patient safety.  However, the design of the discharge summary template did not 
consider the views of GPs or patients and should be considered as part of any future 
developments (Mahfouz et al, 2017). 
 
In this current study the results for some of the ‘gold standards’ are very high with 
adherence >90%, eg route (E1), generic name (E3a), dose (E3b) and frequency (E3c).  An 
explanation for this maybe because the design of the Evolve® discharge summary 
template had considerable input at the time by senior pharmacists and it was stipulated 
that this was a minimum dataset requirement.  This gives a practical example of how the 
appropriate design and implementation of an electronic discharge system can influence 
the quality of a discharge summary.  
 
Efforts should be made to ensure that the next generation of HEPMA products adopt a 
standardised approach to having a minimum dataset of content of a discharge summary 
based on the gold standards.  It is therefore recommended that future studies are carried 
out to agree a national gold standard and evaluate their impact on the quality of 
information generated from an HEPMA system. 
 
 
5.1.4  Education and training issues 
An important issue when considering themes and strategies to reduce the risk of 
medication errors in elderly patients at discharge is that of the experience and education 
and training undertaken by doctors who complete the discharge summary.  A lack of 
sufficient training would cause a latent-type error.  It has been suggested that discharge 
summaries reviewed by a senior doctor prior to discharge may improve quality (Wilkin et 
al, 2018).  However, consultants do not generally have enough time to undertake this duty 
and most are written by a junior doctor, FY1 or FY2 level, with 71.6% in this study and up 
to 86% in the report by Dornan et al, (2009).  Junior doctors often rely on a pharmacist to 
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check the accuracy of a discharge prescription with 95.5% in this current study but cannot 
be guaranteed all the time.  In this study FY1 and FY2 doctors had an adherence score for 
the essential standards of 64.09% and 66.15% respectively and at a similar level to the 
average score (64.63%).  Interestingly the lowest scores were for ST2 level medical staff 
at an adherence score of only 57.57%, albeit with a small sample size of five.  Consultants 
scored lower than FY1 and FY2 medical staff at 61.85%.  It is possible that because senior 
doctors do not routinely complete the electronic discharge summaries they are less 
familiar with the requirements for adequate completion.  It would have been anticipated 
that the more experienced medical staff would score higher on the adherence to the ‘gold 
standards’. Irrespective of the level of medical staff involved with the production of the 
discharge summary, there was still room for improvement. 
 
There has been a recent renewed emphasis on the training requirements for junior 
doctors to reduce medication errors.  The Royal College of Physicians (RCP) has produced 
a guide to support junior doctors in safer prescribing recognising that they are not 
adequately supported to prescribe safely (RCP, 2017).  Several key recommendations are 
made which include providing education and practical resources to support prescribing at 
discharge such as an induction programme in safe prescribing, incorporating prescribing 
into the wider curriculum for junior doctors and assessment of prescribing competency. 
 
Gilbert et al, (2017) carried out an audit of the quality of medication information in 
electronically-generated discharge summaries in Australia.  Strikingly, in the audit of 76 
patients, none of the electronic discharge summaries included a documented reason for 
a change to the medicines despite a standard template for discharge being available.  
Consequently, an action plan was implemented which included engagement with the 
medical consultants to discuss the importance of accurate discharge summaries and 
training in how to complete a discharge summary well.  However, no results have yet been 
published of the value of this intervention but does demonstrate a strategy that could be 
employed. 
 
Medical staff in hospital may not be aware of the importance of the information on a 
discharge summary for the GP. Yemm et al, (2014) found that both GPs and junior doctors 
considered that accuracy was the most important characteristic of a discharge summary.  
The GPs valued the explicit inclusion of details of medication changes more than junior 
doctors and indicated that junior doctors often lack awareness of how GPs use 
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information about patients after discharge as part of the DMR process.  The junior doctors 
reported a lack of training and guidance to produce a discharge summary and the use of 
a guide as described by May-Miller et al, (2015), which included real-life scenarios raised 
by local GPs, would be a useful quality improvement initiative.  Tan et al, (2015) in a 
follow-up study to an audit carried out in 2014, which demonstrated that only 50% 
discharge summaries had any information about indication documented, provided 
training, feedback and an incentive (a voucher for free coffee) to improve the quality of 
discharge information (Tan et al, 2014).  This resulted in a 30% improvement in 
information about medication indication.  Yemm et al, (2014) also found that intra-
professional education between primary and secondary care doctors may improve the 
quality of discharge summaries  
 
Ryan et al, (2014) investigated the prevalence and causes of prescribing errors in junior 
doctors in clinical training.  Whilst the prescribing errors for patients being discharged 
(14.5%) were less than those on admission (56.7%) the doctors involved highlighted that 
they were under pressure to discharge patients quickly, there was a lack of uninterrupted 
time to write the discharge summary and lack of previous involvement in the patient’s 
care - all examples of potential latent failures.  So, any training provided should be 
protected and targeted to the type of speciality or location of work (Keers et al, 2015 and 
Hammad et al, 2014). 
 
A combination of targeted-education, feedback and token incentives can improve the 




5.1.5  Concept of a discharge summary prioritisation tool and risk rating of a discharge 
summary 
A challenge for healthcare professionals is how to provide high-quality care to patients 
that optimises outcomes and patient experience in the context of increasing complex 
treatments and limited time and staff.  This has led to pharmacists considering the use of 
prioritisation tools to target care they can provide.  A clinical prioritisation tool for 
pharmacists or assessment of risk tool (ART) has recently been validated (Falconer et al, 
2017).  The ART is an electronic tool used to stratify patients into those at high, medium 
and low risk for medication errors and ADEs.  A risk factor includes polypharmacy ie ˃8 
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medicines per patient.  The same principles could apply to junior doctors who also have 
limited time to complete a full discharge summary (Ryan et al, 2014).  A risk prioritisation 
approach can therefore be considered using information about patients, diseases or 
treatment to stratify their risk of developing an event (Tangiisuran et al, 2010). 
 
Onder et al, (2010) developed and validated a risk assessment tool to identify ADRs in 
hospital patients over 65 years old - the GerontoNet ADR risk score.  The strongest 
predictor of an ADR was the number of medicines the patient was on, particularly those 
on eight or more medicines.  The Medication Regimen Complexity Index (MRCI) devised 
by George et al, (2004) is a tool that quantifies medication regimen complexity according 
to an individual patient’s medication.  The MRCI tool considers features such as number 
of medications and doses per day, frequency of administration, additional information 
directions and route of administration.  Willson et al, (2014) used the MRCI to examine 
the association between discharge medication regimen complexity and subsequent 
readmission to hospital due to an ADE.  However, because the MRCI did not change 
significantly during the hospital stay the admission MRCI value was used as a predictor of 
post-discharge ADEs leading to readmissions.  More recently a risk model for predicting 
ADRs in elderly people during hospital stay has been described, the BADRI model 
(Tangiisuran et al, 2014).  This tool was validated and used as an ADR risk score in patients 
with a median age of 85 years based on five clinical variables namely: ≥8 medicines, 
hyperlipidaemia, raised white cell count, use of anti-diabetic agents, and length of stay 
≥12 days.  It is therefore proposed as a future area of research to consider the 
development of a risk prioritisation tool to assist in the prioritisation of elderly patients, 
who may be at risk of an ADR following discharge from hospital due to a poor-quality 
discharge summary, to have a high-quality discharge summary.  So, when time and 
resources are limited a high ‘gold standard’ adherence discharge summary score can be 
produced. 
 
There is no specific risk minimisation/prioritisation tool in the literature to target patients 
who require a ‘gold standard’ discharge summary for medication being completed.  So, 
from this current study it is proposed the following tool is considered.  This is based on 
key factors/variables from this current study that contribute to the quality of a discharge 
summary related to medication.  This also relates to the conceptual model described 
earlier whereby to optimise the outcomes for the patient it is important to ensure that 
high priority discharge summaries are completed to a high standard.  For example, in this 
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study this could be reflected in a score of >80% adherence to the ‘gold standards’ as an 
example. 
 
The proposed ‘Quality of Medication for Discharge’ (Q-MedDis) tool by the principal 
investigator is described in Figure 17 below as a hypothetical model for elderly patients 
highlighting the various factors/variables that should be considered. 
 
Figure 17: A schematic to show the factors that may lead to a risk prioritisation tool to 
target patients who would benefit from a ‘gold standard’ discharge summary being 
completed - Q-MedDis. 
 
Although the current study failed to identify factors that affected the quality of the 
discharge information related to medicines, the following have been previously reported 
in the literature as being associated with the elderly experiencing an ADR. Consequently, 
they could highlight patients that require prioritisation to produce a high-quality 
discharge summary and are considered below: 
 
1. Number of medicines and age of patient- there is evidence from Onder et al, (2010) 
and Tangiisuran et al, (2014) that elderly patients on eight or more medicines are 




2. Length of stay- on the basis that elderly patients with a length of stay ≥ 12 days 
have an increased likelihood of developing an ADR (Tangiisuran et al, 2014) and that 
10 days of bed rest can lead to significant deconditioning and increase susceptibility 
to an ADR (Vernon, 2016). 
3. The presence of certain diseases eg heart failure, renal failure have been found to 
be associated with an increased risk of an ADR (Onder et al, 2010). 
 
4. Readmission is included because patients on complex medication regimens may be 
at increased risk of readmission (Willson et al, 2014).  This may be associated with 
the quality of information on the discharge summary. 
 
5. Medicine type is included on the basis that in this current study certain types of 
medicines were found to have a lower quality of discharge adherence score ie 
antithrombotics, loop diuretics. Tangiisuran et al (2014) also found that antidiabetic 
agents may be a risk factor for predicting ADRs in elderly people. 
 
Patients at high risk of MRH could be prioritised to receive a ‘gold standard’ discharge 
summary as a minimum if they satisfy the following criteria: on ≥8 medicines, ≥85 years 
old, with a length of stay of ≥12 days, presence of cardiovascular and/or respiratory 
disease, who have been readmitted within 30 days and are on an anti-thrombotic and/or 
loop diuretic agent. 
 
It should be emphasised that this tool is a proposal only and would need further research 
and validation.  The basis of the factors chosen are from those identified in this study, the 
MRCI, the BADRI tool and the GerontoNet ADR risk score (Willson et al, 2014; Tangiisuran 
et al, 2014 and Onder et al, 2010).  
 
A future comparative study could be designed to test the risk prioritisation tool by 
measuring the quality of the discharge summary that was produced as the ‘gold standard’ 
using ‘Q-MedDis’ as a test group and compare this with a control arm where no 
intervention is made.  The outcome measures could include the incidence of readmission, 
incidence and type of medication discrepancies found after DMR in primary care and the 




5.1.6 Standard setting 
The development of a local gold standard for the quality of medication-related 
information of a discharge summary in this current study and the variable adherence with 
this and the other published compliance levels to standards has highlighted the need for 
a national standard (Aziz et al, 2016 and Hammad et al, 2014).  A recent Dutch study in 20 
hospitals found that 15% of discharge summaries were missing details of changes in 
medication in the discharge summary.  One of the reasons for this was considered a lack 
of standards outlining the contents of a discharge summary (Langelaan et al, 2017). 
 
The recently published PRSB standards updated the HSCIC standards from 2013 and 
outline ‘good practice requirements’ (PRSB, 2017).  Medicines are considered as 
information that is required to be sent to the GP.  Within this the information element 
may be either mandatory or optional.  The PRSB standards only identify four medication 
elements to have mandatory status: medication name, name of medication discontinued, 
nature of any change made to a medicine since admission and medicine name causing an 
allergy or adverse drug reaction.  The PRSB standards do not consider the ‘medication 
changes’ heading as mandatory as it was felt that this would mean that ‘no changes’ 
would be recorded rather than taking time to complete the section correctly (PRSB,2017). 
 
The number of elements for medicines in the detailed general hospital discharge 
spreadsheet available on the PRSB website published in February 2018 is 38 (PRSB, 2017).  
Whilst it is recognised that this is an up-to-date resource that will be used to influence the 
NHS standard contract and design of HEPMA systems there will be some challenges at a 
local level to ensure all the standards are completed.  This current study therefore 
provides a model to inform local decision making on the requirements of the gold 
standards of a discharge summary.  In addition, NHS Digital who are responsible for the 
implementation of the e-discharge standards will need to consider how to make this 
happen at organisation level (PRSB, 2017).  This preliminary study provides a pragmatic 
approach to implement a local standard. 
 
 
5.1.7  The patient’s perspective 
It is known that patients are generally concerned about waiting too long for their 
medication prior to discharge from hospital and there is a lack of counselling by 
pharmacists.  Indeed, in one study over a third of patients were unclear what medicines 
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they should take after discharge and suggests the quality of information given to patients 
is poor at discharge (Wright et al, 2017). 
 
Ziaelan et al, (2012) in a prospective study in the USA of 337 elderly patients found that 
only 53.2% understood about intended medication changes at discharge and prompted a 
need to improve patient education at the point of discharge. 
 
An aspect of medication safety that has emerged is the lack of patient involvement to 
support a reduction in medication errors.  This may be of more relevance to patients on 
long-term medicines or high-risk medicines eg insulin.  The notion of an expert patient is 
not new but there is some evidence that expert patient educational programmes have 
limited impact (Griffiths et al, 2007).  Some patients will be more motivated than others 
to be engaged in their management of medicines but may not be involved.  Bullock et al, 
(2017) evaluated the views of 13 senior pharmacists in England about the hospital 
discharge process.  A significant finding was that patients had limited involvement in their 
own discharge from hospital and there was a deficiency in patients being counselled 
about their medicines.  Garfield et al, (2016) also found that patient engagement or 
involvement in medication safety is limited during the inpatient hospital episode of care. 
 
Mackridge et al, (2017) carried out a survey of patients’ needs for information and support 
with medicines after discharge from hospital.  Interestingly, they found that patients who 
felt that the information was insufficient were most likely to report needing post-
discharge support.  There was quite a lot of variation between hospitals in the way 
information about medicines was provided to patients.  A recent study from Australia 
reported a thematic analysis of the views of 506 patients who had been discharged from 
hospital within the previous month of medication-related problems.  Patients were 
eligible to participate in the study if they were on five or more medicines, over the age of 
50 and had been in hospital for 24 hours or more (Eassey et al, 2017).  A concern found in 
the study was that most patients reported that they felt confused about the changes in 
their medication following discharge from hospital.  The types of concerns expressed 
included possible side-effects and not being told about new or stopped medications.  In a 
separate quantitative study of the same cohort of patients it was found that the most 
commonly used medicines were pain relievers, cardiovascular medicines, cholesterol 
medicines and vitamins and supplements (Eassey et al, 2016).  In this current study 
cardiovascular medicines accounted for 21% of all medicines and again demonstrates the 
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need to prioritise this class of medicines for high-quality discharge information and 
specific patient counselling.  
 
Patients (or their carers) will usually be the only consistent part of the transition of care 
process and may be able to prevent potential medication errors themselves and so reduce 
active and latent errors through their own knowledge and engagement.  It is important if 
patients are to be involved that the discharge information is understandable, and key 
information is pointed out (Cua and Kripalani, 2008).  If patients are more involved with 
the production and understanding of the discharge summary at the point of discharge this 
may result in a reduction in MRH post-discharge.  
 
A recent innovation is the use of a patient’s personal health record across transitions of 
care to improve the quality of information (Greenwald et al, 2010).  It is recognised that 
there is still a lack of agreement on the most effective method to carry out medicines 
reconciliation (Kwan et al, 2013).  An electronic Patient Held Active Record of Medication 
Status (PHARMS) feasibility study will assess whether the introduction of an electronic 
medication record is possible in primary and secondary care.  The electronic patient-held 
medication record device may provide a link to the patient’s GP medication record via a 
Universal Serial Bus (USB) point of a computer.  If this feasibility study is successful then 
it will provide an opportunity to improve the quality of information flow about medication 
at discharge and admission and involve the patient in the medicines reconciliation process 
(Walsh et al, 2018). 
 
This current study provides further evidence of the consequences to a patient about the 
lack of adequate documentation and communication about changes to medication when 
listed on the discharge summary especially if they have cardiovascular disease.   
 
The consequence of these findings suggest again that further research needs to be carried 
out to assess the benefit of involving the patient in the production and understanding of 
the contents of a gold standard discharge summary.  In clinical practice patients may be 
given a copy of the electronic discharge summary in paper form and this provides an ideal 
opportunity to assess their views about the type and format of information contained 




5.1.8  Quality of discharge summaries performance indicators 
There is a need for discharge summaries to be of a high quality to support patients post-
discharge (Kripalani, 2016).  There is also considerable cost in introducing a HEPMA 
system and there is a need to evidence a return of investment by focusing on certain 
quality indicators which measure system impact (Cresswell et al, 2016).  There is still some 
considerable variation in the NHS about the functionality and adoption of HEPMA and this 
will consequently affect the quality of information on discharge in relation to medication 
and indicators of performance (Mozaffar et al, 2014).  It is proposed to consider a measure 
of the quality of discharge summaries as a local and national performance management 
tool when either e-discharge or HEPMA-generated discharge summaries are produced. 
 
A local hospital discharge performance indicator was described by Singh et al, (2015).  A 
hospital discharge scorecard was used as a quality improvement tool.  An exemplar high 
quality discharge summary was used as a standard to train junior doctors who were 
subsequently given feedback at intervals on how well they improved the quality of the 
discharge summaries.  There is the potential to use a similar type of performance indicator 
such as the level of adherence to the gold standards as a local hospital-wide indicator to 
measure the quality of discharge summaries. 
 
At a national level it is recommended to introduce a national ‘gold standard’ for discharge 
summaries related to medication performance score.  The gold standards in this study 
could form the basis of the performance score with a method of scoring adapted from 
that described by Aziz et al, (2016). 
 
Compliance of organisations with this performance standard could be assessed on an 
annual basis via the Pharmacy NHS Benchmarking exercise (NHS Benchmarking, 2017), 
incorporated into the benefits realisation guidance for e-prescribing projects (Slee, 2014) 
or report to the NHS Improvement (NHSI) Model Hospital dashboard (NHSI, 2018). 
 
The Model Hospital is a digital information service designed to help NHS providers 
improve productivity and efficiency.  The Model Hospital is part of NHS Improvement and 
contains a component related to pharmacy and medicines to reduce unwarranted 
variation (Carter, 2016).  The pharmacy and medicines dashboard has a wide array of 
metrics to assess performance which include safety and effectiveness.  It is proposed 
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5.2 Implications and recommendations for policy, practice and research  
In a systematic review of measures to improve the quality of discharge summaries many 
similar themes to this current study were identified as being important ie education and 
training, use of national guidelines and considering the patient’s perspective (Unnewehr 
et al, 2015).  This current study to evaluate the quality of medication-related information 
in the discharge summary of elderly patients discharged from an acute hospital has 
identified several areas for further policy, practice and research which are identified 
below: 
 
(a) There is still a need for nationally agreed and mandated standards for the quality 
of medication-related information at discharge to be implemented in the NHS.  This 
study and review has highlighted that there is still poor adoption of a quality 
improvement approach to discharge standards for medication despite national 
recommendations being available.  Consideration needs to be given to how to 
implement any national standards locally and further research needs to be carried 
out in this area. 
 
(b) Hospitals should define the roles and responsibilities of staff involved with the 
completion and verification of a discharge summary, to ensure standards are 
improved and maintained of the quality of discharge summaries.  
 
(c) GP practices should ensure there is a timely DMR of the e-discharge summary and 
there are defined staff responsible, trained and authorised to make changes to the 
GP medication records. 
 
(d) A modified e-Delphi technique can be used to establish a consensus for a ‘gold 
standard’ discharge summary in relation to medication.  This pilot study should be 
considered for a larger, multi-site study to validate the essential and desirable 
standards to inform a national standard for a ‘gold standard’ discharge summary in 
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relation to medicines that is practical to implement and compliments the recently 
published PRSB standards. 
 
(e) A risk prioritisation tool for discharge summaries for elderly patients should be 
developed and evaluated based on the ‘Q-MedDis’ risk prioritisation model 
proposed in this study to support clinical prioritisation of discharge summaries 
completion to ensure that scarce resources are utilised effectively and efficiently.  
 
(f) The specifications for the design and content of discharge summaries for either 
paper, electronic discharge summaries or HEPMA templates should incorporate the 
‘gold standards’ for medication-related information as mandatory fields.  The 
requirement to implement this should be overseen by a national body such as NHS 
Digital, to ensure that as a minimum, commercial suppliers of HEPMA systems 
include this as part of their product specifications and functionality. 
 
(g) Hospitals should, as a minimum review their current discharge summaries 
templates and processes to ensure they meet the minimum requirements of the 
PRSB (2017). 
 
(h) Education and training programmes for junior doctors should be targeted on how 
to improve the quality of a discharge summary (RCP, 2017). An educational 
intervention that could be carried out is to undertake a training session on “How to 
write a gold standard discharge summary” at induction. This could be delivered as 
practical prescribing exercises with reference to exemplar high-quality discharge 
summaries. A quality improvement method can then be used to measure the 
effectiveness of the intervention (Singh et al, 2015). Following the training session 
random samples of discharge summaries would be periodically reviewed by a 
senior doctor of the medical team according to the “gold standards”. A scorecard 
of performance can be produced and used to provide feedback and training to 
make further improvements.  There should also be greater training and awareness 
for hospital pharmacy staff about the need to ensure that when discharge 
summaries are verified at discharge that they can improve the quality of 
medication-related information.  Consideration should be given to developing 
intra-professional education and training to support this as well. 
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(i) There is a need to undertake larger collaborative research with other hospitals and 
academic centres to validate a national ‘gold standard’ for medication-information 
in a discharge summary and consider the variables that may influence the level of 
adherence to the gold standard.   
 
 
5.3 Ideas for dissemination  
 
The results of this research study will be disseminated locally, regionally and nationally.  
 
(a) Local measures: 
(i)  Present the key findings and recommendations to local key stakeholders at 
the hospital and county-wide Medicines Optimisation and Quality and 
Patient Safety committees. 
(ii)  Present the findings to the local HEPMA steering group to ensure that any 
future system designs meet the “gold standards” for an electronic discharge 
summary.   
 
(b) Regional measures:  
(j) Present the key findings at an East of England Chief Pharmacists Network 
meeting to raise awareness of the issues and to decide whether to carry 
out a region-wide audit of the quality of medication-related discharge 
information.  
(ii)  Present the results to the Eastern Academic Health Science Network to 
ensure future support for research and audits.  
 
(c) National measures: 
(i) Present a poster at a national medication safety conference of the 
findings to raise awareness of the issues.  
(ii) Collaborate with the Chief Pharmacist of NHS Improvement to share the 
key findings to stimulate a national debate.  
(iii) Collaborate with the research team at Newcastle University to take 
forward the recommendation to undertake a national e- Delphi 




5.4  Future studies - what we still don’t know? 
The role of the patient in the completion and quality of the discharge summary has not 
been explored in this study but there is an emerging awareness that in some cases the 
patient may be a valuable resource themselves to reduce any medication-related harm.  
A future study should therefore be focused on gaining the patient’s perspective of the 
content and ease of understanding of a discharge summary. 
 
This study is essentially preliminary to a larger study as the results are not yet validated 
to define the gold standards and desirable standards of a discharge summary for elderly 
(or other) patients.  There is still a need to confirm if any therapeutic classes of medicines, 
diseases or CCI scores influence the outcome for patients if a poor-quality discharge 
summary is completed.  
 
Also, the relationship between the quality of the discharge summary content and 
potential for readmission requires further study with a larger sample size and follow-up 
30 days after discharge and longer, such as 90 days or one-year post-discharge to establish 
if there is any relationship or not. 
 
A crucial area of further study is to investigate the adoption of HEPMA systems in hospitals 
and adherence to the standards of a discharge summary whether used from the results 
of this current study or other published standards.  This will be critical to measure 
adherence levels and any reduction of medication-related harm post-discharge that may 




There has been a significant amount published considering the extent and level of 
medication-related harm that can occur at transition of care for patients.  Consequently, 
most of the implementation of strategies to reduce harm have focused on the admission 
part of the care pathway.  However, more recently there is an awareness that more 
emphasis needs to be placed on reducing risk at the point of discharge and post-discharge 
using a DMR service. 
 
It has been demonstrated that a modified e-Delphi technique can be employed as a 
method to gain consensus of the essential and desirable standards of a discharge 
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summary at a local level.  The essential standards are best described as the gold standards 
and a level of 64.6% was found in this current study. 
 
This preliminary pilot study and review has therefore demonstrated that the quality of 
medication-related information in a discharge summary for elderly patients is variable.  
The method employed in Phase I and Phase II of this study could be used to undertake a 
larger, multi-site and multi-ward-type study to provide a basis for an evidence-based 
consensus.  Whilst recent national recommendations for an e-discharge summary have 
been made the practical implementation of these have yet to be realised and are likely to 
be difficult (PRSB, 2017).  This current study provides a template for local implementation 
of the national standards and to influence the national discussion for a standardised 
approach to producing a gold standard discharge summary. 
 
A larger study is also needed, as we still do not know which variables (patient, medication 
or service), influence the outcome of the quality of medication-related information on a 
discharge summary and ultimately reduce post-discharge medication discrepancies and 
readmission rates. 
 
There is also still a need to develop more awareness and evidence-based processes in 
hospitals and GP practices for elderly patients to ensure a high-quality discharge summary 
is produced and accurately reconciled in the GP practice records. 
 
 
5.6 Personal reflections on the current study 
The interest in undertaking a Doctorate in healthcare has been partly driven by the need 
to be able to more critically understand how practice research can be undertaken and 
then be translated into real-life situations and services.  I have observed that there are 
often significant risks to patients associated with medicines that are not always well 
recognised.  These risks can occur at any point of a patient’s pathway during their hospital 
stay.  I have always had an interest in understanding how and why medication errors occur 
and the use of strategies to reduce or stop them occurring.  
 
In undertaking this study, I have learned a lot about how to undertake a research study 
and the rigour, hard work and detail that is entails.  Ideally this study would have been 
larger, across more than one site (I had originally met with the chief pharmacist of a 
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neighbouring hospital to act as a second site for this study).  However, for pragmatic 
reasons I was unable to do this.  Despite this, I now have more skills, confidence and 
knowledge of how to undertake research but also critically assess and present evidence 
to influence change at local and/or national level. 
 
This preliminary study has limitations, but the principles and methods employed can be 
used to develop more robust research studies that could be applied more widely.  There 
is a challenge for pharmacy practice research to not only produce good quality evidence 
but also influence and support change in a hospital or GP practice.  One of the main 
reasons why we work in healthcare is to ensure we improve outcomes for our patients 





















Appendix 2:  Criteria for assessment of readmission form 
 
Criteria for assessment of 
readmission due to MRI 
Expert panel response 






Patient suffered MRH?  Little/no confidence 
Slight/Moderate 
˂50 percent confidence but a close call 
˃ 50 percent confidence but a close call 
Strong confidence 
Virtually certain 
If MRH what was the main cause?  ADR 
Non- adherence 
Other 
Unable to determine 
Preventable?  Definitely 
Possibly 
Not preventable 
Unable to evaluate 
Was the readmission related to the 
quality of the discharge summary  
Little/no confidence 
Slight/Moderate 
˂50 percent confidence but a close call 
˃ 50 percent confidence but a close call 
Strong confidence 
Virtually certain 








Fatal Patient died due to the incident 
Life threatening Patient transferred to ITU 
Respiratory failure requiring intubation 
Mental status change: patient falls and 
gets intracranial haemorrhage 
Tongue swelling/anaphylactic shock due 
to medication 
Serious Gastrointestinal bleed 
Altered mental status/excessive sedation 
due to medication 
Increased creatinine due to medication 
Decrease in blood pressure, patient feels 
lightheaded 
Allergic reaction: shaking, chills/fever 




Diarrhoea due to antibiotics 
Nausea and vomiting due to medication 
Any significant event that is identified by 
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